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Abstract 
Introduction: Blepharitis is a chronic inflammatory disorder of the eyelid margin. 
Blepharitis patients routinely present to and are managed by optometrists and 
ophthalmologists in practice. Demodex folliculorum is associated with anterior blepharitis. 
Presently, treatment with 50% tea tree oil is recommended by the American Academy of 
Ophthalmology for Demodex blepharitis. However, over-the-counter products have been 
developed and marketed at being effective for treating Demodex blepharitis. 
Purpose: To examine the efficacy of over-the-counter lid hygiene products and warm 
compress therapy for the treatment of Demodex blepharitis. 
Methods: Two hundred and forty-six participants were examined at multiple visits over 
four studies, for the presence and quantity of Demodex folliculorum. OCuSOFT® Lid 
Scrub® PLUS, dr.organic® tea tree face wash, Johnson’s® No More Tears® baby 
shampoo, MGDRx EyeBag® and the OPTASETM Moist Heat Mask were examined for 
treating Demodex blepharitis. 
Results and Conclusions: OCuSOFT® Lid Scrub® PLUS significantly reduced the 
quantity of Demodex folliculorum when used over two and four weeks. Dr.organic® tea 
tree face wash significantly reduced the quantity of Demodex folliculorum when used 
over four weeks. The OPTASETM Moist Heat Mask significantly reduced the quantity of 
Demodex folliculorum when used over eight weeks. The MGDRx EyeBag® did not 
demonstrate a significant reduction in the quantity of Demodex folliculorum over the 
duration of the study. Johnson’s® No More Tears® baby shampoo had no effect on the 
quantity of Demodex folliculorum and demonstrated a significant increase in tear film 
instability when used over an eight-week treatment period. 
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CHAPTER ONE: DEMODEX BLEPHARITIS 
1.1 Background 
Blepharitis is a common inflammatory disorder of the eyelid margins, that can affect 
patients of all ages and ethnicities.1 It can be classified based on three factors; onset, 
location, and underlying aetiology.2 Firstly blepharitis can be classified as acute or chronic. 
The majority of blepharitis cases tend to be chronic in nature.2,3 Secondly, it can affect the 
anterior eyelid margin, eyelashes and eyelash follicles; or the posterior eyelid margin and 
meibomian glands. Thirdly, it can be classified as staphylococcal, seborrheic or parasitic.1–
3 Blepharitis can disrupt the tear film, leading to signs and symptoms of ocular surface 
disease.1,2  
Anterior blepharitis relates to the anterior eyelid margin, eyelashes and follicles. It is 
typically anterior blepharitis that is classified according to underlying aetiology2: 
staphylococcal, seborrheic or parasitic. Posterior blepharitis relates to the posterior eyelid 
margin and meibomian glands. Meibomian gland dysfunction (MGD) is often considered a 
sub-type of posterior blepharitis; however, MGD can also exist separate from blepharitis. 
Due to their close proximity with one another, there is often overlap in signs, symptoms 
and aetiology between disorders of the eyelashes and meibomian glands.4–7 
Blepharitis is one of the most common conditions presenting at ophthalmology and 
optometry clinics worldwide.8–10 In a questionnaire style survey conducted by Lemp et al10 
in 2009 in the United States, 120 ophthalmologists and 84 optometrists reported blepharitis 
prevalence values of 37% and 47% in their respective clinics. Traditionally the majority of 
blepharitis cases have been treated within ophthalmology departments. However, with the 
development of newer ocular hygiene products, and better training and information 
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available, optometrists are becoming more adept and confident at treating minor eye 
conditions such as blepharitis. In 2008, Needle et al11 surveyed optometrists practicing in 
the United Kingdom (UK) to investigate their current therapeutic practice, and ascertain 
their opinion on the broadening clinical role of optometrists. The results of the survey 
showed that optometrists were routinely managing > 70% of blepharitis and dry eye patients 
in-house.11  
The clinical goal for practitioners is to identify the type of blepharitis, choose an 
effective treatment accordingly, and instruct and involve the patient in the long-term 
management of their condition.1 The Blepharitis Preferred Practice Pattern® (BPPP) 
developed by the American Academy of Ophthalmology (AAO) and the College of 
Optometrists, recognise Demodex folliculorum (DF) is associated with chronic re-calcitrant 
blepharitis.1,3 Ocular hygiene using a 50% tea tree oil (TTO) preparation is the 
recommended treatment by the BPPP and the College of Optometrists.1,3 Briefly this 
involves applying the diluted TTO solution to the eyelid margin three times in 5 - 10 minute 
intervals.6,12–17 The BPPP also recommend systemic ivermectin in the treatment of ocular 
Demodex infestations.1 However, these treatments have several disadvantages (discussed 
in more detail in Section 1.9). Thus, the need to elucidate if less severe treatments can 
provide therapeutic efficacy. This thesis investigates alternative therapeutic options 
available to practitioners for the treatment of DF blepharitis. 
1.2 Systematic Review 
On commencing this research degree, a search of the available literature was conducted 
to collate information on DF. Of particular interest was research that concentrated on the 
prevalence of DF with respect to ophthalmology and current treatment methods. Prevalence 
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of DF in different cohorts was of interest as, at the time, there was limited knowledge within 
the optometric sector on ocular DF, and an early aim of the PhD was to investigate this 
further using a questionnaire. Google Scholar, PubMed, and Scopus databases were 
searched with the following keywords: “Demodex folliculorum” AND (“treatment” OR 
“prevalence” OR “symptoms”, OR “dry eye”) OR “ocular demodicosis” OR “Demodex 
blepharitis” AND (“treatment” OR “prevalence” OR “symptoms” OR “dry eye”) OR 
(“Demodex” AND “meibomian gland dysfunction”).  
The following is a systematic review of the literature available at the start of the 
research project. The search strategy is presented in Figure 1.18 Table 1 summarises the 
literature identified as meeting the study criterion of reporting on prevalence of ocular DF 
among different cohorts and relationship with signs and symptoms of dry eye. Table 2 
examines treatment methods for Demodex blepharitis. Detailed descriptions on Demodex, 
their pathogenic potential, risk factors and associated conditions, associated ocular surface 
inflammation, and methods used for diagnosis and treatment are discussed in more 
throughout the chapter. Subsequent relevant publications have been included in the relevant 
sections throughout the thesis. 
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Figure 1. PRSIMA flow diagram illustrating the search strategy conducted.18 
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24 
 
Table 1. Studies reporting on ocular Demodex folliculorum prevalence, signs and symptoms among different cohorts. 
Study Aim/Purpose Population 
(n) 
Clinical 
Examination 
Symptom 
Assessment 
Sampling Method Main Results 
Kosik-
Bogacka et 
al, (2013)19 
 
Examination of DF 
and DB in healthy and 
immune-compromised 
patients 
n = 1186 Slit-lamp 
examination 
Questionnaire 
– name not 
given 
Lash epilation (2 from 
each upper lid) 
22.9% prevalence in 
controls 
20% in immune-
compromised 
Yamashita et 
al, (2011)20 
 
Prevalence DF in 
patients with 
proliferative diabetic 
retinopathy compared 
to healthy subjects 
n = 84    Modified Coston method 
(3 lashes from each 
eyelid) 
54.8% prevalence diabetic  
38.1% healthy 
Age and gender were not 
found to be significant 
Türk M et al, 
(2007)21 
 
Compare incidence of 
DF in normal versus 
blepharitis patients 
n = 96    Lash epilation 29.72% prevalence 
blepharitis 
9.09% 
blepharoconjunctivitis 
4.16% healthy 
Czepita et al 
(2005)22 
 
Prevalence and role of 
Demodex in 
pathogenisis of 
chronic blepharitis 
n = 435   Lash epilation (4 from 
each eyelid) 
13% ages 3–15 years 
34% ages 19-25 years 
69% ages 31-50 years 
87% ages 51-70 years 
95% ages 71-96 years 
58% in chronic blepharitis 
 
Kemal et al, 
(2005)23 
Prevalence of DF in 
seborrheic blepharitis 
patients and controls  
n = 500    Lash epilation (3 from 
each eyelid) 
28.8% in blepharitis 
subjects 
26.7% in controls 
No significant diff with age 
or gender 
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Ozcelik et al, 
(2007)24 
Prevalence of DF in 
patients with chronic 
kidney deficiency 
n = 85    Skin surface biopsy and 
lash epilation (8 lashes, 2 
each eyelid) 
12.76% in eyelashes of 
patients with kidney disease 
5.26% in controls (not 
significant) 
Kim et al, 
(2011)17 
Analysis of cytokine 
levels in lacrimal fluid 
to evaluate casue of 
ocular surface 
inflammation in 
Demodex blepharitis 
n = 45 Tear sampling 
Slit lamp 
examination 
TBUT 
Schirmer II 
(with 
anaesthetic) 
 Modified Coston method 
(8 lashes, 2 each eyelid) 
Concentration of IL-17 
significantly higher in DF 
blepharitis group than non-
DF blepharitis and control 
groups 
Gao et al, 
(2005)25 
Prevalence of DF in 
eyelashes with CD 
n = 55  Routine eye 
examination 
 Modified Coston method 
(8 lashes, 2 each eyelid) 
100% prevalence in CD 
groups 
22% in non-CD group 
Liang et al, 
(2014)26 
Investigate correlation 
between Demodex and 
chalazia 
n = 155  Slit lamp 
examination 
Surgical 
removal of 
chalazia 
 Lash epilation (2 from 
each eyelid in adults + 4 
from each eyelid in 
paediatrics) 
Demodicosis significantly 
more prevalent in chalazia 
(69.2% vs 20.3%) 
DB more prevalent than DF 
Wesolowska 
et al, 
(2014)27 
Prevalence of 
Demodex in eyelash 
follicles of different 
populations and its 
relationship with eye 
symptoms 
n = 290   Specially 
designed 
questionnaire 
containing 
demographic 
and clinical 
data 
Lash epilation (10 
eyelashes each 
participant) 
54.7% prevalence in-
patients 
40.0% in health 
professionals 
33.7% in medical students 
23.5% in drug abusers 
No difference in gender 
Symptoms not significantly 
associated with Demodex 
Lee et al, 
(2010)28 
Relationship between 
the prevalence of 
demodex in eyelashes 
and the severity of 
ocular discomfort 
n = 170 TBUT 
Schirmer 
Slit-lamp 
Modified 
OSDI 
Modified Coston method 
(8 lashes, 2 each eyelid) 
70% prevalence. 
No difference between sex. 
No relationship with 
systemic disease.  
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Bhandari & 
Reddy, 
(2014)29 
Incidence and density 
of DF on the lashes: 
normal eyelids, 
anterior blepharitis, 
MGD, and mixed 
blepharitis 
n = 200 Standard eye 
examination 
Irritation, 
itchiness, 
eyelid 
heaviness, 
sticky or moist 
sensation of 
the lids, 
mucous 
discharge: 
method not 
given 
Lash epilation 90% incidence in anterior 
blepharitis 
60% in MGD 
90% in mixed blepharitis 
18% in controls 
de Venecia 
& Siong, 
(2011)30 
Incidence and density 
of DF on the lashes: 
normal eyelids, 
anterior blepharitis, 
MGD, and mixed 
blepharitis 
n = 167  Irritation, 
itchiness, 
eyelid 
heaviness, 
sticky or moist 
sensation of 
the lids, 
mucous 
discharge, FB 
sensation, 
transient 
blurring of 
vision, 
redness, eye 
pain, tearing: 
method not 
given 
Modified Coston method 
(8 lashes, 2 each eyelid) 
95% incidence in anterior 
blepharitis 
85% in MGD 
97% in mixed blepharitis 
34% in controls 
Most common symptoms: 
itchiness and FB sensation 
Huang et al, 
(2013)31 
Ocular demodicosis as 
a risk factor in 
pterygium recurrence 
94 Tear sampling  Modified Coston method 
(8 lashes, 2 each eyelid) 
High correlation between 
tear 
IL-17 levels in pterygium 
and demodicosis 
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Hauswirth et 
al, (2014)32 
ARVO meeting 
abstract: comment on 
symptoms associated 
with DF 
72  
 
OSDI 
SESoD 
SEFoI 
TOSS 
Modified Coston method 
(8 lashes, 2 each eyelid) 
OSDI: 36.1% classified as 
symptomatic for dry eye 
SESoD: 23.6% clinically 
significant dryness 
SEFoI: 20.8% clinically 
significant itch 
TOSS: 27.7% clinically 
significant 
 
Li et al, 
(2010)33 
Investigate the 
relationship between 
ocular Demodex 
infestation and rosacea 
59 Routine 
complete eye 
examination 
 Modified Coston method 
(8 lashes, 2 each eyelid) 
Demodex count higher in 
patients with positive facial 
rosacea. 
Prevalence Demodex less in 
patients with aqueous 
deficient dry eye 
DF: Demodex folliculorum; DB: Demodex brevis; CD: cylindrical dandruff; TBUT: tear break-up time; IL: inter-leukin; MGD: meibomian gland 
dysfunction; FB: foreign body; OSDI: Ocular Surface Disease Index; SESoD: Subjective Evaluation of Symptom of Dryness; SEFoI: Subjective Evaluation 
of Frequency of Itch; TOSS: Total Ocular Surface Score 
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Table 2. Studies reporting on current treatment methods for ocular Demodex folliculorum. 
Study Aim/Purpose Population 
(n)  
Clinical 
Examination 
Symptom 
Assessment 
Sampling 
Method 
Intervention Main Results 
Holzchuh 
et al, 
(2011)34 
Treatment of DF by 
systemic ivermectin. 
n = 12 NITBUT  
Schirmer 
TMH 
corneal 
staining 
 Lash epilation: 
12 lashes (3 
each eyelid)  
Ivermectin Prevalence of DF lower 
lid > upper lid.  
Significant reduction in 
quantity DF post 
treatment. 
Gao et al, 
(2005)12 
Effect of TTO on ocular 
Demodex.  
n = 9   Modified 
Coston method 
(8 lashes, 2 
each eyelid) 
Weekly in-office 
scrubs 50% TTO. 
Home lid scrubs 
tea tree shampoo  
In-office scrubs with 
home scrubs reduce DF 
count to zero in 7 out of 
9 patients. 
Gao et al, 
(2012)35 
Treatment of ocular 
itching with 5% TTO 
ointment.  
n = 24 Degree of 
itching 
(Graded 0 – 3 
for increasing 
severity)  
 Lash epilation CTC 
5% TTO ointment 
No change in itching and 
DF counts with CTC. 
Improvement in itching 
and reduced DF count 
with 5% TTO ointment  
Koo et al, 
(2012)13 
Relationship between 
ocular discomfort and DF. 
Therapeutic effects of 
TTO for DF blepharitis.  
n = 160 Slit-lamp 
examination 
OSDI Modified 
Coston method 
(8 lashes, 2 
each eyelid) 
Weekly in-office 
scrubs 50% TTO 
Home lid scrubs 
tea tree shampoo  
DF in 84% patients with 
ocular discomfort.  
Quantity DF associated 
with age and OSDI 
score. 
TTO significantly 
reduced DF count post-
treatment.  
Salem et al, 
(2013)36 
Efficacy of ivermectin 
and combined ivermectin-
metronidazole therapy in 
treatment of ocular DF. 
n = 120   Lash epilation: 
3 lashes from 
each lower 
eyelid  
Metronidazole 
Ivermectin  
Combined therapy 
superior for decreasing 
DF counts to normal 
levels. 
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Kheirkhah 
et al, 
(2007)6 
Retrospective report on 
corneal manifestations 
associated with DF 
infestation.  
n = 6 Slit-lamp 
examination 
 Modified 
Coston method 
(8 lashes, 2 
each eyelid) 
Weekly in-office 
scrubs 50% TTO 
Home lid scrubs 
tea tree shampoo  
Improvement in ocular 
surface irritation and 
pain.  
Improvement in 
conjunctival redness.  
DF count reduced post-
treatment.  
 
Liang et al, 
(2010)14 
Retrospective report on 
DF infestation in 
paediatric blepharo-
conjunctivitis.  
n = 12 Eye 
examination 
 Modified 
Coston method 
(8 lashes, 2 
each eyelid) 
Weekly in-office 
lid scrubs 50% 
TTO 
5% TTO ointment 
eyelid massages  
Resolution of ocular 
irritation and 
inflammation.  
Reduction in quantity 
DF  
Fulk et al, 
(1996)37 
Case series, interventional n = 22  Subjects 
rated feelings 
of itch, 
burning, 
grittiness or 
fullness 
(scale 1-4) in 
a log 
Lash epilation 
6 lashes (3 
from each eye) 
4% pilocarpine 
gel 
Reduction in quantity DF 
with 4% pilocarpine gel 
Filho et al, 
(2011)38 
Efficacy of oral 
ivermectin for the 
treatment of chronic DF 
blepharitis.  
n = 19 TBUT 
Slit-lamp 
examination 
OSDI Lash epilation 
(3 per eyelid) 
oral ivermectin Reduction in quantity DF 
with oral ivermectin 
Gao et al, 
(2007)15 
Retrospective review: 
Treating ocular 
demodicosis with TTO lid 
scrubs. 
n = 11 CD 
MGD 
Self-reported 
symptoms 
Modified 
Coston method 
(8 lashes, 2 
each eyelid) 
Weekly in-office 
lid scrubs 50% 
TTO 
Home lid scrubs 
with tea tree 
shampoo  
DF associated with 
ocular surface 
inflammation – 
MGD/trichiasis/conjuncti
vitis/madarosis. 
Reduction in DF count 
with TTO 
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Kojima et 
al, (2011)16 
Use of in-vivo laser 
scanning confocal 
microscopy in the 
diagnosis of ocular 
demodicosis. 
n = 23  Slit lamp 
examination 
TBUT 
Ocular surface 
staining 
Schirmer I 
Visual 
analogue 
scale scores 
Lash epilation 
(3 lashes from 
superior lid 
one eye) 
 
Confocal laser 
scanning 
microscopy 
Weekly lid scrubs 
50% TTO and 
daily lid scrubs 
with tea tree 
shampoo 
Itch and FB sensation 
greater in DF subjects. 
Ocular surface staining 
greater in DF subjects. 
No significant difference 
in mite count between 
methodologies. 
DF count reduced post 
treatment. 
Kim et al, 
(2011)39 
Investigate clinical and 
immunological responses 
to Demodex on the ocular 
surface. 
n = 10 Slit lamp 
examination 
Tear sampling 
 Modified 
Coston method 
(8 lashes, 2 
each eyelid) 
Weekly lid scrubs 
with 50% TTO 
and daily lid 
scrubs with 10% 
TTO shampoo 
Pre Tx: corneal opacities, 
corneal vascularization, 
corneal erosion and 
infiltration, chronic 
conjunctival 
inflammation. 
Post Tx: Demodex count 
reduced, tear 
concentrations of IL-1β 
and IL-17 significantly 
reduced and clinical 
improvement observed in 
all patients.  
DF: Demodex folliculorum; NITBUT: non-invasive tear break-up time; TMH: tear meniscus height; TTO: tea tree oil; CTC: chlortetracycline 
hydrochloride; OSDI: Ocular Surface Disease Index; TBUT: tear break-up time; CD: cylindrical dandruff; MGD: meibomian gland dysfunction; IL: inter-
leukin; FB: foreign body
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1.3 Introduction to Demodex 
Demodex are a group of microscopic ectoparasites that live in the pilosebaceous units 
of mammals. Although there are more than 100 known species of Demodex parasites, they 
are believed to be host specific. Demodex canis, ubiquitous to dogs, is the most well 
documented and investigated of the Demodex mites, due to its ability to cause demodectic 
mange in immuno-suppressed dogs. There are two known Demodex species that infest the 
pilosebaceous units of humans: DF and Demodex brevis (DB) (collectively referred to as 
Demodex throughout this thesis).  
Demodex folliculorum were first described in the literature by Simon in 1842,40 
although it was not until 1963 that Akbulatova first described DB as a separate species.41,42 
In 1967, Coston first described the potential association between Demodex and 
blepharitis.43 However, it is only in the last 15 years that significant ground has been broken 
in ocular associations of Demodex infestations: including prevalence,23,44,45 symptoms,35,45–
47 complications,6,46,48,49 examination,25,49–51 and treatment.15,52,53  
Demodex mites are photophobic40 and most active at night,54 travelling across the skin 
at a speed of up to 16 mm/hr.42 They feed on skin cells and sebum, and are  most commonly 
found in areas rich in sebaceous glands: cheeks, nose, chin and the periocular area42,43,55; 
although, they have been found in other locations on the body also.56–59  
Demodex are susceptible to desiccation, and therefore cannot live for long outside of 
the body.40 As a result, it is believed that direct contact is required for transference.42,49,54 
Palopoli et al60 discovered that DNA lineages of DF were more likely to be shared within 
families and between spouses than between unrelated individuals; concluding that close 
contact was required for transmission.  
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1.4 Classification 
  
Figure 2. Demodex structure: head, four pairs of legs and a long body tail (x 400 mag). 
Demodex are translucent, spindle shaped mites, with a head, four pairs of legs and a 
long body tail (Figure 2).43,57 Mating occurs at the opening of the hair follicle, and the 
female retreats inside the follicle or sebaceous gland to lay her eggs.42,43 The eggs evolve 
to become larva and then protonypmh, inside the follicle. Finally, they move to the follicle 
orifice to complete maturation to deutonymph and adult.40,42,43 The overall lifespan of 
Demodex mites is believed to be approximately 14 - 18 days.40,42,43,61  
1.4.1 Demodex folliculorum 
Adult DF is approximately 0.4 mm in length, and is larger at all developmental stages 
than the corresponding DB stages.41,42 Demodex folliculorum reside in clusters in the 
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eyelash follicles,41,43,62 and are therefore often associated with anterior 
blepharitis.22,46,49,63,64 Figure 3 shows multiple DF found on one eyelash. 
 
 Figure 3.   Several Demodex folliculorum along an epilated eyelash (x 200 mag). 
1.4.2 Demodex brevis 
Adult DB is smaller than DF, approximately 0.2 mm.42 Demodex brevis typically 
resides in solidarity in the eyelash sebaceous glands and meibomian glands, and therefore 
has been associated with MGD.26,41,61,62,65 Figure 4 shows a single DB found on eyelash 
epilation.  
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Figure 4.  Demodex brevis (x 400 mag). 
1.5 Pathogenicity 
Demodex mites have a complex role to play as microflora in our cutaneous ecosystem. 
Several investigators believe they are simply commensal organisms66–68: feeding on their 
host, without causing damage, but without purpose. It has also been suggested that there 
may be a mutualistic Demodex – host relationship, whereby Demodex ingest bacteria and 
other micro-organisms within the follicular canal, helping the host.66 The host’s immune 
system then appears to regulate the quantity of Demodex present, preventing mite 
proliferation that could cause an inflammatory response. However, when Demodex 
quantities increase beyond a ‘critical level’, they acquire a pathogenic role, causing injury 
to the host.69,70 Thus, pro-inflammatory cytokines/chemokines are released, and the 
immune inflammatory response follows with clinically visible cutaneous changes.17,66,69 
Although studies have discovered the presence of Demodex on normal, healthy 
individuals71,72; associations have been repeatedly made between an increased presence of 
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Demodex and inflammatory conditions such as rosacea and blepharitis.6,28,46,47,70 Thus, it 
has been suggested that Demodex mites are in fact opportunistic parasites: beginning as 
commensals, but have pathogenic potential in susceptible individuals.66 It appears that the 
pathogenic potential of Demodex increases as the quantity of mites present increases.61,66 
Underlying factors that may affect Demodex proliferation are further discussed in detail in 
Section 1.6. 
A third theory on the pathogenicity of Demodex is that they may act as vectors for 
bacteria. Researchers have begun to question whether it is not the presence of Demodex that 
causes problems, but whether the Demodex are ‘ill’.68 This hypothesis has arisen from the 
fact that treatment with tetracycline antibiotics resulted in clinical improvement of rosacea, 
even though the antibiotics had no effect on the Demodex mites themselves.54  Bacillus 
oleronius is a Gram-negative bacterium that has been found on Demodex mites in rosacea 
patients.33,73 Neutrophils are a type of white blood cell, that are released as part of our 
immune response to bacterial infections.74 O’ Reilly et al75 examined the response of 
neutrophils to inflammatory proteins released from Bacillus oleronius. The authors found 
that neutrophils exposed to proteins from Bacillus oleronius increased their levels of 
migration, degranulation and production of inflammatory cytokines75: suggesting that 
bacteria play a role in the inflammation associated with Demodex infestation.  
 In 1993, Forton & Seys71 examined the density of DF in skin samples of rosacea 
participants compared to healthy control participants. The authors discovered a mean 
density of 10.8 mites/cm2  in rosacea participants in comparison to a mean of 0.7 mites/ 
cm2, and < 5 mites/cm2 in 98% of the healthy control skin samples; and concluded that low 
quantities of DF could be considered normal.71 In 2014, Thoemmes et al72 investigated the 
prevalence of Demodex on adults (> 18 years of age) using DNA extracted from individual 
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skin scrapings. Briefly, a metal laboratory spatula was gently scraped across the nose and 
cheek to extract sebum from the pores in the skin. After extraction, the sebum was placed 
in a drop of mineral oil on a cover slip and the sample was examined to note presence or 
absence of visible Demodex mites. Each sample was then transferred to a microcentrifuge 
for DNA extraction. The result of their study discovered the presence of Demodex DNA on 
100% of individuals tested.72 In the same study, the authors discovered only a 14% 
prevalence of Demodex mites based on visually observing the presence of Demodex within 
their samples.72 These findings are in keeping with other studies that have also found low 
prevalence of Demodex among normal individuals.23,76  
1.6 Risk Factors and Associated Conditions 
There are several factors that may affect an individual’s susceptibility to proliferation 
of Demodex to a pathogenic level. These factors, in addition to potential inhibitory factors, 
are outlined in detail below. 
1.6.1 Age 
Increasing age is the most prevalent risk factor with regards to the presence of 
DF.13,28,77,78 Since DF have been located on the nipple, one theory that has been proposed 
is that human infants acquire DF from their mothers during nursing; and as the child grows, 
the mites proliferate.79 This results in a naturally higher prevalence of DF among older 
individuals. It has also been suggested that proliferation of DF increases with age due to a 
natural change in sebum composition and secretion that facilitates the growth of DF in the 
elderly.27,80  Other studies have indicated a link between ocular hygiene and age: suggesting 
that older individuals may have a reduced ability to clean the eyelids thoroughly, thus 
resulting in an increased prevalence of DF.28 This conclusion was established when Lee et 
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al28 found that the prevalence of DF was higher among younger individuals with poor eyelid 
hygiene, in comparison to older individuals with good eyelid hygiene.  
1.6.2 Rosacea 
The hair follicles and sebaceous glands of the skin are the main sites of involvement 
for DF and DB; therefore, it is not surprising that Demodex have been associated with 
several skin conditions, such as rosacea, pityrisasis folliculorum, and pustular 
folliculitis.33,54,70,81,82 However, Demodex mites, unlike other mites such as scabies, have 
not been proven to cause dermatologic issues.83 This is due to the fact that low numbers of 
Demodex mites can be found in healthy skin.71 It is has been established that it is an increase 
in density of Demodex mites that appears to cause issues.71  
Rosacea is a chronic, inflammatory, non-contagious skin disease that predominantly 
affects facial skin. It most commonly presents with various degrees of facial flushing, 
telangiectasia and papulo-pustular rashes.54,84,85 The majority of cases are diagnosed after 
the age of 30 years, and it is consistently found to be more common in women than in 
men.86–88 There are several underlying factors that are believed to play a role in the 
underlying pathophysiology of rosacea.84 Genetics is considered an important factor 
regarding susceptibility of an individual to developing rosacea.84 Up to one third of 
individuals with rosacea have a relative with rosacea.84,89 Rosacea can affect patients of any 
ethnicity; however, it is more common in fair skinned individuals, with a 
Scandinavian/Celtic ancestory.84,87 It has been proposed that darker skin pigmentation 
could conceal some of the distinguishing features, thus causing potential underdiagnosis in 
darker skinned individuals.90 Exposure to UV light is considered to contribute to the 
development of rosacea by altering the elastic and collagen fibres of the blood vessel walls, 
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making them more susceptible to damage over time.84 Heat, stress, spicy food and alcohol 
have all been considered secondary triggers for rosacea development in susceptible 
individuals.84 However, smokers appear to have a lower risk of developing rosacea to non-
smokers.86 
The association between rosacea and Demodex has been well established in the 
literature.69,70,81 However, the underlying aetiology remains a much debated topic. As 
mentioned previously in Section 1.4, one hypothesis on the aetio-pathogenicity of Demodex 
in rosacea is that Demodex act as a vector for bacteria and micro-organisms that cause skin 
inflammation, such as that seen with rosacea.54 Another hypothesis is that Demodex cause 
perifollicular inflammation when they penetrate the dermis, stimulating the release of 
lymphohistiocytic infiltrates within the follicles.71 A third hypothesis is that Demodex 
proliferate in favourable conditions: hyper-vascularised skin, lack of washing and immune 
status.70 When mites proliferate, some individuals experience a type IV hypersensitivity 
immune reaction against the mites, causing the development of the redness and papulo-
pustular rash commonly associated with rosacea.69–71 
1.6.3 Immunodeficiency  
Researchers have been looking at associations between Demodex mites and the 
underlying health status of an individual. As a broad variety of patients, with a wide range 
of underlying health conditions, present daily to clinical practice for eye examinations and 
ocular health checks, it is important to understand how their systemic conditions may affect 
their ocular health: both internal e.g. retinopathy, and external e.g. blepharitis and dry eye. 
The immune status of the individual is believed to play a major role in suppressing 
Demodex proliferation to pathogenic levels.66 A deficient immune system cannot control 
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the numbers of Demodex, the mites proliferate, and induce an inflammatory response.66  
Several case reports in the literature have found significant DF infestation among 
individuals with acquired immunodeficiency syndrome (AIDS) and human 
immunodeficiency virus (HIV), supporting this theory.91–94 However, larger scale studies 
have found no association between immune-deficiency and DF infestation.19,27 In the study 
conducted by Wesolowska et al,27 the authors inferred that the use of anti-retroviral therapy 
for the treatment of HIV may have improved participants immune condition to the extent 
where they were no longer immunocompromised enough to facilitate Demodex 
proliferation. Although DF infestation has been reported among immunocompetent 
children,14,95,96 the majority of cases of paediatric demodicosis reported in the literature 
have been associated with leukaemia and HIV92,97–101; as such, practitioners should be 
suspicious of an underlying immune condition in children who present with severe DF 
infestation.   
Diabetes is a group of metabolic diseases, characterised by hyperglycaemia, resulting 
from abnormal insulin secretion, action or both.102  Several studies have found an increased 
prevalence of DF among diabetics,20,103,104 suggesting that hyperglycemia and the 
immunosuppressive nature of diabetes may play a role.104,105 A recent study examining the 
effect of blood glucose regulation on the presence of DF infestation in type II diabetics, 
showed a higher incidence of DF infestation in diabetics with poor blood glucose control; 
suggesting that good glucose control reduces susceptibility to DF infestation in type II 
diabetics.106 In 2014, Kurt et al107 demonstrated a significantly higher prevalence of DF 
infestation in participants with gestational diabetes compared to controls (pregnant 
participants without gestational diabetes) (24.2% versus 3.3%; p < 0.001). Furthermore, in 
agreement with earlier research,106 participants with gestational diabetes with poor blood 
 40 
 
glucose control were found to have a higher density of DF compared to those with good 
blood sugar control.107 
Chronic kidney disease is a progressive loss of kidney function that may occur over 
many years. The main function of the kidneys is to maintain homeostasis; by filtration of 
waste products from the blood, reabsorption and transportation of nutrients from the blood, 
balancing electrolyte levels in the body, and controlling blood pressure. When kidney 
function is impaired, there is a loss to homeostasis within the body, and skin changes similar 
to those seen with DF infestation develop.108 Researchers have found a positive correlation 
between end stage kidney disease and DF infestation.24,108 Similar to diabetes, an 
underlying impairment in the immune system of such individuals, may allow proliferation 
of DF to pathogenic levels.109 
Polycystic ovarian syndrome is a common, endocrine disorder affecting up to 10% of 
premenopausal women110: causing anovulation, increased androgen secretion and increased 
insulin resistance.111,112 A higher prevalence of DF has been discovered in participants with 
polycystic ovarian syndrome.111,113 This is likely due to the associations of polycystic 
ovarian syndrome with hyperglycaemia,110 and the associations of Demodex infestation 
with uncontrolled blood sugar levels.106  
1.6.4 Contact Lenses 
Jalbert and Rejab114 found contact lens wearers were prone to higher rates of DF 
infestation. The reason for this is unknown, however it is postulated that increased handling 
of the eyelids by contact lens wearers can increase the presence of bacteria at the eyelid 
margin, resulting in a higher prevalence of blepharitis. Thus, making the eyelids of contact 
lens wearers a more desirable environment for DF to inhabit. Tarkowski et al115 also 
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discovered a positive correlation between DF infestation and a significant increase in 
contact lens discomfort causing contact lens drop out, among previous successful 
comfortable contact lens wearers. Contact lens wearers were included in the preliminary 
epidemiological study, and the relationship found between contact lens wear and DF 
infestation is discussed further in Chapter 3. 
1.6.5 Makeup 
Horváth et al116 and Elston and Elston79 have proposed that makeup may act as a 
deterrent for DF infestation; suggesting that the lipids in cosmetics may affect DF growth 
and therefore could be responsible for the lower presence of DF found among women. It is 
also possible that the use of makeup may increase good lid and facial hygiene; which has 
been shown to be associated with reduced numbers of DF.28 Horváth et al116 and Elston and 
Elston’s79 investigations into Demodex and makeup were conducted using skin surface 
biopsies. Currently, no data exists that examines the relationship between ocular Demodex 
and use of makeup. Chapter 3 reports on the prevalence of DF discovered amongst makeup 
wearers in a preliminary epidemiological study conducted during this research project.  
1.7 Ocular Surface Inflammation 
1.7.1 Dry Eye 
Dry eye has been defined as: 
“… a multifactorial disease of the ocular surface characterised by a loss of 
homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film 
instability and hyperosmolarity, ocular surface inflammation  and damage and 
neurosensory abnormalities play etiological roles.” 117  
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Dry eye disease (DED) can be classified into two main types: aqueous deficient dry 
eye and evaporative dry eye. There are many underlying factors that can cause or exacerbate 
DED including but not limited to age, female sex, ethnicity, contact lens wear, blepharitis, 
refractive surgery, medications, auto-immune disease, air-conditioned dry environment, 
computer use, and smoking.118–124 The prevalence of DED varies from approximately 5% - 
33%,125,126 depending on the definition of DED incorporated and study conditions; with 
increasing age and female sex being the predominant risk factors for disease progression.121 
Demodex mite infestation can be associated with DED through its close association with 
blepharitis and MGD. 
1.7.2 Blepharitis 
Blepharitis has been previously defined in Section 1.1. As mentioned previously, 
blepharitis has been classified in different ways; however at present, the general accepted 
classification is by location of inflammation on the eyelids: anterior and posterior.2,9 
Demodex folliculorum infestation is associated with anterior blepharitis, due to its residence 
and effect within the eyelash follicles.7,43,46,49,78,127 Researchers have also linked DB with 
posterior blepharitis,41,61,62,65 this is discussed in more detail in Section 1.6.3 below.  
In susceptible individuals, the existence of Demodex causes direct damage to the 
anterior ocular structures.43,62 Demodex folliculorum use their claws to scrape at the internal 
walls of the lash follicles. This causes the follicles to widen, the eyelashes within to become 
looser, and increased hyperkeratinisation of the epithelial cells: which becomes visible as a 
gelatinous collar at the base of the eyelash.62 This is clinically known as cylindrical dandruff 
(CD) and is now considered a pathognomonic sign for presence of DF (refer Figure 5).25 
Cylindrical dandruff is believed to be caused by the abrasive movement of the mites within 
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the eyelash follicles,62 or as an inflammatory cicatrix formed from dead mites within the 
follicle.128 As there is a greater quantity of eyelashes on the upper eyelids than one th lower 
eyelids, it may be easier to detect, and there may be a greater amount of CD present, on the 
upper eyelids. 
 
Figure 5. Cylindrical dandruff:  collar at the base of the eyelashes (x24 mag). 
 
The presence of CD at the base of the eyelash follicles is one of the methods utilised 
to differentially diagnose between the subtypes of blepharitis. Demodex blepharitis has CD: 
gelatinous collars at the base of the eyelashes (as shown in Figure 5).25 By comparison, 
staphylococcal collarettes tend to be crusty sleeves, often stuck together, that can leave a 
bleeding ulcer when removed, and may be present anywhere along the length of the 
eyelash.129 Seborrheic collarettes are usually greasy and soft, they don’t leave a bleeding 
ulcer when removed, and are associated with seborrheic dermatitis.9,129  
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Despite the relatively high prevalence of blepharitis in ophthalmic clinics, the exact 
aetiology remains unknown, and there is still no ‘cure’ for chronic blepharitis.2  
1.7.3 Meibomian Gland Dysfunction 
Meibomian gland dysfunction is a chronic, diffuse abnormality of the meibomian 
glands, that is associated with posterior blepharitis and is the most common cause of 
evaporative dry eye.130 
The meibomian glands provide the main source of lipids for the human tear film. Their 
functions include: preventing evaporation of the aqueous layer, stabilising the tear film and 
providing a smooth optical surface for light refraction and improved visual acuity.131–136 
Disruption to this lipid layer causes tear film instability, hyperosmolarity and subsequent 
ocular surface inflammation, which further increases the instability of the tears, causing 
DED. Although DF typically inhabits the eyelash follicles, a high prevalence of DF has 
been found in patients with MGD and mixed blepharitis (anterior blepharitis and 
MGD).30,127,137 As DB inhabits the sebaceous glands, often in solitude, it is suggested that 
DB contributes to MGD by causing granulomatous changes to the glandular cells, and 
physically blocking the gland orifice and preventing the flow of meibum to the ocular 
surface.41,61,62,65  
At present, the most common treatment for MGD involves using compression 
therapies to unblock the glands.138–141 It is postulated that frequent and regular heating of 
the abnormal meibum clears any obstructions allowing a smooth passage of meibum to the 
ocular surface. This increased availability of meibum thickens the lipid layer of the tear 
film, reducing evaporation of the aqueous layer, thus increasing the stability of the tears, 
restoring normal osmolarity and normal tear function.138,139,141   
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Although it is DB that tends to reside in the meibomian glands, a high prevalence of 
DF has been found in the eyelashes of MGD sufferers.30 Chapter 7 discusses the efficacy 
of warm compresses in the treatment of MGD and DF blepharitis. 
1.7.4 Symptoms 
The symptoms of DF infestation, blepharitis and DED are very similar, as they all 
involve the ocular adnexa and manifest on the ocular surface: dryness, itch, irritation, 
burning sensation and foreign body sensation have all been recorded in the 
literature.6,13,15,16,45–47,49 Demodex can promote an inflammatory reaction on the ocular 
surface.17 Kim et al17 demonstrated that the presence of DF caused an increase in the tear 
protein IL-17, which is associated with lid margin inflammation.  
Previous research has shown that the type and severity of symptoms can vary 
depending on the condition and time of day.142 Blepharitis and MGD are often associated 
with a foreign body sensation and sticky eyes in the morning; while aqueous deficient dry 
eye tends to worsen as the day goes on.142 Several studies have found itch to be the symptom 
most significantly associated with Demodex infestation.16,46,47 The movement of DF within 
the follicle may indirectly be accountable for the signs and symptoms exhibited by many 
affected patients. As DF are photophobic and only active at night, one might expect patients 
to be most symptomatic at night or in the morning after the mites have been most active. 
However, at present there is no data available regarding the diurnal variation of symptoms 
with respect to DF infestation.  
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1.7.5 Ocular Morbidity  
Ocular surface inflammation as a result of DF infestation and subsequent DED not 
only causes physical symptoms but can cause functional symptoms also. Ocular morbidity 
associated with DED and inflammation of the ocular surface has been recognised as a public 
health concern.121 As previously discussed, DF infestation can cause ocular surface 
inflammation which can manifest as DED and blepharitis in many patients. Subsequently, 
this can cause physical and functional symptoms, ranging from mild to severe, requiring 
differing levels of treatment and management. Chronic inflammation of the eyelids and 
eyelashes from DF infestation can cause loss of lashes, ocular discomfort, corneal 
neovascularisation, infiltration, opacities and scars.6,143 This can impact an individuals’ 
quality of life in several ways: physically, socially, emotionally, professionally, and 
financially.121,142 Chronic inflammation from underlying DF and DED can cause physical 
discomfort, reduced vision and increased discomfort in contact lenses.115 It can interfere 
with leisure activities and social interactions causing stress, anxiety and depression in 
severe cases.144 It can also cause a reduction in productivity and time out of work and it can 
require many visits with a clinician, with ongoing cost of treatment resulting in increased 
medical bills. Early intervention and patient education could go a long way towards 
preserving good ocular health, comfort and vision, and preventing chronic disease that can 
cause ocular morbidity. 
1.8 Diagnostic Methodologies 
Diagnosis of Demodex infestation will often depend on the discipline. Dermatologists 
use skin surface biopsy techniques to assess density of DF in the skin. Whereas 
ophthalmologists and optometrists are concerned with DF and DB infestation of the eyelids 
 47 
 
and eyelashes. Confirming the presence of DF, and thus diagnosis of Demodex blepharitis, 
is most commonly achieved by eyelash epilation and microscopic examination the eyelash 
with a light microscope,25 or smartphone.145 In recent years, laser confocal microscopy has 
also been utilised to view DF in vivo.16,65,146  
Investigation of the eyelashes by epilation involves gently rotating an eyelash using 
sterile forceps and epilating the lash in order to count the number of DF mites present. There 
is no standard technique for epilating the eyelashes. However, the two most utilised 
methods discussed in the literature for epilating the eyelashes and counting the DF are the 
conventional Coston method and the modified Coston method. 
1.8.1 Conventional Coston Method 
The conventional Coston method was described by Coston43 in 1967 and involves the 
random epilation of non-adjacent eyelashes on the eyelid. The epilated eyelash is placed on 
a microscope slide, one drop of peanut oil is placed on the eyelash and the coverslip is 
placed on top. However, there are several limitations to the conventional Coston method. 
Firstly, randomly selecting any eyelash could result in under-counting, as there is a much 
better chance of detecting DF if lashes with CD are present and are selectively chosen.25 
Secondly, by adding the peanut oil before the coverslip, non-adherent DF may float away, 
resulting in under-counting.25,29 Thirdly, if DF are embedded in compact CD they cannot 
be counted accurately.25,29 Finally, very often not all DF get removed with the eyelash 
leaving some DF behind in the follicle, resulting in under-counting.25,29 These limitations 
led to investigators utilising the modified Coston method in more recent studies. 
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1.8.2 Modified Coston Method 
The modified Coston method was developed by Gao et al25 in an attempt to overcome 
some of the limitations outlined above. The modified Coston method firstly involves 
selectively choosing lashes with CD, if present, then placing the coverslip on top of the 
epilated eyelashes, and finally pipetting a drop (20µl) of saline at the edge of the microscope 
slide on lashes without CD, and alcohol and fluorescein on lashes with retained CD. By 
selectively choosing lashes with CD there is a greater chance of finding DF. Placing the 
coverslip on top of the microscope before the saline/alcohol prevents loose DF from 
floating away. The alcohol dissolves compact CD allowing embedded DF to become visible 
and easier to count. Fluorescein increases the proficiency of counting DF mites embedded 
in CD.51  
The modified Coston method was utilised for counting DF after eyelash epilation in 
all studies discussed in this thesis. Eyelashes were prepared and examined immediately 
after removal. 
1.8.3 Confocal Laser Scanning Microscopy 
Confocal laser scanning microscopy is a modern technique that has been used in recent 
years to detect DF in-vivo.16,65,146 It is a non-invasive technique in which a probe is 
positioned against the area of interest and the underlying tissue structure, at different depths, 
can be pictured with histological resolution.146 Confocal laser microscopy has the advantage 
of being less invasive than eyelash epilation, and may be more sensitive to detecting 
presence and quantity of Demodex.147 Although, several studies comparing laser confocal 
microscopy to the modified Coston method have found no significant difference in 
prevalence or quantity of DF detected between either method.16,65  
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1.8.4 Eyelash Manipulation 
Previous investigators have described the use of eyelash manipulation as an adjunct 
procedure prior to eyelash epilation in an attempt to stimulate DF, if present, to move 
towards the opening of the eyelash follicle.12,61 In 2013, Mastrota50 indicated that it was 
possible to view, on the slit-lamp biomicroscope, DF tails emerging from the eyelash 
follicles as the eyelash was rotated in-situ. This involved the rotation of the eyelash in 
clockwise and counter-clockwise directions using sterile forceps. If DF were present, this 
stimulated the mites to emerge from the eyelash follicles and could be seen on slit lamp 
magnification and counted. Anecdotally, higher magnifications on slit-lamps (x 40 mag) 
have been accepted as the required magnification to identify Demodex within the follicle.50 
However, in the current study it is possible to identify Demodex tails at lower 
magnifications also (circa x 16-24 mag). It has been noted, that eyelash epilation alone often 
results in miscounting, as many DF remain within the follicle after the eyelash has been 
removed.25,29,50 
Chapter 8 will discuss the clinical use of eyelash manipulation in the examination of 
Demodex blepharitis, showing that complete epilation of the eyelash is not always 
necessary in a clinical setting; and that eyelash manipulation may be a better indicator for 
severity of infestation than eyelash epilation. 
1.9 Current Treatment Methods 
1.9.1 Tea Tree Oil 
Tea tree oil is an essential oil that comes from the tea tree, Melaleuca alternifolia. It 
has been used historically among the Aborigines for its medicinal benefits. In more recent 
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years, investigators have attempted to examine the efficacy of TTO as an antibacterial, 
antimicrobial and anti-inflammatory agent, with promising results.53,148,149 Terpinen-4-ol 
has been found to be the active ingredient in TTO effective at killing DF.53 Studies have 
shown 50% TTO to be effective in reducing quantity of DF.6,13,15 This is an important 
discovery in the treatment of chronic, recalcitrant blepharitis. At present 50% TTO applied 
in-clinic by an experienced practitioner is the recommended treatment for Demodex 
blepharitis by the AAO and the College of Optometrists.1,3 However, the use of TTO at the 
eyelid margin is not without its disadvantages. It is toxic to the ocular surface, 3,150  can be 
irritating and uncomfortable for the patient,13,15 and needs to be applied weekly in-house by 
an expert clinician resulting in increased chair-time and cost to the patient. 
1.9.2 Ivermectin 
Ivermectin is a very effective anti-parasitic drug, and recent studies investigating the 
efficacy of ivermectin in treating DF infestation are showing promising results.34,36,38 
Single-dose oral ivermectin or combined therapy may be recommended treatment options 
for chronic, recalcitrant blepharitis or patients with poor compliance.34,36,38 However, 
ivermectin is a broad-spectrum anti-parasitic drug primarily prescribed to treat human 
threadworm, and control river-blindness.151 The use of ivermectin for the treatment of 
parasitic infections has been associated with several adverse reactions with varying degrees 
of severity: diarrhoea, dizziness, nausea, abdominal pain, hypotension, hepatitis, headache, 
paraesthesia, allergic reactions, ocular pain, skin swelling, tachycardia, breathing 
difficulties, fever, joint pain.152–157 The safety of ivermectin for use by pregnant and nursing 
mothers, and young children has not been well established and its use is therefore contra-
indicated by the Food and Drugs Administration (FDA).151 The FDA have also advised 
caution in the treatment of elderly individuals with ivermectin; as it is not well established 
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whether older individuals respond differently to younger individuals, and in general there 
is an increased frequency of hepatic, renal, cardiac or concomitant disease and other drug 
therapy in elderly patients.151  It does appear that the severity of adverse reactions is directly 
associated with the severity of parasitic infection, suggesting adverse reactions are due to 
the effect of dying parasites in the skin and not as a result of drug toxicity.153 The majority 
of these adverse reactions have been associated with severe parasitic infections such as river 
blindness and Lao filariasis in developing countries and may not apply to DF infestations.  
The off-label use of ivermectin in the treatment of Demodex blepharitis has been 
successfully examined in clinical studies.34,36,38 However, there is a need to be cautionary 
when prescribing the drug, and potentially only consider when other treatment options have 
been unsuccessful.  
1.9.3 Metronidazole 
Metronidazole is a commonly used anti-protozoal agent, prescribed for the treatment 
of bacterial vaginosis in non-pregnant women. However, several studies have investigated 
its efficacy at treating DF infestation.158–160 As with ivermectin it has some side effects 
which can be severe; nausea, vomiting, anorexia, dizziness, dry mouth, metallic taste, 
insomnia, vertigo have all been reported in the literature.161 Metronidazole is 
contraindicated in patients with a previous hyper-sensitivity reaction to other 
nitroimidazole derivatives;  in patients who have taken disulfiram concurrently; and alcohol 
use.162 Its use is also cautioned in patients with kidney and liver disease, blood disorders, 
pregnant and nursing mothers, and paediatric and geriatric patients.162 Metronidazole has 
been found to be carcinogenic in mice and rats; the FDA recommend avoiding un-necessary 
use of the drug.162  
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Recent studies have shown that ornidazole, an anti-amoebic agent from the same 
family as metronidazole, is a safer and more effective treatment option, with fewer side 
effects than metronidazole.160 Nausea, headache and dizziness have been reported in the 
literature.161 Also initial treatment with ornidazole and metronidazole causes an initial 
aggravation of facial inflammation due to foreign body reaction in the skin to dead mites; 
therefore anti-inflammatory therapy is also required with these treatments.160 However, 
ornidazole does not feature on the FDA register, the European Medicines Register, or the 
Irish Health Products Regulatory Authority register at present. 
1.9.4 Honey 
Honey has historically been used for dressing wounds due to its natural antimicrobial 
properties.163 However, it was dismissed in the 1970’s as harmless but ineffective,164 and 
has since begun to make its comeback.165 This is in part due to the recent growth of 
antibiotic resistant bacteria, promoting the need to look at ‘alternative’ antimicrobial 
options.165 Kanuka honey has shown to be effective as a topical treatment for rosacea.166 In 
2018, researchers in New Zealand found that methylglyoxal (MGOTM) Manuka honey is as 
effective at killing DF in vivo as 50% TTO.167 A micro-emulsion prepared for ocular use 
has also shown good antimicrobial potency, with no immediate adverse reactions noted 
when applied to rabbit eyes; thus leading the way for future studies to look at the efficacy 
of MGOTM Manuka honey for the treatment of blepharitis in human studies.168 
1.10 Conclusion 
As mentioned earlier, optometrists are increasingly managing blepharitis, including 
Demodex blepharitis, in practice, often without the need for further referral.11 As Demodex 
blepharitis gains increased recognition, practitioners are investigating for and treating it 
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more frequently. As mentioned in Section 1.1 and Section 1.9, the current guidelines 
available for practitioners recommend 50% TTO and/or ivermectin for treating Demodex 
blepharitis.1,3 However, as 50% TTO is toxic to the ocular surface and should be used with 
caution, and ivermectin would require a prescription and is not currently available for 
medical practitioners to administer in Ireland or the UK; the aim of this post-graduate 
research project was to examine if any other lid hygiene products, that could be comfortably 
recommended by practitioners for patients to use at home, were effective at treating 
Demodex blepharitis.  
On commencing this research project the vast majority of previous Demodex research, 
regarding associated risk factors and underlying health conditions, was focussed on 
Demodex within skin samples. There was limited literature available on ocular Demodex 
infestation and its associated risk factors. The main aim of the research project was to 
examine efficacy of treatments for Demodex blepharitis. However, as presence of ocular 
Demodex was being examined in participants, the opportunity was taken to look for 
commonalities within the population that may pre-dilect or prevent Demodex infestation. 
Research methodologies used throughout the course of this research project are 
discussed in Chapter 2. The products included in each study and reasoning for each is also 
discussed in Chapter 2.  The results on the safety and efficacy of lid hygiene products and 
warm compresses are discussed in Chapter 5, Chapter 6 and Chapter 7.   
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CHAPTER TWO: RESEARCH METHODOLOGY 
The research consisted of four recruitment phases; encompassing four prospective 
randomised interventional studies (discussed in Chapters 5, 6 and 7) and two observational 
studies (discussed in Chapters 3, 4 and 8). Inclusion and exclusion criteria varied for each 
phase of recruitment. Detailed inclusion and exclusion criteria are discussed for each phase 
in relevant chapters throughout. All participants involved in the research project were 
recruited through the National Optometry Centre’s student and private optometry clinics in 
the Technological University Dublin (TU Dublin). Informed consent was obtained from all 
participants prior to enrolment, to permit the use of their data pseudo-anonymously 
(participants were assigned a number-letter code) for research purposes (refer Appendix 1). 
All examinations and data analysis were conducted by the PhD Candidate (Murphy, O). 
New participants were recruited for each stage of the research project. All participants were 
Caucasian. Sample size calculations were carried out for each study and are described in 
detail in their relevant sections. A brief outline of the four recruitment phases of this 
research project is outlined in Table 3. below. The recruitment phases do not follow 
chronological order, as the recruitment phase four was a follow-on study from recruitment 
phase two. As such, results from recruitment phase four are discussed in Chapter 6. 
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Table 3. The four recruitment phases of the PhD research project. OCuSOFT® Lid 
Scrub® PLUS (OCuSOFT), Johnson’s® No More Tears® baby shampoo (baby 
shampoo), dr.organic® tea tree face wash (TTFW), MGDRx EyeBag® (Eyebag), 
OPTASETM Moist Heat Mask (Optase). 
Chapter  Aim Phase Treatment Duration 
No. of 
Participants 
Chapter 5 
Compare 
efficacy of 
treatments 
Phase One 
(Pilot 
Study) 
OCuSOFT vs 
baby shampoo 
Two 
weeks 
41 
Chapter 5 
Compare 
efficacy of 
treatments 
Phase Two 
OCuSOFT vs 
TTFW vs 
BlephExTM 
Four 
weeks 
86 
Chapter 6 
Evaluate the 
effect of 
treatments on the 
tear film and 
ocular surface 
Phase 
Four 
OCuSOFT vs 
TTFW vs baby 
shampoo 
Eight 
weeks 
48 
Chapter 7 
Compare 
efficacy of 
treatments 
Phase 
Three 
Eyebag vs Optase 
vs warm face 
cloth 
Eight 
weeks 
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2.1 Ethics Statement 
All studies described in this report were conducted under the Tenets of Helsinki 
Declaration of Human Studies169 after approval by the TU Dublin, formerly known as 
Dublin Institute of Technology, Research Ethics Committee (refer Appendix 2). 
2.2 Statistical Analysis 
All data was examined for normality using Shapiro Wilk statistical test. Parametric 
data is expressed as mean ± standard deviation (SD), non-parametric data is expressed as 
median and inter-quartile range (IQR) where relevant throughout the report. For all 
statistical tests p ≤ 0.05 was considered statistically significant unless otherwise stated. A 
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brief explanation of each of the statistical tests applied throughout the thesis are outlined 
below. 
One-way analysis of variance (ANOVA) was used on parametric data to examine for 
differences between the means of three or more independent groups, where the dependent 
variable was continuous or ordinal in nature. 
Repeated measures ANOVA was used for parametric data to compare means of 
repeated measurements. It was used to detect change after treatment at follow-up visits. 
Kruskal-Wallis (KW) statistical test was used as the non-parametric equivalent of a 
one-way ANOVA. It was used to examine for statistically significant difference between 
two or more groups of an independent variable with a continuous or ordinal dependent 
variable. 
Friedman’s was used as the non-parametric equivalent to the repeated measures 
ANOVA: used to detect change after treatment at follow-up visits.  
Wilcoxon Signed Ranks (WSR) test was used as the non-parametric equivalent of the 
paired t-test; to compare two related, matched or repeated measurements to examine for 
differences in their population mean ranks.  
Mann Whitney – U (MWU) test was used as the non-parametric equivalent of the 
independent t-test. It was used to compare two independent groups where the dependent 
variable was either continuous or ordinal. 
Spearman’s correlation (rs) was used to assess the strength and direction of a 
relationship between two continuous variables.  
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Chi-square (X2) analysis was used to examine the relationship between categorical or 
nominal variables.  
2.3 Examination 
The following sub-sections consist of a list of examinations that were carried out in 
order of least invasive to most invasive, in order to best preserve the integrity of each test, 
at each appointment.170,171 As the research progressed, several procedures were included or 
removed as required; this is highlighted where relevant throughout. 
2.3.1 Questionnaire 
The development and validation of the general health and lifestyle (GHL) 
questionnaire (refer Appendix 3) is discussed in Chapter 3. The development and validation 
of the modified ocular surface disease index (OSDI) symptom questionnaire (refer 
Appendix 4) is discussed in Chapter 4. The GHL questionnaire was completed by 
participants who took part in the pilot study and four-week treatment study: discussed in 
Chapter 5. The modified OSDI symptom questionnaire was completed by every participant, 
at every visit, throughout all of the studies. 
2.3.2 Habitual Visual Acuity 
Habitual visual acuity was measured as a means of monitoring the safety of treatments; 
ensuring the treatments did not have a negative effect on vision. Each participant’s habitual 
VA was measured using a Thompson logMar chart (Test Chart 2000, Thompson Software 
Solutions, London, UK). Habitual VA was defined as a participant’s general everyday 
distance vision: recorded as aided or unaided as appropriate. Best acuity was recorded using 
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letter by letter scoring with each letter corresponding to 0.02 logMar units.172,173  Due to 
time restrictions and number of appointments, refraction was not measured. 
2.3.3 Non-Invasive Tear Break-Up Time 
Non-invasive tear break-up time (NITBUT) is a method frequently utilised to assess 
the quality of the tear film.171 This was measured in seconds using the tear film analysis 
function on the Medmont E300 corneal topographer (Medmont International Pty Ltd., 
Victoria, Australia). The Medmont E300 has been shown to have a sensitivity of 81.5% and 
specificity of 94.4% for diagnosing DED, with good repeatability (coefficient of variation 
9.4%, 95% CI 7.1% - 14.0%).174 Looking straight ahead, participants were requested to 
focus on the central fixation target, blink twice gently and then to hold open their eyelids 
for as long as possible. An average of three readings were recorded for each eye, beginning 
with the right eye and alternating between them.174 Due to availability of equipment, 
NITBUT has only been measured for studies conducted in phase three and four only 
(Chapters 8 and 6 respectively). The system was calibrated by external technicians every 
six months, as required. 
2.3.4 Osmolarity 
Osmolarity refers to the concentration of dissolved particles in a solution. 
Hyperosmolarity of the tears occurs as a result of evaporation of aqueous tear from the 
ocular surface, or aqueous deficiency, or a combination of these.117 Increased tear 
osmolarity has been recognised as one of the hallmark signs of DED.175 Due to availability 
of equipment, the TearLabTM osmolarity system (TearLab Corporation, San Diego, 
California) was used in phases three and four of the research only (Chapter 7 and Chapter 
6, respectively). One measurement from each eye was taken. Participants were asked to 
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gaze superior-nasally, and a measurement was taken from the lower temporal tear meniscus 
in each eye. The recommended threshold, using the TearLabTM, most sensitive for detecting 
dry eye is 308 mOsm/L, with a sensitivity of 90.7% and specificity of 81.3%.176 Increasing 
inter-eye difference has been found to correlate with increasing disease severity: variability 
between two eyes in normal, mild to moderate dry eye and severe dry eye patients has been 
found to be 6.9 ± 5.9 mOsm/L, 11.7 ±10.9 mOsm/L, and 26.5 ± 22.7 mOsm/L, 
respectively.176  An inter-eye variability of ≥ 8mOsms/L is associated with tear film 
instability and dry eye: with the higher reading indicating greater disease severity.176,177 The 
eye with the highest tear osmolarity measurement at baseline was chosen as the study eye; 
and this eye was used for all data analysis in each relevant study. TearLabTM has been shown 
to provide repeatable and reproducible tear osmolarity measurements (coefficients of 
variation 1.6% - 1.9%).178 Quality control checks, as recommended by the manufacturer, 
were conducted: daily using the electronic check cards and with each new supply of test 
cards using the control solutions. 
2.3.5 Ocular Surface Staining and Fluorescein Tear Break-Up Time 
Ocular surface staining was assessed using fluorescein dye and graded using the 
Oxford Scheme.179 A fluorescein impregnated strip (Fluorets; Chauvin Pharmaceuticals, 
UK) was wetted with a single drop of saline. Excess saline was shaken off, and the tip of 
the strip was lightly touched off the lower bulbar conjunctiva while participants looked 
upwards. Fluorescein was instilled in the right eye first at each visit. Staining was assessed 
30 seconds after instillation.180 Corneal, nasal and temporal bulbar conjunctival staining 
were graded individually on a 6 point scale (0 - 5 for each location) to provide a composite 
score (0 - 15) for each eye.179 A yellow Wrattan filter was used to enhance any ocular 
staining present.181 The Oxford scheme is not widely used in clinical practice, however it 
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is recommended for grading ocular surface staining in clinical trials; as it uses a wider range 
of scores, thus allowing for the detection of smaller changes.182 
After staining was assessed fluorescein tear break-up time (TBUT) was measured. 
Fluorescein TBUT is an alternative method for measuring the evaporation rate of the tears. 
In many practices, using fluorescein is the only way practitioners have to determine TBUT. 
Participants were requested to blink twice and then hold their eyes open for as long as they 
could, during which time the tear film was observed and the time to the 1st visible dry spot 
appearing was counted.  This was measured in seconds using the slit lamp (x 24 mag) and 
a Wrattan filter. An average of three readings was recorded. Fluorescein TBUT was 
measured in phase one and two only (Chapter 5). As NITBUT is considered more accurate 
than fluorescein TBUT171; NITBUT was incorporated for the subsequent phases of 
research.  
2.3.6 Schirmer I 
The Schirmer I test is an invasive procedure, commonly used in dry eye clinics to 
measure a participants’ ability to produce tears. The Schirmer strip (Tear Flo; HUB 
Pharmaceutical, UK) was folded at the notch, and positioned into the lower lateral eyelid 
margin. Participants were asked to close their eyes,183 and the score was measured as the 
wetting length in mm/5 min. No anaesthetic was used. This was performed for phase three, 
MGD warm compress treatment study only (Chapter 8). The Schirmer test has been known 
for its poor repeatability. However, at the time of developing study protocol,  Schirmer 
remained on the recommended battery of dry eye tests according to DEWS I, and it had 
previously been used in many Demodex related studies (Table 1).  
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2.3.7 Cylindrical Dandruff 
As previously described in Section 1.7.2, CD is pathognomonic for DF infestation. 
The degree of CD present on the base of the eyelashes of each eyelid was graded as 
described by Milton Hom at the American Academy of Optometry annual meeting in 2013, 
on the diagnosis and treatment of Demodex infestation (Table 4).184 ‘Clumps’ refer to the 
joining of CD from two or more adjacent lashes to form one CD ‘clump’. 
Table 4. Cylindrical dandruff grading scheme (Milton Hom)184 
Grade Description 
G0 Normal, clean eyelid margin 
G1 Occasional fragments, 1 – 5 collarettes 
G2 Few fragments, 6 – 20 collarettes 
G3 
Many fragments, 21 – 40 collarettes ± 1 – 2 
clumps 
G4 > 3 clumps ± 40 collarettes 
 
2.3.8 Meibomian Gland Dysfunction Evaluation 
Slit-lamp bio-microscopy (Topcon SL-D701, Topcon Medical Systems Inc., Dublin, 
Ireland) was conducted to examine the meibomian glands in accordance with the diagnostic 
subcommittee of the International Workshop on Meibomian Gland Dysfunction185; firm 
digital pressure was applied to the centre of each eyelid margin, and the quality of meibum 
expressed and the number of glands expressible was graded on a four-point scale: Table 5. 
As recommended, composite scores derived from the expression of both upper and lower 
eyelids were generated and used for statistical analysis.185   
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Table 5. Meibomian gland dysfunction grading as recommended by the International 
Workshop on Meibomian Gland Dysfunction.185 
Grade Quality Expressibility 
G0 Clear fluid All glands expressible 
G1 Cloudy fluid 3 – 4 glands expressible 
G2 Cloudy particulate fluid 1 – 2 glands expressible 
G3 Inspissated like toothpaste No glands expressible 
2.3.9 Demodex Investigation 
Finally, each participant was assessed for the presence and quantity of DF. This 
involved the rotation of the eyelash in clockwise and counter-clockwise directions using 
sterile forceps. If DF were present, this stimulated them to emerge from the eyelash follicles 
and could be seen on slit lamp magnification (circa X 16 – 24 magnification). There is no 
gold standard method for manipulating eyelashes to investigate for the presence of DF. In 
an attempt to standardise eyelash manipulation, each eyelash was manipulated by rotating 
it four times anti-clockwise and then four times clockwise, in situ, using sterile forceps 
(Figure 6). 
 
Figure 6. Demodex folliculorum visible emerging from the follicle during eyelash 
manipulation with sterile forceps, black arrow (x24 mag). 
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Following this, the manipulated eyelashes were removed and placed on a microscope 
slide and counted using the modified Coston method described earlier (Section 1.8.2). This 
method was used to count DF in all studies described in this thesis. Chapter 8 compares the 
two techniques, eyelash manipulation and eyelash epilation, and their use in the 
investigation of DF blepharitis. 
Two eyelashes from each eyelid were removed at each visit in the pilot study (Chapter 
5). Only one eyelash was removed from each eyelid at each visit in the subsequent studies. 
This decision was made due to an increase in number of appointments, and therefore an 
increase in the number of eyelashes that would need to be removed. Many of the 
participants were older, some with chronic MGD and blepharitis and therefore had a 
reduced number of eyelashes. Hence, it was difficult to get participants to agree to have 
double the quantity of eyelashes removed at each visit.  
2.4 Treatments 
The most recent official guidelines for the initial management and treatment of all 
types of blepharitis from The College of Optometrists and the AAO in 2018 are to first 
advise warm compresses and eyelid cleansing; which can be accomplished in several ways, 
including diluted baby shampoo or dedicated commercial eyelid cleansers.1,3  If this is in-
effective topical/systemic antibiotic therapy followed by topical/systemic anti-
inflammatory therapy is advised. In recalcitrant cases, it is then recommended to consider 
Demodex as the underlying aetiology and treat accordingly. Products targeted at treating 
DF are continuously being developed and marketed. However, there is little evidence 
available that examines the efficacy of these treatments being administered to patients. The 
aim of this research is to investigate the safety and efficacy of several of these blepharitis 
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treatments available for the treatment of Demodex blepharitis. The treatments used 
throughout this study are described below. 
2.4.1 Baby Shampoo 
For years, lid scrubs with diluted baby shampoo was considered the ‘go-to’ or 
‘traditional’ method practitioners use to treat general blepharitis. As mentioned previously, 
it remains a recommendation on the guidelines developed for practitioners to use.1 
However, baby shampoo has no medicinal qualities; and furthermore, a recent study 
conducted by Sung et al186 discovered that long-term use of baby shampoo could have 
negative effects on the goblet cell function, thus causing damage to the ocular surface. 
However, at the time the studies were being developed, baby shampoo remained a 
recommendation for blepharitis treatment on the guidelines by the College of Optometrists 
in the UK. 
Baby shampoo was utilised in the phase one, pilot study (Chapter 5) and in phase four 
(Chapter 6) of this research project. Participants were provided with instructions to create 
a 10% solution of baby shampoo for home lid scrubs. These instructions can be seen in 
Appendix 5 (a) and Appendix 5 (b) for the pilot study and phase four, respectively. 
Guidelines given to participants for home lid scrubs with baby shampoo is described in 
Table 4. 
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Figure 7. Johnson’s® No More Tears® Baby shampoo. 
2.4.2 OCuSOFT® Lid Scrub® PLUS 
OCuSOFT wipes (Figure 8) were supplied by Scope Ophthalmics Ltd (Dublin, 
Ireland). The active ingredient in OCuSOFT is 1,2-Octanediol; a substance with 
pediculicide potential in as low as 1% concentration.187 At higher concentrations 1,2-
Octanediol is considered toxic to the ocular surface.150 A 0.5% concentration of 1,2-
Octanediol is used in OCuSOFT wipes to ensure the wipes are non-irritating, and their 
efficacy when used repeatedly for a period of time was examined. OCuSOFT wipes were 
utilised in the pilot study and the extended study to examine the efficacy against DF 
blepharitis (discussed in Chapter 5). OCuSOFT foam was utilised in phase four to examine 
the effect OCuSOFT has on the tear film and ocular surface (discussed in Chapter 6). The 
guidelines given to participants for home lid scrubs are described in Table 6. 
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Figure 8. OCuSOFT® Lid Scrub® PLUS. 
2.4.3 dr.organic® Tea Tree Face Wash 
The TTFW utilised in phase two and four of the research project (discussed in Chapters 
5 and 6, respectively) was supplied by dr.organic Ltd. (Swansea, UK) (Figure 9). The active 
ingredient in TTO, terpinen-4-ol, has been found to be effective at killing DF in a dose 
dependent manner.12,53 At the time of study development, previous studies had shown 50% 
TTO applied weekly was effective at reducing DF infestation,6,12,13 and a new lid wipe 
containing 0.5% terpinen-4-ol (Cliradex®) was showing promising results in the US,188 
however, it was not available for purchase in Ireland at the time. Chapter 5 examines the 
efficacy of daily lid scrubs with TTFW for the treatment of DF blepharitis. The TTFW used 
in this research project had a 38% concentration of terpinen-4-ol. The guidelines given to 
participants for home lid scrubs is described in Table 6. 
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Figure 9. dr.organic® Tea Tree Face Wash. 
 
Table 6. Home Lid Scrub Instructions. Step-by-step instructions provided to 
participants for nightly lid scrubs at home. Baby shampoo: Johnson’s® No More Tears®, 
OCuSOFT: OCuSOFT® Lid Scrub® PLUS, TTFW: dr.organic® tea tree face wash. 
 Control OCuSOFT Foam OCuSOFT Wipes 
TTFW/Baby 
shampoo 
Step 1: 
Using cooled 
boiled water, wet 
one of the cotton 
pads provided 
Place a small 
amount of 
OCuSOFT foam on 
a cotton pad 
Remove the 
OCuSOFT wipe 
from its packet 
Place a small 
amount of shampoo 
dilution/ face wash 
on a cotton pad 
Step 2: 
Gently but thoroughly scrub the eyelid and lash margin in circular movements, ensuring 
to scrub along the base of the eyelashes 
Step 3: 
Begin with the eyes closed to scrub along the top of the lashes. To scrub along the inner 
layer of lashes, look downwards to avoid contact with the cornea and gently pull the 
upper eyelid upwards. To scrub along the lower eyelashes, look upwards and gently pull 
down on the lower lid. 
Step 4: 
Using a clean 
cotton pad, repeat 
on the other eye 
This is a leave-on 
formula, do not rinse 
until morning 
This is a leave-on 
formula, do not rinse 
until morning 
Using a clean cotton 
pad, rinse the 
shampoo/face wash 
from the eyelids 
Step 5:  
Using a clean cotton 
pad, repeat on the 
other eye 
Using a new wipe, 
repeat on other eye 
Using a clean cotton 
pad, repeat on other 
eye 
 
 68 
 
2.4.4 Microblepharoexfoliation 
Microblepharoexfoliation is the mechanical debridement and exfoliation of the eyelash 
margin using a hand-held electromechanical unit189: BlephExTM (Figure 10). The 
BlephExTM device was utilised in phase two (Chapter 5), and was supplied by Scope 
Ophthalmics Ltd. (Dublin, Ireland).  
 
 
Figure 10. BlephExTM device. 
BlephExTM is a patented hand-held device, developed for the treatment of ocular 
surface disorders including blepharitis.190 Manufacturing guidelines and instructions for use 
are described in Table 7 
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Table 7. In – house microblepharoexfoliation procedure with BlephExTM, as per 
manufacturer’s guidelines. 
 BlephExTM Microblepharoexfoliation procedure 
Step 1: Soak the sterile micro-sponge tip in cleaning solution (OCuSOFT® Lid Scrub® 
Plus foam was used for this study) 
Step 2: Once soaked, insert one tip into the BlephExTM chuck 
Step 3: Instruct the patient to lean their head back. Treat one eyelid at a time, using a new 
tip for each lid. 
For the upper eyelid; gently pull up on the upper eyelid and instruct the patient to 
look downwards. 
For the lower eyelid; gently pull down on the lower eyelid and instruct the patient 
to look upwards. 
Step 4:  To scrub; apply the spinning micro-sponge to the edge of the eyelid and lash line 
and sweep from nasal to temporal and back again in a scrubbing motion for 20-30 
seconds or until as much debris as possible is removed.   
Step 5: After scrubbing with BlephExTM, clean the patient’s eyelids with saline to rinse off 
the formula. 
 
2.4.5 Warm Face Cloth 
Face cloths were utilised in phase three as part of the MGD treatment study, to act as 
a control ‘traditional’ style warm compress (Chapter 7). Each participant received a clean, 
new face cloth to use for the duration of the study. Participants were instructed to pour 
200ml of boiled water into a bowl and allow it to cool for 10 minutes before beginning 
treatment. This created a water temperature ranging from 50 °C to 39 °C over the 10-minute 
treatment time (tested using a HYGIPLAS Easy temperature pocket catering thermometer 
and porcelain bowl). Participants’ were then required to re-heat the face cloth every two 
minutes, by immersing it in the same bowl of cooled, boiled water: to maintain temperature 
at therapeutic levels.191,192 Each participant was directed to use the treatment for 10 minutes 
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twice a day for the first two weeks. Frequency of treatment was reduced to 10 minutes once 
a day from weeks three to eight. The instructions given to participants are attached in 
Appendix 6 (a). 
2.4.6 MGDRx EyeBag® 
The MGDRx EyeBag® (Eyebag) is a silk and cotton microwaveable device that has 
been shown to be a safe and effective treatment method for MGD (Figure 11).141 The 
Eyebag is filled with flax seed, providing a dry heat compress. Manufacturers recommend 
it for the relief of MGD, blepharitis, dry eye syndrome, and rosacea, amongst others. The 
Eyebags utilised in the MGD treatment study (Chapter 8) were supplied by Scope 
Ophthalmics Ltd. Participants were instructed to heat their compress in the microwave for 
15 – 30 seconds depending on the power of their microwave, as per manufacturers’ 
guidelines. Each participant was directed to use the treatment for 10 minutes twice a day 
for the first two weeks. Frequency of treatment was reduced to 10 minutes once a day from 
weeks three to eight. The step-by-step heating instructions given to participants are attached 
in Appendix 6 (b). 
 
Figure 11. MGDRx EyeBag® 
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2.4.7 OPTASETM Moist Heat Mask 
The OPTASETM Moist Heat Mask (Optase) is a microwaveable warm compress 
(Figure 12). It contains HydroBeadTM Technology, which absorbs moisture from the air, 
and when heated, releases the moisture to provide a natural moist heat. The manufacturers 
of Optase claim that the moist heat helps to soften and loosen collarettes in patients with 
anterior blepharitis and re-establishes moisture to the eye and surrounding area; while 
improving meibum flow, tear film quality and reducing tear film evaporation.193 The Optase 
masks utilised in the MGD treatment study (Chapter 8) were supplied by Scope 
Ophthalmics Ltd. Participants’ were instructed to heat their compress in the microwave for 
15 – 30 seconds depending on the power of their microwave, as per manufacturers’ 
guidelines. Each participant was directed to use the treatment for 10 minutes twice a day 
for the first two weeks. Frequency of treatment was reduced to 10 minutes once a day from 
weeks three to eight. The step-by-step heating instructions given to participants are attached 
in Appendix 6 (c). 
 
Figure 12. OPTASETM Moist Heat Mask 
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2.5 Summary 
This thesis focuses specifically on DF blepharitis and the safety and efficacy of the 
over-the-counter treatments listed above, in the treatment of DF blepharitis. The following 
Chapters 3 – 8 discuss the results of the interventional and observational studies that have 
stemmed from the four recruitment phases of this research project.  
Chapter 3 focusses on the development, validation and use of the GHL questionnaire 
and Chapter 4 on the development, validation and use of the modified OSDI questionnaire. 
A paper on the validation and use of the modified OSDI questionnaire has been published 
in International Ophthalmology (refer List of Publications). 
Chapter 5 discusses the results of the pilot study (phase one) and the extended four-
week treatment study (phase two). A paper on the results of the extended four-week study 
has been published in Contact Lens Anterior Eye (refer List of Publications). 
Chapter 6 examines the results of phase four of the research project: an extension of 
phase one and two, developed from peer-reviewed feedback received throughout the 
research project. This study extended treatment to eight weeks, eliminated the confounding 
effect of age on results, and facilitated the investigation of the effect eyelid hygiene had on 
the tear film and ocular surface. A paper discussing the results of this study has been 
recently accepted for publication in Contact Lens Anterior Eye (refer List of Publications). 
Chapter 7 discusses the effect of heat on DF infestation, and examines the efficacy of 
warm compresses in the treatment of DF blepharitis. A paper discussing the results of the 
effect of heat therapy on DF has been recently accepted for publication in Current Eye 
Research (refer List of Publications). 
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Finally, Chapter 8 considers the second observational finding derived from phase’s 
one and two: comparing eyelash manipulation and eyelash epilation in the examination of 
DF blepharitis. These techniques are both described in detail in Section 1.8.4 and Section 
1.8.2 respectively, and in Chapter 8. A paper discussing this observation has been accepted 
for publication in Eye & Contact Lens (refer List of Publications). 
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CHAPTER THREE: DEVELOPMENT AND VALIDATION OF A GENERAL 
HEALTH AND LIFESTYLE QUESTIONNAIRE FOR THE INVESTIGATION OF 
DEMODEX FOLLICULORUM BLEPHARITIS  
3.1 Abstract 
Purpose: To develop and validate a GHL questionnaire that could be used to evaluate 
the relationship between general health and lifestyle choices, and DF infestation. To 
determine the prevalence of DF infestation in an Irish population.  
Methods: One hundred and fifty-six participants were enrolled in an epidemiological 
cross-sectional prevalence study. Each participant completed the novel questionnaire on 
general health and lifestyle. Participants were assessed for the presence and quantity of DF. 
Data was analysed to search for significant links between general health and lifestyle and 
DF infestation. 
Results: The overall prevalence of DF detected was 67.99%. The total median number 
of DF detected was 1.00 mites (IQR: 0.00 – 5.00). Significant associations were found 
between the presence and quantity of DF with age (p = 0.001 and p < 0.001, respectively), 
and makeup (p = 0.03 and p = 0.04, respectively). No significant association was 
demonstrated between DF infestation and contact lens wear, frequency of bed linen hygiene 
or frequency of cleaning eyelids. The GHL questionnaire demonstrated moderate but 
acceptable inter-rater reliability (κ ≥ 0.61).  
Conclusion: Increasing age remains the most significant risk factor for DF infestation. 
Makeup may provide a preventative effect to reduce the occurrence of DF.  
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3.2 Introduction 
Demodex mites are common human ectoparasites, described in detail in Section 1.3 
and Section 1.4. Their clinical importance and association with underlying medical 
conditions is discussed in Section 1.6.3. As previously described in Section 1.5, although 
Demodex have been found in larger quantities in certain individuals, there remains a 
question mark surrounding their pathogenicity. Therefore, researchers are attempting to 
explain why certain individuals appear to be more susceptible to greater proliferation of 
mites, and therefore pathogenic DF infestation, than others. 
General health and lifestyle choices as risk factors for many ocular disorders have been 
well documented. Family history is a risk factor for some posterior eye diseases: age-related 
macular degeneration194  and glaucoma.195 Diabetes and high blood pressure are risk factors 
for potentially sight threatening vascular changes at the back of the eye.196 Laser surgery, 
contact lens wear, smoking, working in an air-conditioned environment are risk factors for 
dry eyes.121 Demodex folliculorum infestation is a relatively newly recognised condition, 
and researchers are currently investigating risk factors that may exist causing a predilection 
to higher or lower numbers of mites for an individual.  
Previous research has shown that factors such as increasing age (Section 1.6.1), health 
factors (Section 1.6.3), and contact lens wear (Section 1.6.4) are associated with increased 
risk of developing pathogenic DF infestation.13,20,24,77,108,113–115 It has also been suggested 
that the anatomical position of the eyelids, protected by the bony protrusion of the cheek 
and brow bones, creates an area that is unlikely to receive as vigorous a hygiene regime as 
the rest of the face: causing a potential habitat for increased DF numbers.61 To further 
strengthen this hypothesis, lower numbers of DF were found among participants with better 
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lid hygiene regardless of age.13,28 The routine use of makeup has also been associated with 
lower numbers of DF.79,116 To investigate these areas further, questions on type and 
frequency of lid hygiene, and use of makeup were included in the questionnaire. 
As mentioned previously in Section 1.3, DF are photophobic and most active at night 
while one is asleep.40,54 Therefore, it could be expected that DF may be found on pillow 
cases. Thus, the longer the period between changing pillowcases, the higher the potential 
for a greater risk for DF proliferation. Furthermore, the kill temperature of DF is between 
54 - 58 oC.197 Hence, in theory, cleaning bed-linen above this temperature would kill any 
DF present on the bed-linen and therefore potentially reduce the risk of DF proliferation. A 
previous study examining the role of water temperature in reducing dust mites found that 
temperatures below 45oC were ineffective.198 Questions regarding frequency and 
temperature of bed-linen cleaning, and method of drying bed-linen were included in the 
GHL questionnaire to investigate if there were any associations with DF infestation. 
The GHL questionnaire was developed in an effort to gain a better understanding of 
potential underlying risk factors for DF infestation (Appendix 3). These may provide the 
basis for a screening mechanism for the presence of DF in the future. 
3.3 Methods 
3.3.1 Examination 
Participants attending the National Optometry Centre private and student optometry 
clinics, and staff and students of TU Dublin were invited to take part in a cross-sectional 
prevalence study for DF blepharitis. Signed informed consent was received before 
participation. 
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Minimum sample size required for statistical significance was calculated using 
G*Power analysis. A priori analysis for two-tailed t test, difference between two 
independent means was conducted; alpha = 0.05, Power = 0.8, arbitrary effect size = 0.5; 
minimum sample size required n = 128. 
• Inclusion criteria: ≥ 18 years of age.  
• Exclusion criteria: participants presently being treated for blepharitis or who 
had used treatment in the past 6 months, active ocular infection (excluding 
blepharitis) or ocular surgery within the past 6 months.  
One hundred and fifty-six participants were examined between October 2014 and May 
2016. Seventy males and 86 females, with a median age of 45.00 years (IQR: 28.25 – 62.00) 
completed the novel questionnaire and were assessed for the presence of DF. Presence of 
DF was defined as: positive observation of DF on eyelash manipulation (Section 1.8.4) 
and/or one or more DF counted on microscopic examination (Section 1.8.2). The overall 
prevalence of DF, and any association between general health and lifestyle choices, and 
symptoms, and the presence and quantity of DF was examined. 
3.3.2 Questionnaire Development 
The GHL questionnaire was developed to observe potential correlations between DF 
and certain lifestyle choices and health status of participants’ (refer Appendix 3). 
Participants were questioned about the use of contact lenses, makeup, current lid hygiene 
regime, the presence of any medical conditions, and several other questions, to examine for 
potential risk factors for DF infestation. Participants were allowed to tick multiple answers 
on the GHL questionnaire where relevant. Answers from these questions may provide the 
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foundation for a screening mechanism for the presence of DF. It was not intended that the 
GHL questionnaire be used to assess the severity of DF infestation, if present.  
3.3.3 Questionnaire Validation 
Cross tabulation and Cohen’s kappa (κ) co-efficient were calculated to assess the inter-
rater reliability of the GHL questionnaire. These validation methods were chosen as they 
are appropriate for measuring agreement in categorical data.199 This was measured by 
giving the GHL questionnaire to 50 individuals not included in the study and asking them 
to repeat the questionnaire two weeks later with no change in their general circumstances. 
This sample size was below the desired number for several questions, this is discussed later 
as a limitation (Section 3.5.1). A value of ≥ 0.6 was desirable and considered to have a 
moderate level of agreement, ≥ 0.8 considered strong level of agreement and ≥ 0.9 was 
considered almost perfect agreement.200 
3.3.4 Statistical analysis 
Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS) version 25.0 (IBM Corp, Armonk, NY, USA). Data was assessed for normal 
distribution using Shapiro-Wilk. All outcome measures investigated were determined to 
have a non-normal distribution (p < 0.001). The data between categorical variables was 
assessed using X2 analysis. Between group data was assessed using the MWU test and KW 
test where appropriate. Spearman’s correlation co-efficient was used to assess scaled and 
continuous variables. All summarised continuous data was expressed as median and IQR, 
p ≤ 0.05 was considered statistically significant. 
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3.4 Results 
3.4.1 Questionnaire Validation 
Response frequencies and their respective κ values from the cross-tabulation of 
answers for the GHL questionnaire are shown in Table 8.  Questions on makeup and contact 
lens wear showed strong agreement. For all other questions, κ values fell between 0.61 – 
0.79, indicating a moderate but acceptable reliability.199
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Table 8. Cohen’s kappa co-efficient and cross-tabulation of test re-test results. 
 1st attempt: n, (%) 2nd attempt: n, (%) κ 
CL None, 
45(90%) 
Daily, 3 (6%) Two Weekly, 1 
(2%) 
Monthly, 1 
(2%) 
None, 46 
(92%) 
Daily, 2 (4%) Two Weekly, 
1 (2%) 
Monthly, 1 
(2%) 
0.88 
MU Yes, 23 (47%) No, 26 (53%) Yes, 24 (49%) No, 25 (51%) 0.92 
Lid 
Hygiene 
None, 
14 
(29%) 
Every 
Night, 24 
(49%) 
3-4 times a 
week, 4 
(8%) 
1-2 times a 
week, 5 
(10%) 
< once a 
week, 2 
(4%) 
None, 
12 
(24%) 
Every 
Night, 25 
(50%) 
3-4 times a 
week, 1 (2%) 
1-2 times a 
week, 5 
(10%) 
< once a 
week, 7 
(14%) 
0.63 
Type Lid 
Hygiene 
None, 
16 
(33%) 
C/T, 7 
(15%) 
MUR
, 4 
(8%) 
FW, 5 
(10%) 
JJ, 1 
(2%) 
Other, 8 
(17%) 
Multi, 7 
(15%) 
None, 
12 
(25%) 
C/T, 7 
(15%) 
MUR, 
1 (2%) 
FW, 8 
(17%) 
JJ, 1 
(1%) 
Other, 
12 
(25%) 
Multi, 7 
(15%) 
0.79 
Bed linen 
Freq 
> once a 
week, 4 
(8%) 
Once a 
week, 14 
(28%) 
Once a 
fortnight, 
20 (40%) 
Once a 
month, 11 
(22%) 
< once a 
month, 1 
(2%) 
> once a week, 
3 (6%) 
Once a 
week, 13 
(26%) 
Once a 
fortnight, 
19 (38%) 
Once a 
month, 
12 (24%) 
< once a 
month, 3 
(6%) 
0.72 
Temp No ≤ 30 oC, 7 (14%) 40 oC, 30 (61%) ≥ 60 oC, 12 (25%) ≤ 30 oC, 7 (14%) 40 oC, 26 (54%) ≥ 60 oC, 15 
(31%) 
0.66 
Linen 
Dried 
Air Dry, 27 
(54%) 
Tumble Dry, 
17 (34%) 
Laundrette, 
2 (4%) 
Air + Tumble 
Dry, 4 (8%) 
Air Dry, 30 
(60%) 
Tumble Dry, 
14 (28%) 
Laundrette, 
1 (2%) 
Air + Tumble 
Dry, 5 (10%) 
0.61 
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 1st attempt: n, (%) 2nd attempt: n, (%) κ 
Med 
Cond 
Yes, 4 (8%) No, 46 (92%) Yes, 5 (10%) No, 44 (90%) 0.63 
Meds Yes, 5 (10%) No, 45 (90%) Yes, 5 (10%) No, 45 (90%) 0.78 
Allergies None, 22 
(44%) 
SL, 11 
(22%) 
AA, 1 
(2%) 
SS, 4 
(8%) 
DT, 4 
(8%) 
MTPL, 8 
(16%) 
None, 23 
(47%) 
SL, 15 
(31%) 
AA, 1 
(2%) 
SS, 3 
(6%) 
DT, 1 
(2%) 
MTPL, 
6 (12%) 
0.65
2 
Skin 
Conds 
None, 
29 
(58%) 
ROS, 
9 
(18%) 
ECZ, 
4 
(8%) 
ANE, 
2 
(4%), 
PSRS, 0 
(0%) 
SnS, 5 
(10%) 
M, 1 
(2%) 
None, 32 
(64%) 
ROS, 
9 
(18%) 
ECZ, 
1 (2%) 
ANE, 
2 (4%) 
PSRS, 
1 (2%) 
SnS, 4 
(8%) 
M, 1 
(2%) 
0.76
4 
* κ = Cohen’s kappa; CL = Contact Lens Modality; MU = Makeup; Lid Hygiene: C/T = cleanser/toner, MUR = makeup remover, FW = 
face wipes, JJ = Johnson + Johnson lid scrubs, Other = other lid scrubs, Multi = multiple lid hygiene methods; Allergies: SL = seasonal, AA = 
asthma, SS = skin sensitivity, DT = dust, MTPL = multiple allergies; Skin conditions: ROS = rosacea, ECZ = eczema, ANE = acne, PSRS = 
psoriasis, SnS = sensitive skin, M = multiple skin conditions
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3.4.2 Questionnaire Application 
One hundred and fifty-six participants (median 45.00 years, IQR: 28.25 – 62.00) 
completed the questionnaire and were assessed for the presence and quantity of DF. An 
overall prevalence of 67.99% DF was detected amongst the study cohort. The overall 
quantity of DF discovered, per participant, on microscopic examination was median 1.00, 
IQR: 0.00 – 5.00. There was no significant difference in presence or quantity of DF between 
genders (p = 0.13 and p = 0.17, respectively) (refer Table 9).  
Table 9.  Comparison of age and presence and quantity of Demodex folliculorum for male 
and female study participants. Age (median, IQR), Demodex folliculorum quantity (median, 
IQR); A = Mann Whitney-U: B = Chi-square. 
 N Age (yrs.) Presence 
(%) 
Quantity 
Demodex (n)  
Male 70 44.50 (27.00 – 59.00) 74.29 2.00 (0.00 – 5.00) 
Female 86 45.50 (29.00 – 63.00) 62.79 1.00 (0.00 – 6.00) 
 p = 0.43 (A) p = 0.13 (B) p = 0.17 (A) 
  
There was a significant increase in prevalence of DF with increasing age (MWU; p < 
0.001). Similarly, there was also a low but significant correlation between increasing 
quantity of DF and increasing age (rs 0.39; p < 0.001) (refer Figure 13). 
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Figure 13. Correlation between increasing age and increasing quantity of Demodex 
folliculorum (rs 0.39; p < 0.001). 
 
Table 10.  shows the relationship between contact lens wear and DF. A slightly higher 
presence and quantity of DF was detected among the non-contact lens wearers. However, non-
contact lens wearers were significantly older than contact lens wearers (MWU: p = 0.046). 
Furthermore, the difference in DF presence and quantity between contact lens wearers and non-
contact lens wearers was not found to be significant (refer Table 10).   
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Table 10.  Contact lens wear descriptives: age, prevalence and quantity Demodex 
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR); A = 
Mann Whitney-U: B = Chi-square. *Significant results highlighted in bold. 
 N Age (yrs.) Prevalence (%) Quantity Demodex (n)  
No 128 46.00 (29.00 – 62.00) 69.67 2.00 (0.00 – 5.00) 
Yes 28 34.00 (25.50 – 48.00) 57.14 0.50 (0.00 – 4.00) 
 *p = 0.046 (A) p = 0.20 (B) p = 0.22 (A) 
 
Table 11 shows relationship between DF and makeup. Overall, the presence and 
quantity of DF was significantly lower amongst makeup wearers than non-makeup wearers 
(X2: p = 0.03 and MWU: p = 0.04, respectively). Age was not found to be an influencing 
factor in the result; but both male and female participants were included in the analysis.  
Table 11.  Overall makeup descriptives: age, prevalence Demodex folliculorum and 
quantity Demodex folliculorum. Age (median and IQR), Demodex folliculorum quantity 
(median, IQR);         A = Mann Whitney-U: B = Chi-square. *Significant results 
highlighted in bold. 
 N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
No 85 46.00 (29.00 – 62.00) 75.29 2.00 (0.00 – 7.00) 
Yes 71 40.00 (28.00 – 62.00) 59.15 1.00 (0.00 – 5.00) 
 p = 0.33 (A) *p = 0.03 (B) *p = 0.04 (A) 
 
 85 
 
Females accounted for 100% of makeup wearers, and 82.56% of females reported 
wearing makeup. When analysing for females alone, the presence and quantity was still 
lower amongst makeup wearers, although not significantly (X2: p = 0.13 and MWU: p = 
0.21, respectively). Furthermore, female makeup wearers were significantly younger than 
non-makeup wearers (MWU p = 0.005) (refer Table 12), which is likely to have impacted 
the results. 
Table 12.  Female-only makeup descriptives: age, prevalence and quantity Demodex 
folliculorum.  Age (median, IQR), Demodex folliculorum quantity (median, IQR); A = 
Mann Whitney-U: B = Chi-square. *Significant results highlighted in bold 
 N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
No 15 69.00 (55.00 – 70.00) 80.00 1.00 (0.00 – 10.00) 
Yes 71 40.00 (28.00 – 62.00) 59.15 1.00 (0.00 – 5.00) 
 *p = 0.005 (A) p = 0.13 (B) p = 0.21 (A) 
The majority of makeup wearers (63.38%) reported cleaning their eyelids every night, 
however, the frequency of eyeld hygiene among female makeup wearers was not found to 
be significant (KW p = 0.32). The most popular methods of removing makeup were: 
cleanser/toner (25.35%), eye makeup remover (25.35%) or a combination of methods 
(21.13%). The method of lid hygiene used by female makeup wearers was also not found 
to be significant (KW p = 0.30). 
The relationship between the presence and quantity of DF and wearing mascara was 
found to be significant (X2: p = 0.01 and KW: p = 0.01 respectively). As only females 
reported wearing mascara, only female participants were included in the analysis.  Post-hoc 
analysis demonstrated: quantity DF was lowest amongst participants using waterproof 
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mascara. Applying Bonferroni correction α ≤ 0.05/6 = 0.0083. The only significant 
difference in quantity of DF was between participants not wearing mascara (median: 3.50, 
IQR: 1.00 – 10.00) and those wearing waterproof mascara (mean: 0.00, IQR: 0.00 – 1.00) 
(MWU: p = 0.003). Similarly, these results are significantly influenced by age: those not 
wearing mascara were significantly older (MWU: p < 0.001). When analysing for female 
makeup wearers only, mascara and eyeliner were not found to be significant factors (KW 
p = 0.06 and p = 0.26, respectively). 
Table 13 illustrates the relationship found between presence and quantity of DF and 
reported frequency of eyelid hygiene. As can be seen from Table 13, those that reported the 
lowest frequency of eyelid hygiene demonstrated the highest presence (74.42%) and 
quantity (median: 3.00, IQR: 0.00 – 9.00) of DF, although the difference was not found to 
be significant (X2: p = 0.69 and KW: p = 0.35, respectively). Nonetheless, participants with 
the lowest frequency of eyelid hygiene appeared to be significantly older than those that 
reported more regular eyelid hygiene (KW: p = 0.02), which is likely to have influenced 
the result. However, after post-hoc analysis (with Bonferroni correction 0.05/10 = 0.005), 
none of the comparisons between the subgroups were found to be significant (MWU p > 
0.005 in all groups). Lid hygiene frequency was significantly associated with grade of CD 
(KW p = 0.02). After post-hoc analysis (with Bonferroni correction 0.05/10 = 0.005) the 
only significant difference was between participants who cleaned their eyelids nightly and 
those that never cleaned their eyelids (median CD grade: 0.00 IQR 0.00 – 1.00 versus 1.00 
IQR 0.00 – 2.00, respectively. MWU p = 0.001). 
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Table 13.  Frequency of lid hygiene descriptives: age, prevalence and quantity 
Demodex folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, 
IQR); A = Kruskal-Wallis: B = Chi-square. * Significant results highlighted in bold 
Nights/7 N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
0/7 43 55.00 (37.00 – 69.00) 74.42 3.00 (0.00 – 9.00) 
< 1/7 17 36.00 (25.00 – 46.00) 70.59 1.00 (0.00 – 5.00) 
1-2/7 14 49.00 (33.00 – 58.00) 71.43 3.00 (0.00 – 7.00) 
3-4/7 20 35.00 (24.00 – 47.50) 70.00 2.00 (0.00 – 5.00) 
6-7/7 62 44.00 (28.00 – 62.00) 61.29 1.00 (1.00 – 2.00) 
 *p = 0.02 (A) p = 0.69 (B) p = 0.35 (A) 
 
Table 14 examines the type of lid hygiene reported by participants. As can be seen 
from the results in Table 14, no significant relationship was found between type of lid 
hygiene and presence or quantity of DF.  
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Table 14.  Type of lid hygiene descriptives: age, prevalence and quantity Demodex 
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR);  
    A = Kruskal-Wallis: B = Chi-square. 
 N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
None 48 52.00 (30.50 – 66.00) 75.00 2.50 (0.00 – 9.00) 
Cleanser/
Toner 
20 35.00 (26.00 – 45.00) 40.00 0.00 (0.00 – 3.50) 
Makeup 
Remover 
18 34.00 (28.00 – 60.00) 61.11 0.50 (0.00 – 2.00) 
Face 
Wipes 
12 52.50 (25.00 – 63.00) 83.33 5.00 (1.00 – 7.50) 
J+J Lid 
Scrubs 
6 60.00 (48.00 – 69.00) 83.33 9.50 (1.00 – 15.00) 
Other Lid 
Scrubs 
5 46.00 (39.00 – 49.00) 60.00 1.00 (0.00 – 21.00) 
Other 
Method 
31 45.00 (31.00 – 59.00) 77.42 2.00 (0.00 – 5.00) 
Multiple 16 36.00 (27.50 – 55.00) 56.25 0.50 (0.00 – 6.50) 
 p = 0.24 (A) p = 0.71 (B) p = 0.06 (A) 
 
Table 15 presents the relationship between the frequency of cleaning bed linen and DF 
presence and quantity. One might expect higher prevalence and quantities of DF among 
participants who clean their bed linen less frequently. However, as can be seen from Table 
15, the frequency of cleaning bed linen did not influence presence or quantity of DF.  
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Table 15.  Frequency of bed linen cleaned descriptives: age, prevalence and quantity 
Demodex folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, 
IQR);         A = Kruskal-Wallis: B = Chi-square. 
Freq N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
> once a 
week 
38 45.00 (33.00 – 56.00) 73.68 1.50 (0.00 – 5.00) 
once a 
week 
46 46.50 (24.00 – 63.00) 65.22 1.00 (0.00 – 7.00) 
once a 
fortnight 
48 48.50 (31.50 – 67.50) 66.66 1.00 (0.00 – 3.50) 
once a 
month 
17 34.00 (30.00 – 51.00) 70.59 2.00 (0.00 – 6.00) 
< once a 
month 
7 62.00 (24.00 – 78.00) 57.14 2.00 (0.00 – 12.00) 
 p = 0.062 (A) p = 0.88 (B) p = 0.97 (A) 
 
Similarly, as DF are affected by higher temperatures, one might expect that the 
temperature bed linen is washed at could influence DF presence or quantity. Table 16.  
presents the relationship between temperature of bed linen washing and DF presence and 
quantity. Eleven participants reported not knowing what temperature the bed linen was 
washed at, and they were removed from analysis. As can be seen from Table 16, as the 
temperature increased, the prevalence of DF decreased. However, the difference between 
the groups was not found to be significant (X2: p = 0.06)  
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Table 16.  Temperature bed linen washed descriptives: age, prevalence and quantity 
Demodex folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, 
IQR);         A = Kruskal-Wallis: B = Chi-square. 
Temp (°C) N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
30  53 40.00 (24.00 – 60.00) 71.70 1.00 (1.00 – 6.00) 
40 66 43.50 (29.00 – 62.00) 66.70 2.00 (0.00 – 7.00) 
60 26 49.00 (33.00 – 62.00) 46.15 0.00 (0.00 – 2.00) 
 p = 0.34 (A) p = 0.06 (B) p = 0.10 (A) 
 
Table 17 examines the relationship between the presence and quantity of DF with self-
reported allergies: seasonal (hayfever), asthma, sensitive skin, dust or a combination of 
allergies. However, no significant relationship between allergies and presence or quantity 
of DF was detected. 
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Table 17.  Allergies descriptives: age, prevalence and quantity Demodex 
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR);                                                       
A = Kruskal-Wallis: B = Chi-square. 
Allergies N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
None 63 49.00 (31.00 – 64.00) 69.84 2.00 (0.00 – 5.00) 
Seasonal 13 44.00 (28.00 – 65.00) 76.92 1.00 (0.00 – 4.00) 
Asthma 6 29.50 (27.00 – 42.00) 33.33 0.00 (0.00 – 3.00) 
Skin 
Sensitivities 
13 52.00 (34.00 – 56.00) 61.54 1.00 (0.00 – 9.00) 
Dust 40 44.50 (22.00 – 60.00) 70.00 1.50 (0.00 – 8.00) 
Multiple 21 39.00 (33.00 – 60.00) 66.66 1.00 (0.00 – 7.00) 
 p = 0.21 (A) p = 0.52 (B) p = 0.79 (A) 
 
Table 18 illustrates the relationship between the presence and quantity of DF and self-
reported skin conditions. The current study did not find any association between DF and 
skin conditions. However, the numbers of individuals with skin conditions were limited 
(refer Table 18).  
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Table 18.  Skin conditions descriptives: age, prevalence and quantity Demodex folliculorum. 
Age (median, IQR), Demodex folliculorum quantity (median, IQR); A = Kruskal-Wallis: B = 
Chi-square. 
 N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
None 71 49.00 (30.00 – 63.00) 66.20 1.00 (0.00 – 4.00) 
Rosacea 6 60.00 (47.00 – 68.00) 83.33 6.00 (1.00 – 11.00) 
Dermatitis 1 24.00 (24.00 – 24.00) 100 1.00 (1.00 – 1.00) 
Eczema 4 31.50 (27.00 – 56.00) 75.00 4.50 (2.00 – 8.50) 
Acne 6 27.50 (23.00 – 39.00) 33.33 0.00 (0.00 – 1.00) 
Sensitive Skin 23 46.00 (33.00 – 59.00) 78.26 2.00 (1.00 – 5.00) 
Psoriasis 4 37.00 (29.00 – 45.50) 75.00 2.50 (0.00 – 5.00) 
Multiple 4 36.00 (28.00 – 54.00) 75.00 5.00 (1.00 – 12.50) 
Other 37 45.00 (22.00 – 60.00) 64.86 1.00 (0.00 – 8.00) 
 p = 0.07 (A) p = 0.64 (B) p = 0.54 (A) 
 
The current study found participants who reported an underlying systemic medical 
condition to have a significantly greater presence and quantity of DF (X2; p = 0.03 and 
MWU: p = 0.01, respectively) (refer Table 19). However, on further analysis this was 
significantly influenced by increasing age (MWU; p < 0.001). 
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Table 19.  Medical Conditions descriptives: age, prevalence and quantity Demodex 
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR);                         
A = Kruskal-Wallis: B = Chi-square. *Significant results highlighted in bold. 
 N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
No 93 37.00 (26.00 – 49.00) 63.44 1.00 (0.00 – 4.00) 
Yes 63 61.00 (40.00 – 70.00) 74.60 3.00 (0.00 – 9.00) 
 *p < 0.001 (A) *p = 0.03 (B) p* = 0.01 (A) 
 
3.5 Discussion 
The overall prevalence of DF detected in the current study (67.99%) was in good 
agreement with that previously reported in the literature. Similarly, Lee et al28 reported a 
general prevalence of 70% in their demographic epidemiology study. Kabataş et al46 
reported a prevalence of 67.2% in participants with blepharitis compared to 54.9% in 
control participants. Roth77 described a general prevalence of 84% that increased to 100%  
in participants over 70 years of age. The current study discovered a prevalence of 88.89% 
in participants over 70 years of age. 
Increasing age continues to be the most dominant risk factor for DF infestation.13,28,77 
The current study is in agreement with those of previous studies regarding significant 
associations between both presence and quantity of DF and increasing age.  As mentioned 
previously in Section 1.6.1, one potential reason for an increase in DF with age is the 
continued, progressive colonisation of DF within the epidermal hair follicles and sebaceous 
glands over the years. A second hypothesis is that changes in the skin and oil of older 
 94 
 
individuals may be more favourable to mite proliferation and widening of the follicle orifice 
may make detection on mites easier in older individuals.201 
The GHL questionnaire was developed to investigate potential correlations between 
DF and certain lifestyle choices, such as the use of makeup and contact lens wear, and the 
health status of participants. As mentioned earlier (Section 1.6.5), Elston and Elston79 
suggested that men were typically more heavily infested than women, due to a greater 
androgen–induced sebum production in men. The present study did find a higher prevalence 
among men, although it was not significant (X2; p = 0.13). Elston and Elston79 also proposed 
that the lipids in cosmetics may affect DF growth, and therefore could be responsible for 
the lower presence of DF found among women. Similarly, Horváth et al116 studied the risk 
factors of Demodex among young adults and also found that the use of makeup reduced the 
likelihood of Demodex infestation.  All makeup wearers in this study were women, and on 
further analysis, when gender was taken into consideration, the difference between makeup 
wearers and non-makeup wearers was not found to be significant. Given that 82.56% of 
females wore makeup, and none of the males reported wearing makeup, it cannot be ruled 
out that this influenced the slightly lower rate of DF infestation detected amongst females, 
and higher rate of DF infestation detected amongst the males in the study population.  
Previous studies have looked at the relationship between eye makeup usage and ocular 
discomfort and found that the use of eye makeup, such as eyeliner and mascara, was 
associated with ocular discomfort.202 However, to the best of the author’s knowledge, no 
previous studies have been conducted on whether wearing eyeliner or mascara is 
preventative or proliferative to DF infestation. The current study found a lower quantity of 
DF amongst females wearing mascara. However, those that did not wear mascara were 
older and would be naturally more pre-disposed to higher DF infestation rates. Therefore, 
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further age and sex matched control studies would be warranted to investigate any potential 
relationships. Theoretically, those that wear mascara may be more inclined to clean their 
eyelids at night, thus reducing the numbers of DF present. On the other hand, wearing 
makeup/mascara and not removing it could help harbour DF, thus increasing the risk of DF 
proliferation. As mentioned in Section 1.5, previous studies have shown an association 
between eyelid hygiene and Demodex infestation.13,28 However, the GHL questionnaire 
questioned participants on the frequency of eyelid hygiene, and no significant association 
was established between eyelid hygiene and DF infestation. 
Contact lens wear is becoming an increasingly popular form of refractive correction. 
Previous studies have found significant links between contact lens wearers and DF 
infestation.114,115 As such, the GHL questionnaire included questions regarding contact lens 
wear frequency and modality in order to further evaluate contact lens wear as a potential 
risk factor for DF proliferation. Jalbert and Rejab114 investigated the relationship between 
DF and contact lens wear; observing a higher density of DF among contact lens wearers. It 
was suggested that contact lens wearers may be at a higher risk of DF infestation as they 
handle their eyelids more frequently. However, the authors could not come to any further 
conclusion on their finding as they were unable to establish any association between DF 
infestation and other signs and symptoms of discomfort and DED.114 Conversely, 
Tarkowski et al115 discovered greater quantities of DF amongst contact lens wearers with 
discomfort, and previously successful contact lens wearers who dropped out due to 
discomfort, compared to contact lens wearers with no comfort issues. Therefore, in contact 
lens wearers who were previously comfortable, and begin to complain of discomfort, or 
completely drop-out of contact lens wear as a result of discomfort; it is worth investigating 
for the presence of DF and treating as required. In contrast to Jalbert and Rejab114, the 
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current study demonstrated lower numbers of DF among contact lens wearers. However, 
there were only 28 contact lens wearers involved in the study in comparison to 128 non-
lens wearers, and furthermore, contact lens wearers were significantly younger than the 
non-wearers. Thus, no real value could be taken from this finding. Further investigation 
into the relationship between contact lens wearers and DF is warranted. 
The GHL questionnaire also asked participants to report on frequency of cleaning bed 
linen and temperature at which bed linen was washed and dried, in an effort to uncover 
associations with DF. It was conceived that reduced frequency of cleaning bed linen, similar 
to lid hygiene, would be associated with increased prevalence of DF. As the kill temperature 
of DF is between 54-58 oC,197 it was also speculated that participants who commonly clean 
their bedlinen at temperatures ≥ 60 oC would have a lower prevalence of DF.  However, no 
association was found between frequency of cleaning bed linen or temperature at which the 
bed linen was washed and dried. Demodex folliculorum cannot survive outside of the human 
body for longer than a few hours.40 Therefore, it is unlikely that they would survive on a 
pillow case from one night to the next. Furthermore, cleaning bed linen at ≥ 60 oC is not 
likely to impact DF infestation on humans, as they are unlikely to survive outside of the 
body for prolonged periods of time.  
The current study did not find any association between DF and skin conditions or 
allergies. However, it has been well established previously in the literature that Demodex 
mites are associated with many pustular skin conditions.54,70,75,81,82 Therefore, it is important 
to consider Demodex when treating blepharitis in patients with a history of rosacea and 
papulo-pustular skin conditions. 
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There appears to be some discrepancy in the literature about the relationship between 
DF and the health status of an individual. As mentioned previously in Section 1.5.3, several 
studies have found an increased prevalence of DF among individuals with health 
conditions: a weakened immune system,91–93 renal failure,24,108 diabetes.20,106,107 Several 
case reports have found a high prevalence of DF causing rosacea like lesions in children 
with leukaemia92,97 and adults with AIDS and HIV.71,93,94 The results of these case reports 
suggest that an immune-deficient state favours increased numbers of DF. However, no 
significant difference in density of DF between healthy and immunocompromised patients 
has also been reported in the literature19,71; suggesting no significant relationship between 
DF infestation and patient immune status. In an adult who is naturally going to have higher 
density and prevalence of DF with time, it is difficult to quantify the contribution of a 
reduced immune system to density/prevalence of DF. Participants were questioned about 
systemic conditions such as high blood pressure, diabetes, and under-active thyroid. The 
current study found participants who reported underlying systemic medical conditions to 
be at a higher risk of increased numbers of DF; however, this was significantly influenced 
by increasing age, and the number of participants with medical conditions was too low to 
take any statistically relevant meaning from the results.  
3.5.1 Limitations 
The GHL questionnaire lacked a continuous structure throughout. Response items to 
questions varied from two to seven choice responses. This affected the minimum sample 
size required for statistical significance: higher numbers were required for the dichotomous 
questions.203 While further investigation into the relationship between DF infestation and 
for example; contact lens wear, makeup and lid hygiene is required, a new questionnaire 
with a solid structure and less ambiguous questions would need to be constructed. The use 
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of focus groups would be beneficial to check wording of questions during the design 
process for future questionnaires. Due to the limitations outlined above, the GHL 
questionnaire was not administered to participants in any of the subsequent recruitment 
phases. Furthermore, changes to exclusion criteria, such as excluding participants with 
underlying systemic conditions e.g. diabetes, meant the GHL questionnaire was no longer 
suitable for the study cohort being represented. 
3.6 Conclusion 
The novel questionnaire demonstrated moderate to good reliability. Several findings 
from the study would suggest possible associations that warrant further investigation: the 
association between makeup, mascara, and contact lens wear.  
Chapter 3 examined the relationship between DF and participant lifestyle choices, such 
as contact lens wear and makeup usage; general day to day habits, such as eyelid hygiene 
frequency and methods, frequency and temperature of cleaning bed linen; and underlying 
systemic conditions, such as medical conditions, allergies or skin conditions. In practice it 
is important to be aware of general risk factors for problematic DF infestation, such as 
increasing age and rosacea. However, it is also important to be able to recognise symptoms 
that may be more indicative of DF infestation. The next chapter, Chapter 40, will discuss 
the development and validation of a modified OSDI symptom questionnaire; and will 
examine it’s use in the detection of DF, and the association between DF infestation and 
symptoms, in particular the symptom ‘itchy eyes’.  
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CHAPTER 4: DEVELOPMENT AND VALIDATION OF A MODIFIED OCULAR 
SURFACE DISEASE INDEX SYMPTOM QUESTIONNAIRE FOR THE 
INVESTIGATION OF DEMODEX FOLLICULORUM BLEPHARITIS  
4.1 Abstract 
Purpose: To modify and validate the OSDI symptom questionnaire for use in the 
examination of the relationship between DF infestation and ocular symptoms. 
Methods: One hundred and fifty-six participants were enrolled in an epidemiological 
cross-sectional prevalence study. Each participant completed the modified OSDI symptom 
questionnaire. Participants were assessed for the presence and quantity of DF. Data was 
analysed to examine any association between DF infestation and ocular symptoms. 
Results: The overall prevalence of DF detected was 67.99%. The total median number 
of DF detected was 1.00 mites (IQR: 0.00 – 5.00). Participants with DF were more 
symptomatic (p = 0.04). The presence and quantity of DF was most significantly associated 
with the symptom ‘itchy eyes’ (p = 0.03 and p = 0.04 respectively). The modified OSDI 
questionnaire demonstrated good internal consistency (Cronbach’s alpha; α > 0.7) and good 
reliability (Intra-class Correlation Co-efficient; ICC > 0.7). A positive symptom result using 
the modified OSDI questionnaire exhibited a sensitivity and specificity of 70.75% and 
46.00%, respectively. 
Conclusion: Although not all participants with DF will become symptomatic, the 
prevalence of DF was significantly associated with an increase in symptoms, in particular 
the symptom ‘itchy eyes’. The newly developed modified OSDI symptom questionnaire is 
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reliable for measuring change in symptoms over a period of time and is suitable for 
monitoring patient self-reported outcomes in interventional treatment studies. 
4.2 Introduction 
Anterior blepharitis, MGD, aqueous deficient and evaporative dry eye, amongst other 
ocular abnormalities, share similar symptoms involving the ocular surface: itchiness, 
grittiness, inflammation, burning and foreign body sensations.13,49,204 This can cause 
difficulties for practitioners, to distinguish between each condition, if screening patients’ 
based on symptoms alone. Furthermore, dry eye is a multifactorial disease, and the 
symptoms of DED and ocular surface disease fluctuate, and often do not correlate well with 
the degree of ocular signs present.205–207 
As mentioned previously in Section1.7.4, individual symptoms reported by 
participants, and the severity of those symptoms can fluctuate depending on the underlying 
aetiology, and often, time of day.142 Blepharitis and MGD have been linked with symptoms 
of foreign body sensation and sticky eyes, commonly in the morning; whereas participants 
with aqueous deficient dry eye often report worsening of symptoms towards the evening.142 
Previous studies have found itchiness to be one of the most frequently reported symptoms 
associated with DF infestation.16,45–47 As suggested earlier (Section 1.6.4), this may be as a 
result of the movement of the mites across the surface of the skin. As Demodex are most 
active at night,54 this could potentially cause the severity of symptoms for participants 
suffering with pathogenic DF infestation to worsen at night, or in the morning, subsequent 
to the Demodex being most active.  
Patient reported outcomes have an increasingly important role in clinical trials.208,209 
Research has shown that observing patient reported outcomes after treatment is beneficial 
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for examining the effect of treatment on the patients.209 In 2011, the International Workshop 
on Meibomian Gland Dysfunction considered the significance of patient reported outcomes 
in clinical trials. A recommendation was made to try to ascertain distinctive symptoms for 
specific conditions: as the difficulty in discerning between symptoms of different anterior 
abnormalities is a continuous challenge.210  The modified OSDI symptom questionnaire 
was developed and validated, to assess the relationship between DF and dry eye symptoms. 
The questionnaire’s ability to function as a diagnostic screener for DF blepharitis, and its 
ability to detect change in symptoms post treatment were investigated. 
4.3 Methods 
4.3.1 Questionnaire Development 
The modified OSDI symptom questionnaire was adapted from the validated OSDI 
symptom questionnaire. The OSDI format was chosen as it has shown suitable repeatability 
and validity for assessing the severity of dry eye.211 Furthermore, it is one of the most 
commonly used symptom questionnaires that has been administered to participants in DF 
related clinical trials.13,28,114 In keeping with Lee et al28,  the questionnaire was modified to 
incorporate questions connecting to blepharitis (itchy eyes and matter along the eyelid 
margin), in order to augment the questionnaires sensitivity to detect DF. Questions from 
several other validated dry eye questionnaires were also included: McMonnies (dryness, 
burning), 5 – item dry eye questionnaire (DEQ-5) (dryness, watery), Standard Patient 
Evaluation of Eye Dryness (SPEED) (dryness, burning sensation, watery eyes). Equally, 
questions not found in previous dry eye questionnaires, such as itch and red eyes, were 
included due to increased reports of such symptoms previously in the literature (refer 
Appendix 4).13,49  
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As recommended by Schiffman et al211, a formula was applied to calculate the 
modified OSDI symptom score, described below; which in turn could be used to establish 
severity of symptoms.  
Total symptom number (A) x 25/number of questions answered (B).211,212 
The OSDI symptom score is marked from 0 – 100: increasing scores indicating 
increasing symptoms. Each question is marked on a 4 - point Likert scale, indicating 
frequency of the symptom in question: 0 = none of the time, 1 = some of the time, 2 = half 
of the time, 3 = most of the time, and 4 = all of the time. Since the formula takes into account 
the number of responses, it is possible to use the formula to get OSDI values for the separate 
sub-scales also.211 Questions from different sub-scales have also previously been merged 
to produce separate sub-scores using the OSDI formula.213 
To examine the relationship between DF and symptoms, the symptom results were 
analysed in three ways: the presence of symptoms, the total modified OSDI score, and the 
severity of symptoms. The presence of symptoms was described as asymptomatic or 
symptomatic (irrespective of severity). The total modified OSDI score was calculated using 
the formula described above. The severity of symptoms was categorised from the total 
modified OSDI symptom score as shown in Table 20. This classification was based on the 
minimal clinically important difference for the 12-item OSDI.214  
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Table 20. Severity of symptoms in accordance with the total modified OSDI score. 
Grade Modified OSDI Score 
G0: Asymptomatic 0 – 12 
G1 Mild 13 - 22 
G2: Moderate 23 - 32 
G3: Severe 33 - 100 
 
The modified OSDI questionnaire has been completed by all participants who have 
taken part in the research project.  
4.3.2 Questionnaire Validation 
For a symptom questionnaire to be suitable and fit for purpose it must be reliable, 
reproducible, and responsive and sensitive to change. That is to say, that any change in 
symptoms ascertained by the questionnaire is genuine, and not as a result of poor 
repeatability.121  
The reliability and reproducibility of the questionnaire was calculated in two ways. 
Firstly, Cronbach’s alpha (α) was used to determine the internal consistency of the 
questionnaire. In keeping with the literature, an alpha value > 0.7 was accepted.215,216 
Secondly, intra-class correlation co-efficient (ICC)217 and the test-retest method were used 
to determine the inter-rater reliability of the questionnaire; p < 0.4 indicated poor reliability, 
0.4 ≤ p ≥ 0.75 indicated fair to good reliability and p ≥ 0.75 indicated excellent reliability.218  
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The test-retest method post-treatment for both a treatment group and a non-treatment 
group was used to examine responsiveness and sensitivity to change. A two–tailed t–test 
was used to compare the means between the two groups (p < 0.05 significance). 
Factor analysis is a validation method used on questionnaires to determine if multiple 
variables (questions) have similar response patterns, and therefore load onto similar sub-
scales or ‘factors’. Factor analysis was conducted during validation of the original OSDI 
and was found to have three factors or sub-scales: ocular symptoms, vision related functions 
and environmental triggers.211 A factor analysis was applied to the modified questionnaire 
to determine if the sub-scales of the modified OSDI questionnaire were similar to the 
original OSDI. As the data was non-parametrically distributed, the ‘principal axis factoring’ 
extraction method was chosen.219 Principal axis factoring gives the least number of factors 
that can account for the correlation within a set of variables. Cronbach’s α was then applied 
to the overall questionnaire and to each subscale.  
In distinguishing between normal subjects and ‘all dry eye’ subjects OSDI has 
sensitivity and specificity values of 60% and 83% respectively.211 In distinguishing 
between normal subjects and ‘severe dry eye’ subjects OSDI has sensitivity and specificity 
values of 92% and 83% respectively.211 A receiver operating characteristics (ROC) curve 
was constructed to establish the sensitivity and specificity of the modified OSDI symptom 
questionnaire for the diagnosis of DF infestation.  
4.3.3 Statistical analysis 
Statistical analysis was performed using the SPSS (version 25.0). Data was assessed 
for normal distribution using Shapiro-Wilk. All outcome measures investigated were 
determined to have a non-normal distribution (p < 0.001). The data between categorical 
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variables was assessed using X2. Between group data was assessed using the MWU test and 
KW test where appropriate. Spearman’s correlation co-efficient was used to assess scaled 
and continuous variables. All summarised continuous data was expressed as median and 
IQR; p ≤ 0.05 was considered statistically significant. 
4.4 Results 
4.4.1 Questionnaire Validation 
Factor analysis was applied to the results from the 156 participants who filled out the 
questionnaire at least once, to determine if the sub-scales of the modified OSDI 
questionnaire were similar to the original OSDI. Factor analysis of the modified OSDI 
questionnaire displayed three sub-scales similar to the original OSDI questionnaire; ocular 
symptoms, vision related function and environmental triggers (refer Table 21).211 Burning 
sensation, discomfort in cold air and discomfort in air conditioned environments loaded on 
more than one factor. This was potentially due to the multi-factorial nature of dry eye and 
common crossover between symptoms and causes. 
 
 
 
 
 
 
 106 
 
Table 21. Factor analysis of the modified OSDI questionnaire. 
Symptom 
Factor 
Ocular Symptoms 
Vision Related 
Function 
Environmental 
Triggers 
Dryness 0.53   
Gritty/Irritated 0.70   
Itchy 0.64   
Red Eyes 0.55   
Burning Sensation 0.40 0.37  
Photophobia  0.34  
Watery   0.64 
Lids Stuck 
Together 
0.21   
Reading  0.72  
Night Driving  0.52  
Computer  0.75  
Television  0.50 0.24 
Wind   0.89 
Cold Air 0.23  0.61 
Air Conditioning 0.22 0.25 0.28 
Extraction method: Principal axis factoring; Rotation method: Oblimin with Kaiser 
normalisation; Kaiser-Meyer-Olkin measure of sampling adequacy: 0.78 
 
Cronbach’s α was applied to each subscale, and to the questionnaire as a whole. 
Cronbach’s α for the overall symptom questionnaire was good at 0.84, each of the subscales 
had a slightly lower α value, but were still > 0.7 (Table 22).215,216 
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Table 22. Reliability Analysis: Cronbach’s α measuring internal consistency, and 
Intraclass correlation coefficient measuring repeatability for the questionnaire. Results are 
shown for each sub-scale and for the overall questionnaire. All values > 0.7. 
 Internal 
consistency: 
Cronbach’s α (95% 
confidence interval) 
(n=156) 
Test-retest: Intra-class 
Correlation Co-
efficient (95% 
confidence interval)  
(n=50) 
Ocular symptoms 0.74 0.83 
Vision related 
function 
0.80 0.73 
Environmental 
triggers 
0.83 0.89 
Whole 
questionnaire 
0.84 0.90 
 
Fifty separate participants, not enrolled in any interventional treatment study, 
completed the questionnaire twice for the test-retest method to examine the reliability of 
the questionnaire. Participants completed the questionnaire two weeks apart, at the same 
time of day, with no change to their daily routines or general circumstances between testing. 
The test-retest reliability of the questionnaire was established by calculating the ICC (refer 
Table 22). All scores surpassed 0.7 which was the desired criteria to be met.218 
For the test-retest reliability assessment, it is expected that a participant’s condition 
remains stable between the first test and the retest: as no intervention has taken place. This 
is clear from the strong ICC value ascertained for total symptom score of 0.90. Taking this 
into account, a post-hoc ICC was performed to compare the repeatability of the total 
symptom score after two weeks of treatment in a separate interventional treatment study. It 
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was predicted that the correlation would be much weaker: as participants’ symptoms should 
have changed since commencing treatment. This hypothesis was confirmed with an ICC = 
0.66 < 0.89. A two-tailed t-test was applied to both sets of data. There was no significant 
difference in total symptom score in the test-retest group (p = 0.54). However, there was a 
highly significant difference in retest total symptom score in the group that received 
treatment (p < 0.001). The placebo effect of receiving treatment must be taken into 
consideration when assessing how effective treatments are at improving symptoms. This is 
discussed in further detail in Chapter 6. However, with regards to validating the 
questionnaire and evaluating its ability to measure change in subjective symptoms, the 
placebo effect is considered extraneous. 
The ROC curve was generated to assess the diagnostic capacity of the symptom 
questionnaire to examine for the presence of DF (refer Figure 14). The red line illustrates 
the ROC curve plotted from the study test results. Each point represents a 
sensitivity/specificity pair relating to a specific decision threshold. The closer the curve 
follows the y axis, especially towards the top, the greater the area under the curve and the 
more accurate the test. The closer the curve comes to the diagonal dotted line, the less 
accurate the test. The dotted line symbolises a worthless test result. A moderately flat ROC 
curve was formed, with an area under the curve of 0.61. A positive symptom result, that is 
≥ G1, gives a sensitivity of 70.75% and a specificity of 46.00% for the modified OSDI 
questionnaire. 
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Figure 14. Receiver operator characteristics curve demonstrates the ability of the 
modified OSDI questionnaire to assess for presence of Demodex folliculorum using 
symptom grade (Normal – Severe: 0 – 3). Area under the curve = 0.61.  
 
4.4.2 Questionnaire Application 
One hundred and fifty-six participants completed the questionnaire and were assessed 
for the presence and quantity of DF. An overall prevalence of 67.99% DF was detected 
amongst the study cohort. The median quantity of DF discovered, per participant, on 
microscopic examination was median 1.00, IQR 0.00 – 5.00. There was no significant 
difference in presence or quantity of DF between genders (p = 0.13 and p = 0.17, 
respectively) (refer Table 23). There was a significant increase in prevalence with 
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increasing age and symptoms (MWU; p < 0.001 and p = 0.05, respectively) (refer Table 
23).  
Table 23. Comparison of age and symptoms (presence and modified OSDI score) for 
subjects with and without Demodex folliculorum. Age (median, IQR), Demodex 
folliculorum quantity (median, IQR); A = Mann Whitney-U: B = Chi-square. *Significant 
results highlighted in bold. 
Demodex 
Present 
N Age (yrs) Prevalence 
Symptoms (%) 
Total Modified 
OSDI Score (0-100)  
No 54 29.00 (24.00 – 56.00) 54.00 13.33 (7.69 – 28.57) 
Yes 102 49.00 (34.00 – 66.00) 70.77 20.83 (10.00 – 39.29) 
 *p < 0.001 (A) *p = 0.04 (B) *p = 0.05 (A) 
 
Presence of Demodex folliculorum versus Symptoms: 
As shown in Table 23 above, and in Figure 15 below, there was a significantly higher 
proportion of symptomatic participants (≥ G1 modified OSDI symptom) amongst 
participants with DF than those without DF (70.77% versus 54.00%, X2; p = 0.04). In 
keeping with this, the total modified OSDI symptom score (0 – 100) was also found to be 
significantly higher in participants with DF in comparison to participants without DF (refer 
Table 23). Regardless of DF, symptomatic participants were also found to be significantly 
older than asymptomatic participants (49.00, IQR 33.00 – 66.00 versus 35.00, IQR 24.00 – 
57.00. MWU: p < 0.001). 
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Figure 15.  Percentage frequency distribution of symptomatic and asymptomatic 
participants, with and without DF. Participants with DF were significantly more 
symptomatic (X2; p = 0.04). 
The severity of symptoms (Grade 0 – 3) was also examined. Participants with DF were 
found to have a significantly greater severity of symptoms than those without DF (X2; p = 
0.04). As can be seen from Figure 16, this was most noticeable in the severe symptom 
group. Participants without DF were predominantly asymptomatic, followed by mild to 
moderately symptomatic, and only a small number (n = 7) were severely symptomatic. In 
contrast, participants with DF were predominantly symptomatic; the majority of which 
were severely symptomatic (n=35) (refer Figure 16). As can be seen from Figure 16, 
46.00% of participants without DF were asymptomatic and only 14.00% had severe 
symptoms. Only 29.24% of participants with DF were asymptomatic, however 32.07% had 
severe symptoms. It is also evident that the majority of symptomatic participants with DF 
were severely symptomatic. 
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Figure 16.  Percentage frequency distribution of grade of severity of symptoms 
amongst participants with and without Demodex folliculorum (X2; p = 0.04).  
 
The prevalence of individual symptoms reported by participants with and without DF 
is shown in Table 24. A significant association was detected between the symptom ‘itchy 
eyes’ and the presence of DF. ‘Itchy eyes’ was more commonly reported by participants 
with DF than those without (68.88% vs 52.00%) (X2; p = 0.03). However, the frequency of 
the symptom ‘itchy eyes’ was not found to be significantly associated with the presence of 
DF (X2; p = 0.13). Overall participants with ‘itchy eyes’ were not significantly older than 
those without ‘itchy eyes’ (KW; p = 0.83). However, participant’s with ‘itchy eyes’ and DF 
were significantly older than those with ‘itchy eyes’ and no DF (KW; p < 0.001). 
Asymptomatic individuals with DF were also older, but not significantly (KW; p = 0.30). 
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Table 24. Prevalence of symptoms reported by participants with and without 
Demodex folliculorum; *Significant results highlighted in bold. 
Symptoms 
Participants 
with DF (%) 
Participants 
without DF (%) 
P value (X2) 
Gritty / Irritated 72% 70% 0.69 
Itchy 69% 52% *0.03 
Dryness 68% 68% 0.88 
Wind 57% 62% 0.46 
Air Conditioning 55% 44% 0.25 
Watery 53% 60% 0.35 
Photophobia 45% 46% 0.96 
Red Eyes 45% 40% 0.38 
Computer 43% 40% 0.66 
Cold Air 43% 30% 0.17 
Problems Reading 42% 36% 0.30 
Television 42% 12% *< 0.001 
Burning Sensation 28% 18% 0.14 
Lids stuck together 21% 12% 0.18 
Night Driving 19% 8% 0.06 
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The functional vision symptom of ‘discomfort watching television’ was also found to 
be significantly associated with the presence of DF (41.55% vs 12.00%) (X2; p < 0.001). 
However, on further analysis, participants reporting symptoms of ‘discomfort when 
watching television’ were found to be significantly older than those without those 
symptoms (MWU; p = 0.01). Given that increasing age is one of the most significant risk 
factors for DF infestation; as the symptomatic group were older, they were naturally 
predisposed to having an increased presence of DF, and this is likely to have impacted this 
finding.13,77 
Quantity of Demodex folliculorum versus Symptoms: 
As mentioned previously, the median quantity of DF discovered, per participant, on 
microscopic examination was median 1.00, IQR 0.00 – 5.00. Although DF was detected on 
asymptomatic individuals, the median number of mites was significantly higher amongst 
symptomatic participants in comparison to asymptomatic participants (2.00 IQR 0.00 – 
7.00 versus 1.00 IQR 0.00 – 3.00. MWU; p = 0.02). A low positive correlation was 
established between quantity of DF and the total modified OSDI score; however, it was not 
found to be significant (rs = 0.12; p = 0.13). However, a low, but significant, positive 
correlation was ascertained between the quantity of DF and increasing severity of 
symptoms (rs = 0.16; p = 0.04) (refer Figure 17).  
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Figure 17. Scatter plot illustrating the positive correlation between symptom severity and 
quantity of Demodex folliculorum (rs = 0.16; p = 0.04). 
This correlation is expressed in the equation:  
Y = 0.0267 X (number of DF) + 1.2565 
According to the above formula, on average 1 DF mite = G1.28 symptoms: mild 
symptoms. On average an additional 28 mites are required to cause moderate symptoms, 
and an additional 38 mites (minimum 66 mites) are required to cause severe symptoms. 
A small, but significant, positive correlation was also established between the quantity 
of DF and the severity of ‘itchy eyes’ symptom (rs = 0.17; p = 0.04) (refer Figure 18).   
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Figure 18. Scatter plot illustrating the positive correlation between severity of ‘itch' and 
quantity of Demodex folliculorum (rs = 0.17; p = 0.04). 
Spearman’s correlation demonstrated an equation similar to the one above: 
Y = 0.0264 X (number of DF) + 1.0552 
Similarly, this equation proposes that 1 DF = G1.08 symptoms: ‘itchy eyes’ some of 
the time. On average an additional 36 mites, respectively, are required to cause respective 
increases in severity of symptoms. Thus, the above equations for severity of symptoms and 
severity of ‘itchy eyes’ demonstrates that just 1 DF has the ability to produce mild 
symptoms. However, due to the multifactorial nature of ocular surface disease, participants 
can be symptomatic in the absence of DF, as has been seen previously.  
A low, but significant, correlation was detected between increasing quantity of DF and 
increasing ‘discomfort when watching television’ (rs = 0.16; p = 0.04). Additional analysis 
demonstrated that this increase in quantity of DF was directly correlated to an increasing 
age for the same symptom (rs = 0.24; p = 0.003).  
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Time of day has been reported to have an effect on symptoms depending on the 
underlying aetiology.142 However, in the current study, time of day did not appear to affect 
symptoms with respect to DF. No other individual symptom was found to be significantly 
associated with the presence or quantity of DF. 
Pathogenic Infestation 
Previous studies have proposed that the presence of DF is not necessarily pathogenic; 
but that an increased quantity of DF causes pathogenic infestation.65,71 Incorporating the 
severity scale proposed by Randon et al65, ≥ 4 mites per follicle, data was investigated to 
look at the prevalence of pathogenic DF in the current study population; and any links 
between pathogenic DF infestation and age and symptoms (refer Table 25). 
Pathogenic DF infestation increased significantly with age. Participants with 
pathogenic DF infestation were found to be significantly older than participants with non-
pathogenic DF infestation (MWU; p = 0.01), and participants with no DF (MWU; p < 
0.001). Furthermore, participants with non-pathogenic DF infestation were older than 
participants with no DF (MWU; p = 0.07), but not significantly.  
Participants with either pathogenic or non-pathogenic DF were found to be more 
symptomatic than participants with no DF. Although the difference was not found to be 
significant for either group (MWU; p = 0.08 and p = 0.12 respectively). Similarly, the 
greatest prevalence of the symptom ‘itchy eyes’ was detected amongst participants with 
pathogenic DF. However, when compared to participants with no DF, this was not found 
to be significant (X2; p = 0.08). 
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Table 25.  Comparison of quantity of Demodex folliculorum, age, presence of symptoms, modified OSDI score, and presence of itch for 
participants with; no Demodex folliculorum, mild/normal non-pathogenic infestation, and pathogenic infestation of Demodex folliculorum. 
Continuous variables expressed as median and IQR. A = KW P value: B = X2 P value. *Significant results highlighted in bold.  
 
 
Frequency, 
n (%) 
Quantity mites, n  
Age, yrs 
 
Presence of 
Symptoms 
(%) 
Modified OSDI  
(0-100)  
Presence of 
Itch (%) 
No Demodex 
folliculorum 
50 (32%) 0.00 (0.00 – 0.00) 29.00 (26.00 – 46.00) 54.00 13.33 (11.67 – 23.22) 52.00 
Mild/Normal 
infestation 
(< 4 mites/follicle) 
39 (25%) 1.00 (1.00 – 2.00) 39.00 (35.00 – 52.00) 64.10 25.00 (15.00 – 35.00) 66.67 
Pathogenic 
infestation 
(≥ 4 mites/follicle) 
60 (38.5%) 8.00 (7.00 – 10.00) 52.50 (47.00 – 61.00) 75.00 20.00 (16.67 – 26.67 71.67 
Mites visible on lash 
manipulation but 
not on microscope 
7 (4.5%) 0.00 (0.00 – 0.00) 44.00 (40.00 – 63.00) 71.43 18.33 (8.33 – 81.25) 57.14 
   *< 0.001 (A) 0.14 (B) 0.27 (A) 0.16 (B) 
 119 
 
4.5 Discussion 
There is continued debate over the pathogenicity of the Demodex mites.49,66–68 The 
findings in this study are in agreement with previous authors29,30; that DF can be found 
amongst asymptomatic individuals. The current study discovered a median number of 1.00 
mites (IQR 1.00 – 3.00) amongst asymptomatic participants. As discussed earlier in Section 
1.5, Lacey et al66 suggested that generally DF is a commensal organism with a potentially 
beneficial role: consuming bacteria and other micro-organisms in the lash follicle. The 
presence of DF in normal healthy individuals appears to strengthen this proposal. Baima et 
al 67 proposed that DF becomes pathogenic to the host when quantities of DF increased 
beyond a critical level. With regards to dermatology and density of DF in the skin, Forton 
et al70 suggested that > 5 mites/cm2 was the critical level for pathogenic DF infestation. 
With regards to the eyelash follicles, Randon et al65 suggested the critical level to be ≥ 4 
mites per follicle. As demonstrated in previous studies13,28,46,47 and in the current study also, 
there was a positive association between increasing symptoms and increasing densities of 
DF; which adds to the suggestion that DF has pathogenic potential as the quantity of DF 
present increases. Additionally, as will be discussed in Chapter 5, symptoms were found to 
improve following treatment, further strengthening the case that the DF do have pathogenic 
potential.  
Sędzikowska et al47 recently published results of a large scale study exploring the 
relationship between DF and presence of symptoms as stated by patients, without the use 
of a questionnaire. The results proposed a minimum of seven DF mites per eight epilated 
eyelashes was required to produce one symptom, and a further 18 mites were required to 
produce a second symptom. In the same study, the authors did not quantify the severity of 
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symptoms reported by patients: intermittent vs constant, sometimes vs all of the time; 
merely the presence of the symptom.47 The present study examined the severity of 
symptoms reported by patients using the modified OSDI questionnaire. Applying similar 
statistical analysis to that applied by Sędzikowska et al47, the current study discovered a 
greater quantity (33) of DF was required to produce moderate symptoms. Although the 
results of both studies are in good agreement, that increasing quantities of DF cause 
increases in symptoms, they are not directly comparable: Sędzikowska et al47 counted DF 
mites on eight epilated eyelashes, whereas the present study counted DF mites on four 
epilated eyelashes. As previously mentioned in Section 2.3.9 only four eyelashes were 
epilated as most participants were requested to attend for multiple visits, and repeat tests 
over time, thus increasing the number of eyelashes that needed to be epilated. 
Although there is a positive correlation between symptoms and presence of DF, they 
are not ubiquitous with one another. Participants can be symptomatic in the absence of DF; 
and similarly, participants can be asymptomatic in the presence of DF. A prevalence of 
67.99% DF was found in the current study. Of those with DF, 70.77% (75/106) had 
symptoms (refer Figure 15). It is possible that chronic inflammation of the anterior ocular 
surface caused changes in corneal morphology,220 leading to corneal hypoesthesia; thus 
resulting in reduced symptoms in the presence of severe infestation and 
inflammation.175,221,222 Therefore, subjectively reported symptoms are not always in line 
with clinical signs of ocular surface disease; as was demonstrated in the present study. For 
example, of the 106 individuals with DF, the quantity of DF discovered on microscopic 
examination was similar between asymptomatic and symptomatic participants (3.00 IQR 
1.00 – 7.00 versus 4.00 IQR 1.00 – 9.00 mites, respectively; MWU; p = 0.19). It is possible, 
that chronic infestation and inflammation caused hypoesthesia at the ocular surface, 
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resulting in asymptomatic participants with increased quantities of DF. Although, as DF 
inhabit in the eyelash follicle, the scuttling, scratching movement of DF would be expected 
to cause an itching sensation: which would not likely be affected by corneal hypoesthesia. 
It is more likely that not all DF were removed during lash epilation. This limitation of 
eyelash epilation has been alluded to in previous studies.25,29,50 Throughout the present 
study, it became apparent, particularly in cases where lashes were loose in damaged 
follicles due to the presence of increased densities of DF, that the lash would fall away 
during eyelash rotation: leaving the DF behind inside the lash follicle. Subsequently, further 
investigation was conducted into the relationship between eyelash manipulation and 
eyelash epilation techniques used during Demodex investigation. This is discussed in detail 
in Chapter 8.  
Individual symptoms commonly associated with DF have been reported previously: 
itch, burning sensation, foreign body sensation, redness and crusts along the lid margins, 
blurred vision and misdirection of eyelashes.6,13,15,16,46,47,49 In a study conducted by Koo et 
al13 investigating the relationship between ocular discomfort and Demodex infestation, the 
authors found dryness (74.7%), itching (42.78%), and irritation (39.1%) were the most 
commonly reported symptoms described by participants with Demodex infestation. Kabataş 
et al46 reported redness (80%), itching (63.6%) and foreign body sensation (55.6%) as the 
most commonly reported symptoms in participants with DF infestation. Likewise, 
Sędzikowska et al47 reported similar symptoms, but at lower prevalence values: itching 
(28%), redness (21%), watery eyes (15%), and dryness (6%). It is not clear which symptom 
questionnaire was used by Kabataş et al46, and Sędzikowska et al47 did not use a 
questionnaire. Thus, symptom reporting was not prompted by the use of a questionnaire, 
but depended on each participant complaining of a symptom of their own accord: the likely 
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cause of the lower prevalence values reported in their study.47 The most common symptoms 
reported by participants with DF in the current study were gritty–irritated eyes (72%), 
followed by; itch (69%), dryness (68 %), watery (57%), photophobia (45%), red eyes 
(45%), burning sensation (28%), and lids stuck together (21%). Several of these symptoms 
were also commonly reported by participants that did not have any DF, and were not found 
to be significantly associated with DF (refer Table 24). However, in keeping with previous 
studies,16,46,47 the current study found that the symptom ‘itchy eyes’  was associated with 
an increased presence of DF. Furthermore, one of the main and novel findings of the current 
study was that the severity of ‘itchy eyes’ increased as the number of DF increased. This 
further strengthens the basis for ‘itchy eyes’ as a significant symptom of DF infestation.   
Dry eye is multi-factorial by nature and there can be discrepancy between signs and 
symptoms of dry eye.223 The current study did not investigate the influence of non-dry eye 
related symptoms. For example, the symptom ‘itchy eyes’ was also reported by many of 
the participants who did not have DF. Itch is one of the hallmark symptoms of allergy. As 
data collection took place over two years, it is possible that a history of allergy influenced 
the severity of the symptom ‘itchy eyes’. However, chi-square analysis did not find any 
significant correlation between the presence of allergy and the presence of general 
symptoms, or symptoms of ‘itchy eyes’ amongst participants that did not have DF (X2; p = 
0.79 and p = 0.09 respectively). The findings of the current study do not suggest that ‘itchy 
eyes’ should be considered a diagnostic symptom of DF infestation; simply that ‘itchy eyes’ 
seems to be a more common and repeatedly reported symptom amongst participants 
suffering with DF infestation. Furthermore, it is possible that the presence of the ‘itchy 
eyes’ is in fact an allergic reaction to the presence of DF within the eyelash follicles, which 
has been postulated previously.49,69 
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A low, but significant, correlation was detected between increasing quantity of DF and 
increasing ‘discomfort when watching television’. However, the total prevalence of 
‘discomfort when watching television’ was low (32%), even amongst participants with DF; 
and those that reported this symptom were significantly older. Therefore, it is likely that 
the confounding effect of age – related dry eye changes contributed to this finding. 
Nevertheless, presence and quantity of DF should still be considered as it is an age-related 
change, and very few control participants reported discomfort.   
The original OSDI questionnaire is one of the most commonly utilised symptom 
questionnaires in DF related clinical trials.13,28,114 Results from the current study, and 
previous studies outlined above, have established that a symptom of ‘itchy eyes’ is amongst 
the most frequent complaint in participants with DF. However, no question exists on the 
original OSDI to inquire about ‘itchy eyes’. Lee et al28 modified the OSDI questionnaire to 
include a question on ‘itchy eyes’, and demonstrated that the overall OSDI score was 
significantly associated with higher quantities of DF. Nonetheless, it was not clear if the 
questionnaire modified and used by Lee et al28 had been validated. Therefore, the current 
questionnaire was developed to include a question about ‘itchy eyes’ and has been validated 
as discussed above. As such, the modified OSDI questionnaire was used to assess 
symptoms in all the studies discussed in this thesis. 
4.6 Conclusion 
The novel modified OSDI questionnaire demonstrated good internal consistency 
(Cronbach’s α was > 0.7 for both the total questionnaire and each of the subscales) and 
good to very good repeatability (> 0.75) for both the total questionnaire and each of the 
subscales in the test-retest ICC. The strong repeatability aspect of the questionnaire 
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demonstrated that it can be employed as a valid method of observing subjective symptoms, 
following treatment, over time in a clinical setting. This is progressively becoming more 
important as patient reported outcomes become an essential element of patient-centred 
management in the health sector.208 
The questionnaire exhibited a reasonable sensitivity value of 70.75%, for correctly 
detecting participants with DF infestation. However, with regards to confirming the 
presence of DF infestation and establishing who requires further intervention, this would 
not be sufficient. A thorough clinical work-up, involving eyelash manipulation, will always 
be required for diagnosis but an awareness of risk factors for the disease will help 
practitioners to better diagnose, treat and advise their patients. 
The validation and use of the modified OSDI questionnaire have been published in 
International Ophthalmology (refer List of Publications). A significant link was established 
between the presence and quantity of DF, and severity of symptoms, using the modified 
OSDI questionnaire that was developed during this research project. ‘Itchy eyes’ was 
significantly associated with the presence of DF. In clinical practice it is important to 
consider the presence of DF in patients reporting ‘itchy eyes’. As such, it would be 
advisable to incorporate the modified OSDI questionnaire, or a similar questionnaire that 
contains questions on symptoms of itch, when managing and treating anterior ocular 
disorders such as blepharitis. Nonetheless, as mentioned previously, a detailed clinical 
work-up is still necessary for differential diagnosis between various anterior ocular 
disorders. 
As with many anterior ocular disorders, subjective symptoms are often similar and are 
not always present. As demonstrated in the current study, not all participants with DF were 
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symptomatic, even when infestation was apparently severe. The relationship between DF 
infestation and corneal hypoesthesia requires investigation, including research into the 
triggers that cause a patient to become symptomatic. 
Although not all DF infestation is symptomatic, and not all DF infestation requires 
intervention, it is important to be able to intervene in an effective manner when necessary. 
The following chapter, Chapter 5, will discuss the results of a two-week pilot treatment 
study and an extended four-week treatment study. The pilot study compared the efficacy of 
OCuSOFT with baby shampoo for treating DF blepharitis. The four-week study compared 
OCuSOFT, TTFW, and the effect of in-house microblepharoexfoliation treatment. The 
four-week treatment study has been published in Contact Lens Anterior Eye, and is adapted 
accordingly for Chapter 5. 
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CHAPTER 5: THE EFFICACY OF BABY SHAMPOO, OCUSOFT LID SCRUB 
PLUS, DR. ORGANIC TEA TREE FACE WASH AND 
MICROBLEPHAROEXFOLIATION IN THE TREATMENT OF DEMODEX 
FOLLICULORUM BLEPHARITIS 
5.1 Abstract 
Purpose: To investigate and compare the efficacy of baby shampoo, OCuSOFT, 
TTFW and microblepharoexfoliation at treating DF blepharitis. 
Methods: A randomised, controlled, examiner blind, two – week interventional, pilot 
study was conducted. Eighty-two eyes of 41 participants (21 male/20 female: median age 
45.00 years) were examined for signs and symptoms of DF. Participants completed the 
GHL and modified OSDI symptom questionnaires and were examined for the presence of 
DF. Eight eyelashes, two from each eyelid, were manipulated and epilated for microscopic 
examination. Adult DF count was recorded using the modified Coston method. Each 
participant was given the treatment (OCuSOFT) for one eye, and a control lid hygiene (10% 
solution baby shampoo) for the contra-lateral eye. Participants were advised to clean each 
eye, using the relevant treatment, nightly for a fortnight.  
Subsequently, 86 participants (38 males/48 females: median age 43.50 years) were 
enrolled in a randomised, controlled, examiner blind, four-week interventional treatment 
study. Participants completed the modified OSDI symptom questionnaire and were 
assessed for the presence of DF. One eyelash from each eyelid, right and left, were 
manipulated and epilated for microscopic examination, using the modified Coston method. 
Participants were divided into three groups according to treatment: TTFW (A) (n=28), 
OCuSOFT (B) (n=30), and in-house microblepharoexfoliation before nightly lid scrubs 
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with OCuSOFT (C) (n=28). Participants were advised to clean their eyelids nightly for four 
weeks with the specified treatment. Each participant was re-assessed for symptoms and 
presence of DF after two weeks and four weeks of treatment. 
Results: Demodex folliculorum was found on 61.00% of the 41 participants tested in 
the pilot study. The overall total median number of DF per participant found pre-treatment 
2.00 mites (IQR 0.00 – 8.00) There was no significant difference in quantity of DF pre-
treatment between the treatment and control groups (1.00 IQR: 0.00 – 3.00 and 1.00 IQR 
1.00 – 4.00 respectively, p = 0.77). The quantity of DF was significantly reduced post-
treatment to median 0.00 mites (IQR 0 .00 – 0.00) in the treated eye versus median 1.00 
mites (IQR 1.00 – 2.00) in the control eye (p = 0.01). The presence and quantity of DF was 
higher amongst symptomatic participants pre-treatment, but not significantly (p = > 0.05). 
Demodex folliculorum was detected on 80.23% of the 86 participants tested in the 
extended treatment study. The overall median quantity of DF found per participant pre-
treatment was 2.00 mites (IQR 2.00 – 5.00). There was no significant difference in quantity 
of DF between the three treatment groups pre-treatment (p = 0.22). The quantity of DF 
significantly reduced after four weeks of treatment in all three groups (p < 0.05). There was 
no difference in efficacy between the three treatments at reducing quantity of DF (p = 0.50). 
Subjective symptoms reported were significantly improved after two and four weeks of 
treatment in all three groups (p < 0.05). There was no difference in efficacy between the 
three treatments to reduce symptoms after two or four weeks (p > 0.50).  
Conclusion: There was a relatively high prevalence of DF discovered amongst both 
study cohorts. OCuSOFT applied nightly for two weeks significantly reduced the quantity 
of DF found post-treatment in the preliminary study, but it did not eradicate the presence 
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completely. Similarly, when treatment was extended to four weeks, all three methods tested 
demonstrated good ability to reduce DF quantity, improve subjective symptoms and help 
treat DF blepharitis. However, complete eradication was still not achieved. Baby shampoo 
demonstrated no therapeutic effect on DF infestation and alternative treatment options 
should be considered for the treatment of DF blepharitis. 
5.2 Introduction 
The structure and classification of DF has been described previously in Section 1.4. 
As mentioned, DF are ubiquitous to human skin, feed on sebum and epidermal skin cells 
and are therefore commonly found in larger quantities on the face: cheeks, nose, chin and 
eyelashes.42,43,55 Although often considered a normal saprophytic component of our 
biological flora and fauna,66–68 DF have also been noted as opportunistic parasites: 
proliferating and causing inflammatory reactions in susceptible individuals.69 As such, DF 
have been associated with inflammatory skin conditions such as rosacea,69,70,81 and 
inflammatory eyelid conditions such as anterior blepharitis.7,43,46,49 
Indications of ocular DF infestation reported in the literature include; CD, eyelash 
abnormalities, anterior and posterior blepharitis, MGD, conjunctival and eyelid 
hyperaemia, corneal superficial vascularisation and opacities.6,25,28,49,54,143 Symptoms of 
ocular DF infestation are similar to dry eye symptoms; itch, irritation, redness, burning 
sensation, visual disturbance.6,13,15,16,46,47 However, as was demonstrated in Chapetr 4 and 
previously in the literature,25,49 not all patients with DF will be symptomatic. This can lead 
to difficulties in deciding who requires treatment and when to begin.  
Several of the risk factors associated with DF infestation have been discussed 
previously in Section 1.6 and in Chapter 3. Age has consistently been found to be one of 
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the most significant risk factors for the presence of DF infestation.13,28,77  Due to increasing 
longevity, Demodex blepharitis in the elderly causing anterior eyelid abnormalities and 
subsequent dry eye, ocular discomfort and ocular morbidity will increase, resulting in an 
increased burden on the health system when patients seek treatment.121  
To date, the majority of interventional studies have researched treatment of 
Demodex skin infestation, with varying results.94,158–160,224–227 As mentioned previously in 
Section 1.8.1, in recent years, researchers have found TTO to be effective at killing DF,12,53 
and its use in treating DF blepharitis is expanding.6,13,15,228 It’s effectivity as a treatment is 
undeniable, but it is not without its disadvantages. Even at the diluted concentration of 50%, 
TTO is still toxic to the ocular surface. The College of Optometrists in the UK released 
guidelines for the use of TTO in practice stressing that “daily lid scrub with 50% tea tree 
oil … should be undertaken only by experienced practitioners as such preparations are 
toxic to the ocular surface”.3 Increased chair time with specialist practitioners can be costly 
to patients and or the governing health board. Also, the treatment experience can be 
uncomfortable for patients. Additional studies have examined the efficacy of other anti-
parasitic medications, such as ivermectin and metronidazole, with varying reports of 
success.34,36,38 However, the use of ivermectin and other systemic anti-parasitic drugs are 
not without their complications,152–157 and may not be suitable for all patients.151 Alternative 
therapies need to be available for those not suitable, or in countries were the drug has not 
yet been licensed for human use. 
There are many products available over-the-counter to consumers, marketed for the 
treatment of blepharitis. However, a systematic review recently carried out by Lindsley et 
al2 highlights the lack of knowledge and evidence based research available to clinicians 
regarding the commercial products available and marketed for the treatment of blepharitis. 
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The aim of the current study was to investigate the efficacy of different treatment methods 
at reducing the quantity of DF. This was a patient-outcome focused, clinically relevant 
study, with the potential benefit of being a more practitioner and patient friendly treatment 
alternative to TTO. This study will provide evidence-based results on the performance of 
commercial products available to patients and practitioners for the treatment of DF 
blepharitis in a clinical setting; demonstrating that optometrists and ophthalmologists are 
ideally placed to detect and begin first line treatment in many cases of DF infestation. 
5.3 Methods 
All participants were recruited through the National Optometry Centre, TU Dublin. 
Written informed consent was obtained from all participants prior to enrolment. Participants 
were eligible to participate if they were ≥ 18 years of age. Participants were excluded if 
they; presented with ocular disease (apart from MGD and blepharitis), were currently using 
blepharitis treatment or had used such treatment within the last six months or had ocular 
surgery in the last six months.  
5.3.1 Pilot Study 
Minimum sample size required for statistical significance was calculated using 
G*Power analysis. A priori analysis for repeated measures ANOVA between factors, two 
groups two measurements, was conducted; alpha = 0.05, Power = 0.8, arbitrary effect size 
= 0.5; minimum sample size required n = 26. 
Fifty participants enrolled between October 2014 and March 2015. Following attrition, 
41 participants completed the two-week treatment study. Each participant completed the 
GHL and modified OSDI symptom questionnaires. Severity of subjective symptoms was 
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graded according to the total modified OSDI symptom score (refer Table 20). Calculation 
of the total modified OSDI symptom score, using the formula, has been discussed in detail 
in Section 4.3.1. Slit lamp examination was conducted by one optometrist (the author: 
Murphy, O). Clinical findings recorded were: conjunctival hyperaemia, MGD grade, CD, 
and fluorescein TBUT. Tear break-up time was measured in seconds, approximately one 
minute after the instillation of fluorescein. An average of three measurements was recorded. 
Demodex investigation involved examining eight eyelashes, two from each eyelid, on a slit-
lamp biomicroscope (Topcon SL-D701, Topcon Medical Systems Inc., Dublin, Ireland). 
Each eyelash was first manipulated (as described in Section 1.7.4) using sterile forceps and 
was subsequently epilated for microscopic examination. Adult DF count was recorded 
using the modified Coston method (described in Section 1.8.2).25 
Each participant received a treatment pack containing both the treatment (OCuSOFT) 
and a control lid scrub (10% baby shampoo) to use nightly for two weeks. In order to ensure 
10% was used, vials with the exact measurement of shampoo were made up by the author 
(Murphy, O) and instructions were given to patients on how to fill with water at home and 
scrub the eyes (refer Appendix 5 (a)). The treated eye was randomised and blind to the 
examiner. Participants returned following two weeks treatment and the process was 
repeated and findings were recorded.  
Following peer-review feedback received on the results of the pilot study, suggested 
changes were incorporated, and the extended treatment study was developed. Firstly, the 
study was extended to four weeks, to ensure sufficient time was given to tackle DF 
infestation, given their lifespan is 14 – 18 days.40,42,43,61 Secondly, both eyes were treated 
with the same treatment, to prevent cross-contamination through migration of DF from 
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control eye to the treated eye. Thirdly, reviewers suggested comparing OCuSOFT to a tea 
tree-based product (TTFW) as opposed to baby shampoo.  
5.3.2 Extended Study 
Minimum sample size required for statistical significance was calculated using 
G*Power analysis. Effect size was calculated from the mean difference in quantity of DF, 
pre and post treatment, from the treatment group in the pilot study and the SD of the pre-
treatment group. The pre-treatment group was chosen as it is representative of the 
population not affected by experimental intervention: (2.32 – 0.66)/ 3.30 = 0.50. A priori 
analysis for repeated measures ANOVA between factors, three groups two measurements, 
was conducted; alpha = 0.05, Power = 0.8, effect size = 0.5; minimum sample size required 
n = 33.  
One hundred and six participants enrolled between May 2015 and May 2017. 
Following attrition, 86 participants completed the four-week extended treatment study. As 
with the pilot study, each participant completed the modified OSDI symptom questionnaire. 
Participants underwent the same slit-lamp examination described above, and likewise were 
examined for the presence of DF as previously described.  
Participants were randomly divided into three groups according to treatment: TTFW 
(Group A, n = 28), OCuSOFT (Group B, n = 30) and BlephExTM microblepharoexfoliation 
device (Group C, n = 28). Each treatment has been previously discussed in detail in Section 
2.4. Randomisation was achieved using the random number generator function on Excel. 
Each treatment was randomly assigned a number from 1 to 108. Each participant chose a 
number and was subsequently given the treatment assigned to that number. The examiner 
(author; Murphy, O) was blind to the treatment throughout all stages of the study for Groups 
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A+B. The examiner performed the BlephExTM treatment on participants in Group C and 
was therefore not blind to treatment in this group. 
The lid scrub routine was previously outlined in Table 6. In house 
microblepharoexfoliation was carried out on Group C at the initial visit only. The procedure 
was conducted as per manufacturer’s guidelines (refer Table 7). All participants returned 
for a check-up appointment at two weeks and again for a final check at four weeks. 
5.3.3 Statistical Analysis 
Statistical analysis was performed using the SPSS (version 25.0). Data was assessed 
for normal distribution using Shapiro-Wilk. All outcome measures investigated were 
determined to have a non-normal distribution (p < 0.001). All summarised continuous data 
was expressed as median and IQR. Between group data was assessed using the MWU test 
and KW test where appropriate. Wilcoxon-signed ranks test (WSR) was used to analyse 
within group data. The data between categorical variables was assessed using X2 analysis. 
Spearman’s correlation co-efficient was used to assess scaled and continuous variables; p 
≤ 0.05 was considered statistically significant. 
5.4 Results 
5.4.1 Pilot Study 
Forty-one participants (21 males: 20 females) with a median age of 45.00 years 
enrolled in the two-week pilot treatment study. At baseline, an overall prevalence of 68.23% 
DF was found, with a median quantity of 2.00 mites (IQR 0.00 – 8.00) per participant 
detected. Demodex folliculorum was discovered on 14 males (66.67%) and 11 females 
(55.00%) (X2; p = 0.28). 
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Table 26.  Comparison of age, gender and symptoms for subjects with and without 
Demodex folliculorum: Pilot Study. Age (median and IQR); A = Mann Whitney-U: B = 
Chi-square. *Significant results highlighted in bold.  
Demodex 
Present 
(n) 
Age (yrs.) Modified OSDI score 
(0-100) 
Presence 
Symptom  
No (n = 13) 27.00 (22.00 – 55.00) 10.00 (6.67 – 13.89) 40.63% 
Yes (n = 28) 50.50 (45.00 – 59.00) 15.83 (11.67 – 21.67) 58.00% 
 *p = 0.02 (A) *p = 0.02 (A) p = 0.13 (B) 
 
As can be seen in Table 26 above, participants with DF were significantly older than 
those without (MWU: p = 0.02). Increasing age was also significantly associated with 
increasing quantity of DF (rs = 0.44, p = 0.004). Figure 19 illustrates the positive 
relationship between increasing quantity of DF and increasing age.  
 
Figure 19. Scatter plot illustrating the positive correlation between increasing age and 
increasing quantity of Demodex folliculorum. 
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At baseline, participants with DF had a significantly greater modified OSDI score than 
those without (MWU: p = 0.02).  (refer Table 26). However, no significant correlation was 
detected between increasing quantity of DF and increasing modified OSDI score (rs = 0.21: 
p = 0.19). Likewise, there was no association found between quantity of DF and severity of 
symptoms (KW: p = 0.38). 
Bulbar conjunctival hyperaemia was graded using the Efron grading scale. Presence 
and quantity of DF were not significantly associated with conjunctival hyperaemia (X2 p = 
0.312 and rs = 0.074 p = 0.508). Most subjects with DF did have trace or mild conjunctival 
hyperaemia; however, overall most subjects had trace or mild conjunctival hyperaemia 
(refer Figure 20). A low positive correlation was detected between quantity of DF and 
severity of conjunctival hyperaemia, but it was not significant (rs = 0.074 p = 0.508). 
 
Figure 20. Bar chart illustrating the relationship between presence of Demodex 
folliculorum and severity of conjunctival hyperaemia (X2 p = 0.312). 
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As mentioned previously, CD has been established as a pathognomonic sign for DF.25 
As expected, both the presence and quantity of DF were significantly associated with 
increased severity of CD (X2: p < 0.001 and rs = 0.68: p < 0.001 respectively).  Figure 21 
illustrates the significant relationship between presence of DF and grade of CD. As can be 
seen from Figure 11, the majority of participants without CD also had no DF, and ≥ G2 CD 
was considerably associated with the presence of DF. The definition of CD severity grades 
applied in the study can be seen in Table 4 
 
Figure 21. Bar chart illustrating the relationship between presence of Demodex 
folliculorum and severity of cylindrical dandruff (X2 p < 0.001). 
 
Figure 22 demonstrates the correlation between quantity of DF and severity of CD. As 
can be seen from Figure 22, the quantity of DF increases significantly with increasing 
severity of CD (rs = 0.68, p < 0.001).  
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Figure 22. Box plot illustrating the relationship between quantity of Demodex 
folliculorum and severity of cylindrical dandruff (rs = 0.68, p < 0.001). 
 
Similarly, there was a significant relationship detected between presence and quantity 
of DF and MGD (X2 p = 0.01 and rs = 0.23, p = 0.04 respectively) (refer Figure 23).  There 
was no significant relationship demonstrated between DF presence or quantity and TBUT 
(MWU: p = 0.38 and rs = 0.11: p = 0.50 respectively). 
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Figure 23. Box plot illustrating the relationship between quantity of Demodex 
folliculorum and meibomian gland dysfunction (rs = 0.23, p = 0.04). 
 
Other significant findings from the pilot study included: a higher quantity of DF 
detected amongst participants who cleaned their bed linen more frequently (KW: p = 
0.002), and a lower presence and quantity of DF amongst participants who wore makeup 
compared to those that didn’t (X2 p = 0.03 and MWU p = 0.01) (refer Figure 24). However, 
further analysis showed increasing age was a significant factor amongst those that wore 
makeup and cleaned their bed linen more frequently, which is likely to have skewed that 
result (MWU: p = 0.002 and KW: p = 0.03). No significant relationship was found between 
frequency of eyelid hygiene and presence or quantity of DF (KW p = 0.77).  
Figure 24 shows a box plot illustrating the quantity of DF amongst female makeup 
wearers and non-makeup wearers. Males were excluded from this analysis as no males in 
the study reported wearing makeup. Females who wore makeup demonstrated a lower 
prevalence of DF infestation (45.22% versus 80.00%; X2: p = 0.05) and quantity of DF 
 139 
 
(median 0.00 IQR 0.00 – 2.00 versus median 4.00 IQR 3.25 – 6.00; MWU p = 0.006). 
Participants who wore makeup were younger, but not significantly (47.00 years IQR 33.00 
– 56.00 versus 57.00 years IQR 51.00 – 69.00. MWU: p = 0.07). 
 
Figure 24.  Box plot illustrating quantity of Demodex folliculorum found amongst 
female makeup wearers and non-makeup wearers. 
 
Each participant was given two treatments, OCuSOFT and 10% baby shampoo, one to 
use on each eye nightly for two weeks, to assess the efficacy of each treatment against DF 
infestation. Pre and post treatment results for DF quantity can be seen in Table 27. There 
was no significant difference in mean number of DF pre-treatment between the treatment 
and control eye. OCuSOFT demonstrated better efficacy at treating DF infestation than 
baby shampoo (refer Table 27). The presence of DF pre-treatment in the OCuSOFT eye 
was 65.85%. This dropped slightly to 51.22% post-treatment, but complete eradication of 
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DF was not achieved. Baby shampoo had no impact on DF infestation. Presence of DF in 
the baby shampoo cohort was 56.10% pre-treatment and 58.54% post-treatment.  
Table 27. Quantity of Demodex folliculorum detected pre-treatment and post-
treatment for each treatment group. 
 OCuSOFT Baby shampoo p - value 
Quantity 
Demodex 
folliculorum 
Pre 1.00 (0.00 – 3.00) 1.00 (0.00 – 4.00) MWU p = 0.77 
Post 0.00 (0.00 – 0.00) 1.00 (1.00 – 2.00) MWU p = 0.01* 
p - value WSR p = 0.001* WSR p = 0.71  
 
5.4.2 Extended Study 
Eighty-six participants (median age 43.50 years (IQR 29.00 – 63.50), 38 male:48 
female) completed the four-week extended treatment study. Each participant completed the 
GHL and modified OSDI questionnaires at baseline and were examined for signs of dry 
eye and DF. At baseline, an overall prevalence of 80.23% DF was found, with a median 
quantity of 2.00 mites (IQR 2.00 – 5.00) per participant detected. 
There was no significant difference detected between presence or quantity of DF and: 
contact lens wear (X2: p = 0.28 and MWU: p = 0.96, respectively), use of makeup (X2: p = 
0.19 and MWU: p = 0.36, respectively), frequency of lid hygiene (X2: p = 0.26 and KW: p 
= 0.16, respectively), frequency of cleaning bed linen (X2: p = 0.45 and KW: p = 0.39, 
respectively), medical conditions (X2: p = 0.26 and KW: p = 0.12, respectively), allergies 
(X2: p = 0.52 and KW: p = 0.58, respectively) or skin conditions (X2: p = 0.76 and KW: p 
= 0.51, respectively).  
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The relationship between prevalence and quantity of DF and type of lid hygiene is 
shown in Table 28. As can be seen from Table 28, there was a significant difference in 
prevalence and quantity of DF depending on the type of lid hygiene used. Bonferroni corrected 
post-hoc analysis (p ≤ 0.05/28 = 0.0018) showed that only difference between J+J lid scrubs 
and ‘other method’ was found to be significant (p = 0.001). However, there was considerable 
difference in sizes and age between those two sub-groups which is likely to have had an impact 
on results.  
Table 28.  Type of lid hygiene descriptives: age, prevalence and quantity Demodex 
folliculorum: Extended Study. Age (median, IQR), Demodex folliculorum quantity 
(median, IQR); A = Kruskal-Wallis: B = Chi-square. *Significant results highlighted in 
bold 
 N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
None 24 51.50 (46.00 – 61.00) 87.50 3.00 (2.00 – 9.00) 
Cleanser/
Toner 
14 31.00 (26.00 – 43.00) 35.71 0.00 (0.00 – 1.75) 
Makeup 
Remover 
7 44.00 (28.00 – 82.00) 100.00 1.00 (0.00 – 5.00) 
Face 
Wipes 
6 61.00 (26.00 – 72.00) 100.00 5.00 (1.00 – 7.00) 
J+J Lid 
Scrubs 
3 69.00 (69.00 – 69.00) 100.00 15.00 (9.00 – 17.00) 
Other Lid 
Scrubs 
3 49.00 (39.00 – 81.00) 66.67 1.00 (0.00 – 21.00) 
Other 
Method 
19 36.00 (31.00 – 57.00) 89.47 2.00 (1.00 – 5.00) 
Multiple 10 34.50 (29.00 – 47.00) 80.00 5.50 (0.00 – 8.00) 
 p = 0.17 (A) *p = 0.001 (B) *p = 0.01 (A) 
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The relationship between prevalence and quantity of DF and temperature bed linen 
was washed at was also found to be significant (refer Table 29). Five participants reported 
not knowing what temperature the bed linen was washed at, and they were removed from 
analysis. As can be seen from Table 29, as the temperature increased, the prevalence and 
quantity of DF decreased. However, Bonferroni corrected post-hoc analysis (p ≤ 0.05/3 = 
0.0167) showed that none of the differences between the sub-groups were found to be 
significant (smallest p = 0.018 30°C versus 60°C).  
Table 29.  Temperature bed linen washed descriptives: age, prevalence and quantity 
Demodex folliculorum: Extended Study. Age (median, IQR), Demodex folliculorum 
quantity (median, IQR); A = Kruskal-Wallis: B = Chi-square. *Significant results 
highlighted in bold. 
Temp (°C) N Age (yrs.) Prevalence (%) Quantity Demodex (n) 
30  19 40.00 (31.00 – 61.00) 100.00 5.00 (3.00 – 11.00) 
40 43 43.00 (39.00 – 57.00) 79.07 2.00 (2.00 – 5.00) 
60 19 49.00 (33.00 – 58.00) 57.89 1.00 (1.00 – 5.00) 
  p = 0.93 (A) *p = 0.01 (B) *p = 0.048 (A) 
 
Presence of DF was not significantly associated with grade of conjunctival hyperaemia 
(X2 p = 0.62). There was a significant correlation detected between quantity of DF and 
grade of conjunctival hyperaemia (rs 0.24 p = 0.03). As can be seen in Figure 25, quantity 
of DF appears to be associated with moderate hyperaemia (G2) but not severe (G3).  
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Figure 25. Box plot illustrating the relationship between quantity of Demodex 
folliculorum and conjunctival hyperaemia (rs = 0.24, p = 0.03). 
 
There was a significant correlation between quantity DF and increasing severity of CD 
(rs = 0.61: p < 0.001) (refer Figure 26). There was also a significant positive correlation 
between age and CD (rs = 0.37: p < 0.001). 
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Figure 26. Box plot illustrating the positive correlation between cylindrical dandruff 
and quantity of Demodex folliculorum (rs = 0.61: p < 0.001). 
 
A significant correlation was also detected between quantity of DF and MGD grade (rs 
p = 0.25: p = 0.03). This is illustrated in Figure 27 below. Increasing age was also 
significantly associated with increasing grade of MGD (rs = 0.56: p < 0.001). 
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Figure 27. Box plot illustrating the positive correlation between meibomian gland 
dysfunction and quantity of Demodex folliculorum (rs = 0.25: p = 0.03). 
 
Participants were then divided into three groups according to treatment (refer Table 
30). Participants who did not have any DF were used as controls, therefore statistical 
analysis on quantity of DF was only applied to individuals found positive for DF (n = 69). 
Table 30.  Number of participants with Demodex folliculorum and number of control 
participants in each group. 
 
Participants with DF 
(n) 
Control (n) Total (n) 
Group A: TTFW 22 6 28 
Group B: OCuSOFT 24 6 30 
Group C: BlephExTM 23 5 28 
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Overall, the mean habitual logMAR visual acuity improved post-treatment (logMAR; 
1.08 ± 0.26 at baseline, 1.13 ± 0.27 at two weeks, and 1.16 ± 0.26 at four weeks, Friedman’s 
p = 0.02). Post-hoc analysis using WSR test, after alpha adjusted for Bonferroni correction 
(α = 0.016), showed that only the difference between baseline and four weeks was 
statistically significant (WSR p = < 0.001).   
There was no significant difference in age between the three treatment groups. 
However, DF positive participants in group A and group B were significantly older than 
their respective control participants (refer Table 31). 
Table 31.  Age of participants with Demodex folliculorum and control participants in 
each group. *Significant results highlighted in bold. 
 
Group A       
TTFW (yrs) 
Group B 
OCuSOFT (yrs) 
Group C 
BlephExTM (yrs) 
KW  
Participants 
with DF 
44.00  
(39.00 – 67.00) 
47.00  
(37.00 – 57.00) 
49.00  
(33.00 – 67.00) 
p = 0.99 
Control 
27.00  
(25.00 – 28.00) 
26.00  
(26.00 – 67.00) 
33.00  
(23.00 – 58.00) 
p = 0.62 
MWU  p = 0.01* p = 0.01* p = 0.21  
 
Overall, participants with DF had a higher modified OSDI score compared to those 
without DF (median OSDI 26.67 IQR 20.83 – 35.00 versus 11.67 IQR 8.33 – 33.33, MWU: 
p = 0.03). However, no significant correlation was detected between increasing quantity of 
DF and increasing modified OSDI score (rs = 0.10 p = 0.35). Table 32 shows the breakdown 
of symptoms in all three treatment groups over the duration of the study. Total modified 
OSDI score reduced in all three treatment groups, however only Group B and Group C were 
found to be significant (Friedman’s; p = 0.003 and p < 0.001, respectively). Nonetheless, 
there was no significant difference in symptoms or quantity of DF between each treatment 
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group at any visit over the duration of the study (Table 32). Results are for participants with 
DF only. 
Table 32.  Participants with Demodex folliculorum: Severity of symptoms and 
quantity of Demodex folliculorum in each group at baseline, two weeks, and four weeks. 
Severity of symptoms: Total modified OSDI number (median, IQR). Quantity of 
Demodex folliculorum (median, IQR). *Significant results highlighted in bold 
 
Group A 
TTFW 
Group B 
OCuSOFT 
Group C 
BlephExTM 
KW 
Symptoms     
Baseline 25.00 (10.00 – 36.67) 20.83 (11.67 – 33.33) 25.83 (18.33 – 33.33) p = 0.84 
Two weeks 12.08 (5.00 – 18.33) 8.33 (5.00 – 18.33) 11.52 (8.33 – 11.67) p = 0.63 
Four 
weeks 
12.02 (8.33 – 15.00) 8.33 (3.33 – 10.71) 8.33 (6.67 – 16.67) p = 0.42 
Friedman’s p = 0.16 p = 0.003* p = 0.001*  
Quantity 
DF 
    
Baseline 2.00 (1.00 – 5.00) 1.50 (1.00 – 4.00) 3.00 (2.00 – 6.00) p = 0.22 
Two weeks 0.00 (0.00 – 2.00) 0 00 (0.00 – 3.00) 1.50 (0.00 – 3.00) p = 0.70 
Four 
weeks 
0.00 (0.00 – 2.25) 0.00 (0.00 – 3.00) 0.50 (0.00 – 2.00) p = 0.49 
Friedman’s p < 0001* p < 0001* p < 0001*  
 
Although, overall, the majority of participants with DF were severely symptomatic: 
asymptomatic (n = 18), mild (n = 12), moderate (n = 11), and severe (n = 28): no statistically 
significant correlation was found between DF quantity and severity of symptom grade or 
modified OSDI score at baseline visit (KW: p = 0.47 and rs = -0.08: p = 0.54). As can be 
seen in Table 16; symptoms reduced progressively throughout the four weeks of treatment 
in each group. For groups B and C the reduction in symptoms over the four weeks was 
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significant. For group B post hoc analysis with WSR pairwise comparisons, α adjusted for 
Bonferroni correction (α = 0.016), indicated that the improvement in symptoms was 
significant between baseline and week two (p = 0.001) and baseline and week four (p = 
0.001) only. For group C post hoc analysis indicated that the improvement in symptoms 
was significant between baseline and week two (p < 0.001) and baseline and week four (p 
< 0.001).  
Table 32 also demonstrates the reduction in numbers of DF over the course of the 
four weeks for each treatment group. Post-hoc analysis WSR test pairwise comparison, 
after Bonferroni correction applied, revealed: Group A significant reductions from baseline 
to week two (p = 0.002) and baseline and week four (p < 0.001), Group B significant 
reduction from baseline to week four (p = 0.005), and Group C significant reductions from 
baseline to week two (p = 0.002) and baseline to week four (p = 0.001). Similar to 
symptoms, the quantity of DF did continue to decrease from two weeks to four weeks, 
although the reduction in quantity between week two and week four was not significant 
(WSR; A: p = 0.87, B: p = 0.94, C: p = 0.43). 
Participants with DF were more symptomatic than participants in the control group. 
However, although a significant correlation was found (X2: p = 0.005), it was concluded 
that it was not a valid comparison due to the difference in sample size between the two 
groups. Furthermore, participants with DF were significantly older than control 
participants, and the impact age has on dry eye symptoms has been well established.144 This 
is a confounding factor; therefore it cannot be assumed that the increased symptoms 
witnessed amongst participants with DF were as a result of DF alone. 
 149 
 
There was no significant difference in control participants’ symptoms at baseline 
between the three groups. There was no significant change in control participants’ 
symptoms after treatment in group A and group C (Table 33). Group B did demonstrate a 
significant reduction in symptoms post treatment over time (Friedman’s p = 0.02). 
However, due to the small sample size, it is difficult to take any relevance from this finding 
at present. 
Table 33. Control participants: Severity of symptoms in each group at baseline, 
two weeks, and four weeks. Severity of symptoms: Total modified OSDI number 
(median, IQR). *Significant results highlighted in bold. 
 Group A 
TTFW  
(n = 6) 
Group B 
OCuSOFT  
(n = 6) 
Group C 
BlephExTM  
(n = 5) 
KW 
Symptoms     
Baseline 7.50  
(5.00 - 31.67) 
10.00  
(5.00 – 33.33) 
13.33  
(11.67 – 33.33) 
p = 0.89 
Two weeks 7.50  
(3.33 – 15.00) 
5.28  
(1.67 – 13.33) 
8.33  
(3.33 – 21.67) 
p = 0.97 
Four weeks 7.50  
(1.67 – 15.00) 
3.33  
(0.00 – 26.67) 
8.33  
(0.00 – 35.00) 
p = 0.86 
Friedman’s p = 0.28 p = 0.02* p = 0.17  
 
5.5 Discussion 
A reasonably high prevalence of DF was detected in both the pilot and extended study 
groups (61.00% and 80.23%, respectively), which is in good agreement with previous 
studies.28,46,77 The overall median number of DF detected, per participant pre-treatment, 
was very similar between the two study groups (2.00 mites IQR 0.00 – 8.00 and 2.00 mites 
IQR 2.00 – 5.00 for the pilot and extended study respectively). As has been mentioned 
previously, the accepted consensus at present is that Demodex in low numbers are a normal 
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part of our microbiological flora and fauna.66,229 However, when quantities of Demodex 
begin to proliferate, and the density of the mites increases beyond a critical density,65,71 
Demodex adopt a pathogenic role and can cause skin and ocular abnormalities. No 
significant relationship was detected between DF and skin conditions or allergies in either 
the pilot study or the extended treatment study: however, there were very few participants 
with skin conditions that took part to get statistically relevant results.  
Increased quantities of DF have been associated with blepharitis,7,43,46,49 
chalazia,26,230,231 corneal disturbance6,143 and an increase in symptoms.13,28,46,47 Similarly, 
both the pilot and extended studies, found significant associations between DF and 
increasing severity of CD, MGD and symptoms: adding further evidence to the 
pathogenicity of Demodex. Age was associated with increasing severity of CD and MGD. 
Cylindrical dandruff has been shown to be a bi-product of increased quantities of DF, and 
it is likely that age is not an influencing factor in this finding,25,189 Age-related changes to 
the meibomian glands contribute to MGD,210 and increasing age has also been repeatedly 
associated with increased quantities of DF.13,28,77,78 As such, it is not possible from the 
results of the current studies to say whether the higher quantities of DF detected amongst 
subjects with MGD were as a result of participants with MGD being older, or if MGD alone 
is a risk factor for increased quantities of DF. Future studies should be age and sex-match 
controlled to avoid this. 
Although the presence of DF was found to be significantly associated with increasing 
severity of symptoms, and the majority of participants with DF were found to be 
symptomatic, no correlation was detected between increasing quantity of DF and increasing 
symptoms in either the pilot or extended study. Again, age may be an influencer on this 
result144: it may be age-related dry eye that is causing the symptoms and not just DF. 
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However, treatment administered to reduce the quantity of DF significantly improved 
symptoms to normal levels; even though complete eradication was not achieved. In the 
extended study, the majority of control participants were asymptomatic, and treatment did 
not significantly reduce modified OSDI score. This adds further support to the theory that 
lower quantities of Demodex may be considered normal and of no immediate concern. 
Furthermore, as symptoms improved to normal levels in the absence of complete Demodex 
eradication; it could be argued that the aim of treatment does not need to be complete 
eradication, and that treatment could be considered successful when Demodex density is 
returned to normal levels.  
As mentioned previously in Section 1.1, lid hygiene, using a ‘variety of measures’, is 
the first line management recommended by both the AAO and College of Optometrists, 
regardless of the type of blepharitis.1,3 The aim of lid hygiene is to reduce the bacterial load 
at the eyelid margin, helping to improve signs and symptoms associated with blepharitis.3 
Lid scrubs with diluted concentrations of baby shampoo have been the longstanding ‘go-
to’ treatment for practitioners to advise their patients to use for regular home management 
of blepharitis. It is not entirely clear where baby shampoo as a treatment for blepharitis 
originated. However, in 2018, Sung et al186 demonstrated that baby shampoo has a negative 
effect on goblet cell density, and thus could be more damaging to the tear film and ocular 
surface than therapeutic. Currently the AAO still recommend baby shampoo, or other 
dedicated cleansing pads, as first line management for blepharitis,1 but the College of 
Optometrists have removed it from their clinical management guidelines in their most 
recent review.3 At the time this study was conducted, the effect of baby shampoo on goblet 
cell density had not been established, and it remained on the recommended guidelines for 
practitioners. Furthermore, investigation into the comparative efficacy of different lid 
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hygiene measures had been recommended.2 Gao et al12 found that the survival time of DF 
in 50% baby shampoo solution was > 150 min, and patients treated with baby shampoo lid 
scrubs for up to 350 days showed no significant change in DF quantity. The results from 
the pilot study demonstrated a similar inadequacy by baby shampoo to treat Demodex 
blepharitis. There was no reduction in quantity of DF achieved on the eye treated with baby 
shampoo, compared to a significant reduction in quantity of DF achieved on the eye treated 
with OCuSOFT.   
A ‘variety of measures’ now exist for the treatment of blepharitis.3 Over-the-counter 
eyelid cleansers for blepharitis have become available in recent years, but little evidence as 
to their ability to treat the condition currently exists.2,3 OCuSOFT is marketed as a product 
for moderate to severe blepharitis sufferers, with bacterial/Demodex involvement. The 
active ingredient for killing DF used in OCuSOFT is 1,2-Octanediol. As mentioned in 
Section 2.3.2, 1,2-Octanediol is a surfactant with antimicrobial abilities. Burgess et al187 
investigated the efficacy of 1,2-Octanediol at treating head lice infestation, and 
demonstrated that a 5% solution of 1,2-Octanediol, left on for eight hours over night, 
effectively eliminated an established head louse infestation, with an 80% cure rate after 
only one use. Observations from the same study demonstrated that lower concentrations of 
1,2-Octanediol solutions (1%) also killed head lice, but at a slower rate.187 It was proposed 
that the chemical disrupted the cuticular lipid of the lice, causing them to become 
dehydrated and die.187 It has been established previously that DF die when they become 
dehydrated.40 Thus, it is possible that this proposed method works similarly on Demodex. 
The effect of pediculicides is not always instantaneous and subsequently some micro-
organisms may survive long enough to lay eggs following treatment. Burgess et al187 also 
found that 5% 1,2-Octanediol reduced head lice egg laying. However, previously laid eggs 
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were unaffected, and could potentially survive to start a new infestation.187 OCuSOFT 
formula contains a 0.5% concentration of 1,2-Octanediol to ensure the product is non-
irritating, yet still effective when used repeatedly for a period of time. As the formula is 
non-irritating, this promotes better participant compliance and willingness to use the 
treatment over multiple uses.  The pilot and extended study both found that OCuSOFT was 
effective at reducing quantity of DF over both a two- and four-week period. Even after four 
weeks, complete elimination was not achieved. As the treatment does not appear to effect 
previously laid eggs, it is conceivable that these eggs hatched to give rise to the next 
generation. Additionally, complete coverage is required to be effective. If coverage by an 
applicant is incomplete, some DF mites may survive to lay and hatch more DF: although 
with continuously reducing quantities. However, Burgess et al187 also specified that with 
5% 1,2–Octanediol egg laying was completely inhibited and previously laid eggs did not 
mature to hatch. It is possible that 0.5% 1,2-Octanediol does not have the same toxic effect 
on eggs. Likewise, Burgess et al187 investigated efficacy on head louse and not Demodex. 
Although both are ectoparasites, no study could be found that compared the similarities and 
differences between the two. Furthermore, as mentioned earlier, complete eradication may 
not be necessary for successful treatment. 
In recent years, TTO and ivermectin have emerged as the go-to-treatment options for 
Demodex blepharitis.6,12,13,15,34,36,38 As mentioned in Section 2.4.3, it has been established 
that terpinen-4-ol is the active ingredient in TTO effective at killing DF in a dose dependent 
manner.12,53 Several studies have found that 50% TTO applied weekly is effective at 
reducing DF infestation,6,13,15 and even at as low a concentration as 5% TTO is effective at 
killing Demodex when applied twice a day.35 Although application of 50% TTO is the 
recommended treatment for Demodex blepharitis,1,3 the disadvantages of this (ocular 
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irritation and toxicity) have been discussed in detail in Section 2.4.3. Following feedback 
from the pilot study, the aim was to incorporate a tea tree-based treatment that could 
potentially serve as a good alternative to baby shampoo. Hence, the extended study 
investigated the efficacy of nightly lid scrubs with TTFW for the treatment of DF 
blepharitis. The TTFW used in the current study had a 38% concentration of terpinen-4-ol 
and has shown to effectively reduce DF count over a four-week period. The extended study 
focussed on the use of TTFW as a treatment for blepharitis; as such, participants only 
scrubbed their eyelids. However, the TTFW can be used on the entire face; theoretically 
providing the ability to treat DF, if present, on the facial skin also. Furthermore, if Demodex 
on the face are also being treated, this reduces the risk of migration of mites back to the 
eyelashes again following topical treatment. The results of the extended study show that 
TTFW was effective at reducing signs and symptoms of Demodex blepharitis. An 
advantage of TTFW is that it can be applied at home as part of a routine facial cleaning 
regime, and does not require experienced practitioner application, thus reducing chair time 
and cost for the patient. However, irritation was still a factor with the TTFW, which could 
impact patient compliance in the long run. 
The extended study also included a third treatment group: BlephExTM was used as an 
adjunct therapy with OCuSOFT for Group C. BlephExTM lid scrub was given to participants 
in-office before they began nightly home lid scrubs with OCuSOFT, similar to the way 50% 
TTO lid scrubs were performed in office for participants in previous studies.6,13,15 The aim 
was to incorporate the BlephExTM in an effort to help reduce the bacterial load prior to 
commencing home lid scrubs. The results of the extended treatment study found the greatest 
reduction in DF quantity and greatest improvement in symptoms in the BlephExTM group. 
Even among the control participants who had no DF, they reported a significant 
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improvement in symptoms after two weeks. The authors’ postulate that this is as a result of 
the scrubbing and exfoliation action of the BlephExTM; which leaves the eyelids feeling 
completely cleaned and refreshed regardless of the presence or absence of ocular disease.    
5.5.1 Limitations 
A strength and limitation of the pilot study was that treatment was administered to only 
one eye. This allowed age and sex-match control for treatments and kept compliance of 
treatment and control the same. However, it did not prevent the possibility of cross-
contamination of DF from the control eye to treated eye. Secondly, treatment was 
administered for a two-week period initially, which is slightly less than the lifespan of DF 
(14 – 18 days). This time frame was chosen as the first follow up for participants as the aim 
of the study was to find an effective treatment for Demodex blepharitis that can be easily 
administered and managed by optometrists in practice. Treatment non-compliance is an 
issue affecting efficacy of treatments in all facets of the medical profession.232 As such, the 
treatment protocol was chosen to be easy to follow, as non-time consuming as possible in 
order to fit in with daily routines, and a short duration to help improve compliance. This is 
a realistic working timeframe for practitioners to administer and patients to use in practice 
with good compliance. A third comment made by peer-review was the lack of a tea tree-
based treatment for comparative purposes.  
The extended study attempted to account for these limitations and improve on them. 
Treatment was applied to both eyes, treatment duration was extended to four weeks, and 
TTFW was incorporated as a comparative treatment. However, the extended study was not 
without its own limitations. One such limitation of the extended study is that the group of 
control participants was a much smaller and younger group than the participants with DF 
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(Table 30). As a result, no comparisons have been made between the two groups with 
regards to symptoms. Given the unequal sample sizes, and the association between dry eye 
and increasing age, it was concluded that it would not be a valid comparison. To completely 
understand the relationship between DF infestation and symptoms, and the effect of 
treatment on those symptoms, future study cohorts should be age and sex – matched 
controlled.  
It should also be noted that in both studies, the quantity of DF among some participants 
with DF pre-treatment was recorded as zero. As mentioned previously, a limitation of 
eyelash epilation is that sometimes DF remain within the follicle and are not removed with 
the eyelash, although the DF tails are clearly visible on slit lamp examination. This occurred 
mainly in highly infested damaged follicles where the lashes were loose.  As a result, an 
accurate account of DF quantity that reflects severity of infestation is difficult to achieve 
from eyelash epilation and microscopic counting alone. Mastrota50 describes eyelash 
rotation as an alternative technique to eyelash epilation to confirm DF infestation. This 
finding prompted investigation into incorporating eyelash manipulation to help accurately 
diagnose the severity of infestation and thus provide better information clinically to 
practitioners, in order to understand and know who and when to treat. This is discussed in 
detail in Chapter 8. 
None of the treatment methods tested in both the pilot and extended treatment study 
fully eradicated DF in all participants. Potential reasons for this could be; the duration of 
treatment, frequency of application, participant compliance, and migration of DF. 
Participants scrubbed their eyelids nightly for two to four weeks. This may be too short a 
time frame to treat generations of DF. Similarly, treatment was only applied once a day, at 
night, and may be more successful if applied in the morning also. Furthermore, it is possible 
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that participants did not follow lid scrub instructions carefully, which could impact efficacy 
of treatment. Future studies could monitor compliance by requesting participants to return 
empty and/or unused treatments at the end of the study. Finally, DF can reside in other hair 
follicles on the face and body, not just the eyelashes. Therefore, it is possible that DF may 
have migrated back to the eyelashes from other locations; hence, total eradication of DF 
may not be possible using a local treatment. 
5.6 Conclusion 
These studies have demonstrated that nightly lid hygiene with both OCuSOFT and 
TTFW are effective at reducing DF quantity and symptoms. In-house 
microblepharoexfoliation has a greater impact on symptoms. Baby shampoo has no 
therapeutic effect on quantity of DF and can be considered ineffective for the treatment of 
Demodex blepharitis. The current study provides evidence-based results for the use of 
commercial products available for the treatment of DF blepharitis in a clinical setting. 
The safety of using these products on the ocular surface has not been fully investigated. 
The following chapter examines the effect of OCuSOFT, TTFW and baby shampoo on the 
tear film and ocular surface.  
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CHAPTER SIX: THE EFFECT OF LID HYGIENE ON THE TEAR FILM AND 
OCULAR SURFACE 
6.1 Abstract 
Purpose: To evaluate the effect blepharitis lid cleansers have on the tear film and 
ocular surface, and to examine the prevalence of DF in a young population. 
Methods: Forty-eight university students completed a randomised, controlled, 
investigator-masked, eight-week clinical trial. Three eyelid hygiene products were 
investigated: blepharitis eyelid cleanser (OCuSOFT® Lid Scrub® PLUS foam), diluted 
baby shampoo (10% Johnson’s® No More Tears®) and a TTFW (dr.organic®). Cooled 
boiled water was used as a control. Participants attended for four visits: baseline, two 
weeks, four weeks and eight weeks. At each visit, subjective symptoms, NITBUT, and 
ocular surface staining were assessed to evaluate any positive or negative effect on the tear 
film and ocular surface. DF investigation involving eyelash manipulation and epilation was 
conducted to examine for the presence and quantity of DF. Osmolarity was measured at 
baseline and week eight only. 
Results: The overall prevalence of DF found at baseline was 14.60%. Subjective 
symptoms improved in all groups, including control. There was no significant difference in 
mean osmolarity between the groups or within each group after eight weeks. There was a 
significant increase in osmolarity inter-eye variability in the baby shampoo group (p = 
0.03). There was no significant change in NITBUT or ocular surface staining after eight 
weeks of eyelid hygiene.  
 159 
 
Conclusion: A low prevalence of DF can be found in a young student population. All 
blepharitis lid cleansers used in the current study demonstrated subjective improvement in 
symptoms, with no negative effects on TBUT or ocular surface staining. OCuSOFT and 
TTFW revealed no adverse effect on mean osmolarity or inter-eye variability. Baby 
shampoo did not cause a significant increase in mean osmolarity, but demonstrated a 
significant increase in inter-eye variability, signifying a possible increase in ocular surface 
inflammation.  
6.2 Introduction 
Blepharitis has been previously defined and classified in Section 1.1 and Section 1.7.2. 
This chronic inflammatory process at the eyelid margins has been shown to disrupt tear 
film stability, causing ocular surface irritation and dry eye.233 Despite the relatively high 
prevalence of blepharitis in ophthalmology and optometry clinics, the exact aetiology 
remains unknown, and there is still no ‘cure’ for chronic blepharitis.2 As discussed above 
in Chapter 5 (Section 5.5), lid hygiene remains the first line treatment for anterior 
blepharitis,1,3 and manufacturers are increasingly developing lid scrubs and washes for 
practitioners to recommend and distribute to their patients. At present there is no ‘one-for-
all’ treatment for blepharitis. Antibiotics have shown good efficacy against bacterial 
blepharitis,1,2,234 antifungals against seborrheic blepharitis,235–239 and TTO and anti-
parasitic therapy have demonstrated notable ability to treat Demodex blepharitis.15,35,52  
OCuSOFT and TTFW are two of the over-the-counter treatments that were used in the 
pilot and extended treatment studies (refer Chapter 5) and have shown good efficacy at 
treating Demodex blepharitis.52 The active ingredients and potential toxicity of each product 
has been previously described in Section 2.4.2and Section 2.4.3 respectively. Although at 
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higher concentrations, terpinen-4-ol and 1,2-octanediol are considered toxic to the ocular 
surface,3,150 their therapeutic abilities has meant that these chemical compounds have been 
incorporated into eyelid cleansers at lower concentrations reducing the risk of toxicity: 
TheraTears® SteriLid® (terpinen-4-ol: 0.02 mg/ml = 0.002%), Cliradex® (terpinen-4-ol: 
4.61 mg/ml = 0.461%), OustTM Demodex® SwabstixTM (terpinen-4-ol: 0.29 mg/ml = 
0.029%) and OCuSOFT® Lid Scrub® PLUS (1,2-octanediol: 0.5%).52,240 Several recent 
studies have investigated the safety and tolerability of these eyelid cleansers.186,241,242 
However, TTFW contains 38% terpinen-4-ol, and the impact of using such a high 
concentration of terpinen-4-ol close to the ocular surface has not been established.  
As listed above, many blepharitis products are currently available for practitioners to 
recommend to their patients. However, as previously mentioned in Section 2.4.1, although 
baby shampoo has been shown to have a negative effect on goblet cell function,186 
practitioners still routinely recommend patients to use the ‘traditional’ method of a mild 
dilution of baby shampoo for eyelid hygiene in the treatment of blepharitis.  
The ocular surface comprises of the combination of the cornea, conjunctiva, lacrimal 
glands, meibomian glands, eyelashes, eyelids and nasolacrimal duct.243 The tear film 
lubricates the ocular surface, protecting it from foreign pathogens, maintaining a 
homeostatic environment, preventing infection and inflammation and providing a clear 
smooth refractive surface for vision.244 The migratory effect of substances applied near the 
eyelid margins, such as makeup, to the tear film has been well established.245–249 Topical 
products used for eyelid hygiene to treat blepharitis, inevitably come in close contact with 
the ocular surface. However, to the best of the authors knowledge, the effect the products 
have on the tear film and ocular surface has not been clearly established.  
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Therefore, it is important to investigate the effects products have on the ocular surface, 
to help inform practitioners in clinical practice. The primary aim of the current study was 
to examine and compare the effect of home use lid hygiene products on the ocular surface 
and tear film parameters. A secondary aim of the study was to investigate the prevalence of 
Demodex blepharitis in a young population. 
6.3 Methods 
This was a single-centre, interventional, randomised, controlled, examiner masked 
clinical trial. All participants were students recruited from the Department of Optometry in 
TU Dublin.  Written informed consent was obtained from all participants prior to 
enrolment. 
Power calculations were made with osmolarity as the designated outcome. Effect size 
was calculated with G*Power analysis using mean + SD of baseline osmolarity values of 
the three groups used in the MGD warm compress study (discussed in Chapter 8). Effect 
size computed was 0.518. Minimum sample size required for statistical significance was 
calculated using G*Power analysis. A priori analysis for repeated measures ANOVA 
between factors was conducted; alpha = 0.05, Power = 0.8, effect size = 0.5; minimum 
sample size required n = 32: 8 participants per group. 
Fifty-six participants in total, 14 per group, were enrolled from February to October 
2018. Following attrition, 48 participants, completed the two-month treatment study. In an 
effort to avoid confounding effects of age on tear film and ocular surface parameters,250 
participants aged between 18 – 24 years were included. Participants were excluded if they 
were using any systemic/topical medications known to affect the eyes (including artificial 
tears), had used any blepharitis treatment or had ocular surgery within the previous six 
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months. Contact lens wearers could take part, however, participants were required to wear 
their spectacles on examination days. 
Participants attended the National Optometry Centre for four visits in total: baseline, 
week two, week four, and week eight. Ocular surface parameters were investigated at each 
visit to note any changes over time with treatment. The exception was osmolarity, which 
due to the associated costs was only performed at baseline and week eight only. 
All examinations were performed in the following order at each visit, from least 
invasive to most invasive170,171: Modified OSDI questionnaire (validation discussed in 
detail in Chapter 4), NITBUT (Section 2.3.3), osmolarity (Section 2.3.4), and ocular surface 
staining (Section 2.3.5). Each of these examination techniques has been described in detail 
previously.  
 Previous studies in the literature have used differing parameters and cut-offs to 
distinguish between dry eye and non-dry eye.176,177,251 As mentioned previously, a cut-off 
of 308 mOsm/L is accepted as most sensitive to distinguishing normal participants from 
participants with mild DED.176,177 As such, participants within each group were also sub-
divided into low tear osmolarity (< 308 mOsm/L) and high tear osmolarity (≥ 308 mOsm/L) 
in order to assess the correlation between common signs and symptoms of DED with 
increased tear osmolarity, and the effect that lid hygiene products has on participants with 
low and high tear osmolarity. 
Each participant was finally examined for the presence of DF using the eyelash 
manipulation and eyelash epilation techniques described earlier (Section 2.3.9). Similar to 
the pilot study and extended study discussed in Chapter 5, the presence of DF was defined 
as one or more DF visible on eyelash manipulation and/or microscopic examination. 
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Participants were randomly divided into four groups according to treatment: Group 1: 
Cooled boiled water (control) (n = 12), Group 2: OCuSOFT (n = 12), Group 3: 10% baby 
shampoo (shampoo) (n = 11), and Group 4: TTFW (n = 13). A 2 ml syringe and 20 ml 
plastic test tube were provided to participants in Group 3 to make up the 10% shampoo 
solution nightly (Appendix 5b). Randomisation was achieved using the random number 
generator function on Excel. Each treatment was randomly assigned a number from 1 to 56. 
Each participant chose a number and was subsequently given the treatment assigned to that 
number.  
Step-by-step instructions, similar to those provided in the pilot and extended treatment 
studies, were provided to each participant for nightly lid scrubs at home (refer Table 6). 
The lid scrubbing routine remained consistent between treatments. The only difference was, 
that as per manufacturer’s guidelines, OCuSOFT formula was left on overnight; whereas 
the shampoo and face wash were rinsed off after scrubbing.  
Participants were asked to clean their eyelids nightly with their respective treatments 
following the step-by-step instructions given to them and to return for repeat examinations 
after two, four and eight weeks. The examiner remained blind to all treatments throughout 
all stages of the investigation. 
 In an effort to monitor compliance, participants were asked to self-report, during return 
visits, their treatment compliance for the previous 14 or 28 nights (at week two/four, and 
week eight respectively). Participants were also asked to give feedback: if they would 
recommend the treatment for participants with dry eyes or blepharitis. 
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6.3.1  Statistical Analysis 
Statistical analysis was performed using SPSS (version 25.0). The study eye used for 
data analysis was chosen based on the eye with the greater tear osmolarity value. This 
randomised the process, and is in keeping with previous studies and manufacturer 
guidelines.174,176,177 Data was assessed for normal distribution using Shapiro-Wilk. All 
outcome measures investigated were found to have a non-normal distribution (p < 0.001). 
Friedman’s test was used to analyse repeated measures, within each group, across 
different visits for non-parametric data. Post-hoc analysis was conducted, where 
appropriate, using WSR test for pairwise comparisons, adjusted using Bonferroni 
correction to avoid Type I error (α = 0.05/number of comparisons: α = 0.05/6 = 0.008).252 
Kruskal Wallis H test was used to analyse data between categorical variables at baseline 
and at different visits. Post-hoc analysis was conducted, where appropriate, using MWU 
test for pairwise comparison, adjusted using Bonferroni correction (α = 0.05/number of 
comparisons: α = 0.05/4 = 0.013).252  Data was expressed as median and IQR. Alpha level 
≤ 0.05 was considered statistically significant, with the exception of Bonferroni adjusted 
post-hoc analysis as described above. 
6.4 Results 
Forty-eight participants, with a median age of 19.50 years (IQR 19.00 – 20.75 years), 
enrolled and completed the eight-week treatment study. An overall prevalence of DF of 
14.60% was detected within this young study cohort. The overall median quantity of DF 
detected was 0.00 mites (IQR 0.00 – 0.00) and 0.00 mites (IQR 0.00 – 0.00) on eyelash 
manipulation and microscopic examination, respectively. As the presence and quantities of 
DF found were so low, no further statistical analysis was conducted in that regard.  
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The effect of home lid scrubs on symptoms, osmolarity, NITBUT and ocular surface 
staining was evaluated over eight weeks. Compliance and subjective feedback from 
participants were also analysed. 
 Median total symptom score for each treatment group at each time point is shown in 
Table 34. A box plot illustrating change in symptom score from baseline for each treatment 
groups over the duration of the study is shown in Figure 28. There was no significant 
difference in total symptom score between the treatment groups, at any stage, over the two 
months (KW p > 0.05). At baseline, all four treatment groups had a total symptom score > 
12 and < 22, signifying ‘mild symptoms’ according to the OSDI classification.214  
 
Table 34. Modified OSDI symptom (median, IQR) for each treatment at each 
time point. KW: Kruskal Wallis, F: Friedmans. *Significant results highlighted in 
bold. 
Treatment Baseline Week Two Week Four Week Eight F 
Control 12.92  
(10.83 – 16.67) 
9.17  
(5.83 – 12.50) 
8.33  
(4.17 – 16.67) 
9.17  
(5.83 – 12.50) 
*p = 0.01 
OCuSOFT 10.00  
(5.00 – 23.33) 
9.17  
(3.33 – 23.33) 
5.00  
(2.50 – 19.17) 
9.17  
(3.33 – 23.33) 
*p = 0.047 
Baby 
Shampoo 
15.00  
(3.33 – 31.67) 
10.00  
(3.33 – 16.67) 
6.67  
(0.00 – 8.33) 
10.00  
(3.33 – 16.67) 
*p < 0.001 
TTFW 10.71  
(6.67 – 16.67) 
6.67  
(5.00 – 10.00) 
10.71  
(1.67 – 13.33) 
6.67  
(5.00 – 10.00) 
*p = 0.04 
KW p = 0.78 p = 0.80 p = 0.61 p = 0.82  
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Figure 28. Box plot illustrating change in modified OSDI symptom score for each lid 
hygiene product at each time point. X represents the mean change in modified OSDI 
score, small circles represent outliers. 
The three treatment groups and control group all demonstrated a reduction in total 
symptom score over time (Figure 28; Friedman’s p < 0.05). Wilcoxon signed-ranks test 
post-hoc analysis is shown in Table 19.  As can be seen from Table 35, after Bonferroni 
correction was applied, only the reduction in total symptom score with shampoo from 
baseline to week eight (p = 0.001) and week two to week eight (p = 0.004) was found to be 
significant. 
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Table 35. Total modified OSDI symptom score post-hoc Wilcoxon Signed Ranks test pair-
wise comparisons. Bonferroni adjusted alpha level α =0.0083. Significant results highlighted 
in bold. B = baseline, W2 = week two, W4 = week four, W8 = week eight. 
 B – W2 B – W4 B –W8 W2 – W4 W2 – W8 W4 – W8 
Control 
(Friedmans, p = 0.01) 
0.04 0.07 0.01 0.72 0.06 0.14 
OCuSOFT 
(Friedmans, p = 0.05) 
0.22 0.41 0.03 0.50 0.12 0.24 
Shampoo 
(Friedmans, p < 0.001) 
0.31 0.01 0.001* 0.004* 0.01 0.92 
Face Wash 
(Friedmans, p = 0.04) 
0.03 0.02 0.04 0.94 0.44 0.24 
 
Table 36 illustrates the median and IQR of the maximum osmolarity values recorded 
at baseline, and the subsequent change in osmolarity value found for the same eye after 
eight weeks of treatment, in each group. There was no significant difference in maximum 
osmolarity value found between the treatment groups at baseline and week eight (KW p > 
0.05), or within each treatment group after eight weeks of treatment (WSR p > 0.05).  
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Table 36. Osmolarity (median, IQR) and inter-eye variability (median, IQR) before and after treatment. KW: Kruskal Wallis, WSR: 
Wilcoxon signed ranks test, p < 0.05 significant. *Significant results highlighted in bold. 
Variable Time Control (n=12) OCuSOFT (n=12) Shampoo (n=11) Face wash (n=13) KW 
Osmolarity 
(mOsm/L) 
Baseline 
304.50  
(298.00 – 309.50) 
310.50  
(300.50 – 333.00) 
305.00  
(300.00 – 313.00) 
308.00  
(298.00 – 309.00) 
p = 0.42 
Week 
Eight 
299.50  
(296.00 – 304.00) 
305.00  
(301.50 – 310.50) 
303.00  
(299.00 – 308.00) 
301.00  
(290.00 – 311.00) 
p = 0.50 
 WSR: p = 0.09 p = 0.37 p = 0.22 p = 0.96  
Inter-eye 
variability 
(mOsm/L) 
Baseline 
4.50  
(1.00 – 10.00) 
6.00  
(4.50 – 8.00) 
3.00  
(2.00 – 8.00) 
4.00  
(3.00 – 11.00) 
p = 0.74 
Week 
Eight 
6.00  
(3.00 – 15.00) 
4.50  
(2.00 – 10.50) 
15.00  
(8.00 – 21.00) 
11.00  
(4.00 -18.00) 
p = 0.13 
 WSR: p = 0.15 p = 0.89 p = 0.03* p = 0.10  
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Inter-eye variability is also shown in Table 36.  There was no significant difference in 
inter-eye variability found between the groups at baseline, or at week eight (KW p > 0.05). 
Within group analysis revealed that there was no significant difference in inter-eye 
variability found between baseline and week eight with the control, OCuSOFT and face 
wash treatments (WSR p > 0.05). However, the inter-eye variability with shampoo was 
significantly greater after eight weeks of lid scrubs than it was at baseline (15.00 mOsm/L 
IQR 2.00 – 8.00 vs 3.00 mOsm/L IQR 8.00 – 21.00, respectively; WSR p = 0.03). 
Furthermore, with shampoo, the overall presence of tear film instability increased from 
27.27% at baseline to 81.81%, resulting in a 54.54% increase in the presence of instability 
after eight weeks of treatment. None of the other treatments resulted in such an increase in 
instability. Presence of tear film instability increased by 8.34%, 16.67% and 23.08% with 
control, OCuSOFT and face wash, respectively. 
Data was also analysed for any differences depending on low or high tear osmolarity 
(refer Table 37). There was no significant difference in signs and symptoms associated with 
DED between low and high tear osmolarity at baseline. Expectedly, there was significantly 
greater inter-eye variability in the high tear osmolarity group (MWU p = 0.03).  Statistical 
analysis within each treatment group is not given as there was insufficient data for statistical 
significance. Table 37 also shows eight week results for both osmolarity groups and 
treatment sub groups. Inter-eye variability remained higher in the high tear osmolarity 
group (MWU p = 0.004). Symptoms were found to be significantly lower post-treatment in 
the high tear osmolarity groups (MWU p = 0.047). There was no significant difference in 
NITBUT or ocular surface staining between low and high tear osmolarity after eight weeks 
of treatment. The median and IQR for quantity of DF for all treatment groups in both low 
and high tear osmolarity was 0.00 (0.00 – 0.00) and has not been included in Table 37.  
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Table 37. Baseline and eight week descriptives for low and high tear osmolarity sub-groups. U: Mann-whitney U. *Significant results 
highlighted in bold. 
Baseline Descriptives 
 Low Tear Osmolarity (n = 25) High Tear Osmolarity (n = 23) P value 
Osmolarity 
(mOsm/L) 
299.00 (297.00 – 302.50) 312 (309.00 – 318.00) <0.001U 
Control  
(n = 8) 
OCuSOFT 
 (n = 5) 
J&J (n = 6) 
TTFW  
(n = 6) 
Control (n = 4) 
OCuSOFT   
(n = 7) 
J&J (n = 5) TTFW  (n = 7)  
300.50 (295.50 
– 304.50) 
299.00 (298.00 
– 302.00) 
301.00 (300.00 
– 303.00) 
297.50 (296.00 
– 298.00) 
311.00 (309.50 
– 312.50) 
331.00 (312.00 
– 335.00) 
313.00 (312.00 
– 315.00) 
309.00 (308.00 
– 318.00) 
 
Variability 
(mOsm/L) 
3.00 (1.00 – 7.00) 7.00 (4.00 – 9.00)  0.03U 
Control OCuSOFT J&J  TTFW Control OCuSOFT J&J TTFW  
1.50 (1.00 – 
8.00) 
5.00 (2.00 – 
6.00) 
6.00 (3.00 – 
14.00) 
2.00 (1.00 – 
3.00) 
6.50 (5.00 – 
10.00) 
7.00 (6.00 – 
9.00) 
2.00 (1.00 – 
2.00) 
11.00 (7.00 – 
18.00) 
 
Percentage 
Variability 
(n) 
24.00%  39.13%   
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
25.00% (2) 20.00% (1) 50.00% (3) 0.00% (0) 50.00% (2) 28.57% (2) 0.00% (0) 71.43% (5)  
Modified 
OSDI  
(0 – 100) 
13.33 (6.67 – 31.67) 10.00 (3.33 – 16.67) 0.06U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
13.33 (12.08 – 
25.83) 
11.67 (8.33 – 
11.67) 
23.33 (6.67 – 
45.00) 
18.33 (6.67 – 
32.69) 
10.83 (8.57 – 
12.50) 
6.67 (3.33 – 
35.71) 
3.33 (1.67 – 
20.00) 
10.71 (6.67 -
13.33) 
 
NITBUT 
(secs) 
5.56 (3.29 – 11.82) 4.50 (3.20 – 6.47) 0.46U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
4.77 (3.04 – 
14.85) 
9.70 (5.85 – 
11.37) 
5.94 (4.47 – 
11.73) 
3.93 (2.77 – 
4.03) 
5.49 (3.90 – 
9.89) 
4.93 (3.00 – 
9.20) 
4.13 (3.00 – 
4.23) 
4.53 (3.77 – 
12.93) 
 
Ocular 
Surface 
Staining  
(0-15) 
0.00 (0.00 – 1.50) 0.00 (0.00 – 1.00) 0.74U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
0.50 (0.00 – 
1.00) 
2.00 (1.00 – 
2.00) 
00.50 (0.00 – 
2.00) 
0.00 (0.00 – 
0.00) 
0.00 (0.00 – 
1.00) 
0.00 (0.00 – 
1.00) 
1.00 (0.00 – 
1.00) 
0.00 (0.00 – 
1.00) 
 
DF 
Prevalence 
(%) 
16.00% (4) 13.04% (3)  
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
25.00% (2) 20.00% (1) 16.67% (1) 0% 0% 28.57% (2) 0% 14.29% (1)  
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Eight Week Descriptives 
 Low Tear Osmolarity (n = 25) High Tear Osmolarity (n = 23) P value 
Osmolarity 
(mOsm/L) 
299.00 (296.00 – 303.00) 309.00 (300.00 – 319.00) 0.001U 
Control  
(n = 8) 
OCuSOFT 
(n = 5) 
J&J (n = 6) TTFW (n = 6) 
Control (n = 
4) 
OCuSOFT  
(n = 7) 
J&J (n = 5) 
TTFW 
 (n = 7) 
 
297.50 
(294.50 – 
300.00) 
303.00 
(303.00 – 
304.00) 
299.50 
(299.00 – 
303.00) 
299.00 (290.00 
– 301.00) 
309.00 
(303.50 – 
312.00) 
309.0 (300.00 – 
326.00) 
308.00 
(306.00 – 
311.00) 
310.00 (290.00 
– 349.00) 
 
Variability 
(mOsm/L) 
4.00 (3.00 – 9.50) 15.00 (6.00 – 24.00) 0.004U 
Control OCuSOFT J&J  TTFW Control OCuSOFT J&J TTFW  
5.00 (1.50 – 
12.00) 
4.00 (3.00 – 
5.00) 
8.50 (4.00 – 
10.00) 
3.50 (3.00 – 
14.00) 
10.50 (5.50 – 
16.50) 
8.00 (1.00 – 
16.00) 
21.00 (18.00 
– 27.00) 
13.00 (11.00 – 
29.00) 
 
Percentage 
Variability 
(n) 
40.00% 73.91%   
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
37.50% (3) 20.00% (1) 66.67% (4) 33.33 (2) 50.00% (2) 57.14% (4) 100.00% (5) 85.71% (6)  
Modified 
OSDI  
(0 – 100) 
6.67 (5.00 – 15.60) 3.33 (0.00 – 11.67) 0.047U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
9.17 (6.67 – 
17.86) 
5.00 (1.67 – 
10.00) 
10.00 (5.00 – 
17.86) 
5.18 (5.00 – 
11.67) 
4.17 (0.83 – 
9.17) 
3.33 (1.67 – 
28.33) 
0.00 (0.00 – 
5.00) 
10.00 (0.00 – 
15.00) 
 
NITBUT 
(secs) 
4.77 (3.50 – 9.85) 4.67 (2.83 – 8.90) 0.55U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
3.77 (3.32 – 
4.48) 
7.10 (3.26 – 
7.73) 
6.59 (3.47 – 
11.30) 
7.27 (5.80 – 
10.63) 
4.90 (3.38 – 
8.34) 
6.67 (3.03 – 
10.93) 
4.57 (2.83 – 
5.10) 
4.67 (2.60 – 
5.70) 
 
Ocular 
Surface 
Staining  
(0-15) 
0.00 (0.00 – 0.00) 0.00 (0.00 – 1.00) 0.38U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
0.00 (0.00 – 
0.00) 
0.00 (0.00 – 
0.00) 
0.00 (0.00 – 
1.00) 
0.00 (0.00 – 
0.00) 
0.00 (0.00 – 
0.00) 
0.00 (0.00 – 
0.00) 
1.00 (0..00 – 
2.00) 
0.00 (0.00 – 
1.00) 
 
DF Prevalence 
(%) 
20.00% (5) 4.35% (1)  
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
37.50% (3) 20.00% (1) 16.67% (1) 0% 0% 0% 0% 14.29%  
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Mean NITBUT values, at baseline and subsequent visits, are shown in Table 38. There 
was no significant difference within each treatment group (Friedmans p > 0.05) or between 
the treatments (KW p > 0.05), at any time over the eight weeks. With the control treatment, 
mean NITBUT reduced by approximately 3 seconds after eight weeks, although this drop 
was not found to be significant (Friedmans: p = 0.25). For OCuSOFT, shampoo and face 
wash treatments, NITBUT remained relatively stable over the eight weeks. Thus, none of 
the over-the-counter lid scrub treatments used in the current study appeared to have an 
adverse effect on NITBUT. 
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Table 38. Non-Invasive tear break-up time (median, IQR) and ocular surface staining (median, IQR) before and after treatment. BL: Baseline, 
W2: Week Two, W4: Weeks Four, W8: Week Eight, KW: Kruskal Wallis, F: Friedmans  
Variable Time Control (n=12) OCuSOFT (n=12) Shampoo (n=11) Face wash (n=13) KW 
Non-Invasive 
Tear Break Up 
Time (sec) 
BL 5.24 (3.34 – 13.89) 5.94 (3.12 – 10.54) 4.47 (3.27 – 6.40) 4.20 (3.37 – 8.85) p = 0.92 
W2 4.12 (3.05 – 8.04) 5.50 (3.03 – 10.73) 4.85 (3.30 – 7.33) 4.33 (2.90 – 5.63) p = 0.81 
W4 5.30 (3.27 – 6.30) 6.10 (3.85 – 13.98) 6.27 (3.97 – 7.63) 4.13 (3.37 – 6.93) p = 0.57 
W8 4.04 (3.32 – 5.17) 6.94 (3.23 – 9.91) 4.57 (2.83 – 11.30) 5.70 (4.47 – 7.83) p = 0.63 
F  p = 0.25 p = 0.54 p = 0.81 p = 0.87  
Ocular Surface 
Staining 
(0-15) 
BL 0.00 (0.00 – 1.00) 1.00 (0.00 – 2.00) 1.00 (0.00 – 2.00) 0.00 (0.00 – 1.00) p = 0.34 
W2 0.00 (0.00 – 0.50) 0.00 (0.00 – 1.00) 0.00 (0.00 – 1.00) 0.00 (0.00 – 0.00) p = 0.75 
W4 0.00 (0.00 – 0.50) 0.50 (0.00 – 1.00) 0.00 (0.00 – 1.00) 0.00 (0.00 – 0.00) p = 0.50 
W8 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) 0.00 (0.00 – 2.00) 0.00 (0.00 – 0.00) p = 0.12 
F  p = 0.20 p = 0.07 p = 0.71 p = 0.78  
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Ocular surface staining median and IQR, at baseline and subsequent visits, are also 
shown in Table 38. Due to the nature of the study cohort; young healthy individuals with 
no ocular surface disease; there was very little ocular surface staining present at baseline in 
all groups (KW p = 0.34). The aim was to see if any of the treatments caused an adverse 
reaction, for e.g. increase in ocular surface staining with use. As can be seen from Table 
38, there was no significant increase in ocular surface staining over the duration of the study 
in any group. 
Contact lens wearers accounted for 40% (n = 19/48) of the study cohort. The use of 
contact lenses was not found to have any impact on baseline measurements (Table 39). Raw 
data on the breakdown of baseline measurements between contact lens wearers and non-
contact lens wearers within each treatment group is shown in Table 39. Statistical analysis 
on contact lens wearers within each treatment group is not given, as there was insufficient 
data for statistical significance. The median and IQR for quantity of DF for all treatment 
groups in both contact lens wearers and non-contact lens weaers was 0.00 (0.00 – 0.00) and 
has not been included in Table 39. 
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Table 39. Baseline descriptives (median, IQR) for contact lens wearers and non-contact lens wearers. U: Mann-whitney U test 
Baseline Descriptives 
 No Contact Lens Wear (n = 29) Contact Lens Wear (n = 19) 
P 
value 
Osmolarity 
(mOsm/L) 
307.00 (299.50 = 314.50) 305.00 (298.00 – 311.00) 0.56U 
Control  
(n = 7) 
OCuSOFT 
(n = 9) 
J&J  
(n = 6) 
TTFW  
(n = 7) 
Control (n = 
4) 
OCuSOFT 
(n = 3) 
J&J  
(n = 5) 
TTFW 
 (n = 6) 
 
307.00 
(299.00 – 
311.00) 
315.00 
(303.00 – 
335.00) 
303.50 
(300.00 – 
308.00) 
301.00 
(298.00 – 
310.00) 
304.00 
(297.00 – 
305.00) 
302.00 
(298.00 – 
309.00) 
312.00 
(303.00 – 
313.00) 
308.00 
(297.00 – 
309.00) 
 
Variability 
(mOsm/L) 
6.00 (2.00 – 8.50) 4.00 (1.00 – 12.00) 0.98U 
Control OCuSOFT J&J  TTFW Control OCuSOFT J&J TTFW  
4.00 (1.00 – 
8.00) 
7.00 (6.00 – 
9.00) 
3.00 (2.00 – 
8.00) 
3.00 (1.00 – 
9.00) 
5.00 (1.00 – 
12.00) 
4.00 (2.00 – 
5.00) 
4.00 (1.00 – 
5.00) 
7.50 (3.00 – 
18.00) 
 
Modified 
OSDI  
(0 – 100) 
11.67 (5.00 – 30.83) 11.67 (6.67 – 20.00) 0.84U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
13.33 (11.67 
– 31.67) 
11.67 (3.33 – 
15.00) 
23.33 (3.33 – 
45.00) 
6.67 (3.33 – 
11.67) 
11.67 (10.00 
– 12.50) 
8.33 (6.67 – 
31.67) 
6.67 (5.00 – 
20.00) 
15.00 (10.71 
– 32.69) 
 
NIBUT 
(secs) 
4.93 (3.29 – 11.67) 4.35 (2.99 – 6.14) 0.23U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
13.30 (4.50 
– 15.23) 
4.93 (3.03 – 
9.70) 
6.34 (4.13 – 
11.73) 
4.03 (2.77 – 
4.77) 
3.37 (2.70 – 
3.57) 
6.03 (5.85 – 
11.85) 
4.23 (3.00 – 
4.47) 
4.53 (3.93- 
12.93) 
 
Ocular 
Surface 
Staining 
 (0-15) 
0.00 (0.00 – 1.00) 0.00 (0.00 – 1.00) 0.89U 
Control OCuSOFT J&J TTFW Control OCuSOFT J&J TTFW  
0.00 (0.00 – 
1.00) 
1.00 (0.00 – 
2.00) 
1.00 (0.00 – 
1.00) 
0.00 (0.00 – 
1.00) 
1.00 (0.00 – 
1.00) 
1.00 (0.00 – 
2.00) 
0.00 (0.00 – 
2.00) 
0.00 (0.00 – 
1.00) 
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Participants were asked to self-report on their compliance throughout the study. 
Compliance results are shown in Figure 29. Only the control group demonstrated a 
significant drop in compliance (Friedmans: p = 0.04). Post-hoc Bonferroni adjusted WSR 
test pairwise comparison (adjusted α = 0.05/3 = 0.0167) found significant reduction in 
compliance after two weeks:  from week two to week four (p = 0.01) and from week two 
to week eight (p = 0.007). The overall lowest compliance throughout the eight weeks was 
seen with the shampoo group. After two weeks the compliance within this group was < 
70%. The OCuSOFT group had the highest overall compliance throughout the study and 
remained at > 70% over the eight weeks.  
Figure 29. Self-reported percentage compliance over the duration of the study. 
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Participants were also asked to give feedback regarding if they would recommend the 
treatment for people with blepharitis or dry eyes. After eight weeks of treatment; 66.67% 
of participants using control treatment, 83.33% using OCuSOFT, 72.73% using shampoo, 
and 69.23% using face wash said they would recommend the treatment. The reasons given 
for not recommending the treatments were as follows: The treatment made no difference 
(Control n = 4, OCuSOFT n = 1, Shampoo n = 3, TTFW n = 1), the treatment was 
uncomfortable and irritating during use (TTFW n = 3) and their eyes felt dryer after use 
(OCuSOFT n = 1).  
6.5 Discussion 
As previously described in Chapter 3, Section 3.5, the overall prevalence of DF 
reported in the literature varies greatly; likely due to the differences in participant ages and 
techniques used for detecting presence of the mites. As mentioned in Chapter 1, DF has 
consistently been associated with increasing age (Section 1.6.1),13,28,77,253 blepharitis 
(Section 1.7.2),7,43,46,49,64,253 dermatological conditions (Section 1.6.2),69–71,81,82 and 
systemic diseases (Section 1.6.3).20,24,92,93,107,108,113 Nonetheless, higher prevalence values 
have also been established in normal, healthy individuals.23,46,254,255 Kemal et al23 
discovered an overall prevalence of 26.67% on the eyelashes of normal individuals (mean 
age 37.5 ± 16.5 years). In the same study, in control participants < 20 years of age, the 
authors’ discovered a 16.67% prevalence of DF,23 which is in good agreement with the 
results found in the current study (14.60%). Kaᶀatas et al46 discovered a higher prevalence 
of 54.9% DF on the eyelashes of control participants, however they were considerably older 
than participants in the current study: 54.6 ± 13.4 years. Zhao et al254 discovered an overall 
prevalence of 67.6% DF in the skin of a young study cohort (aged 13 – 22 years). Karaman 
et al255 discovered a 37% prevalence DF among college students living in shared 
 178 
 
accommodation. The higher prevalence values found by Zhao et al254 and Karaman et al255 
in comparison to the current study are most likely due to the sampling methods used: skin 
sampling versus eyelash epilation. The low prevalence of DF discovered in the current 
study further re-enforces that DF can be found among young, normal, healthy individuals. 
Evidence-based practice is steadily becoming a principal element of health care, 
including optometry.256–259 Evidence-based health care is the clear and careful use of 
current ‘best evidence’ in clinical decision making with respect to the treatment and 
management of patients.260 In recent years, several studies have examined the clinical 
efficacy of eyelid hygiene products with respect to Demodex blepharitis.13,15,35,52 However, 
there is limited evidence available for practitioners on the safety of these products. The 
results of the current study will help guide practitioners on the safety of such products that 
are often used in close contact with the ocular surface.  
 Subjective symptoms improved in all treatment groups, including the control group 
with water. In a meta-analysis of placebo controlled trials it was found that there was no 
statistically significant difference in trials with continuous subjective outcome measures 
between treatment and placebo.261 The placebo effect occurs when a participant experiences 
a beneficial effect from the control treatment which cannot be attributed to the properties 
of the treatment itself, and is therefore believed to be a psychological belief by the patient 
in the treatment. However, in the current study, the control treatment used was water. 
Participants were aware that it was water, and as predominantly students of optometry, were 
also aware that the likelihood of water having a therapeutic effect was small. Yet, an 
improvement in symptoms was demonstrated. It is possible that the control used did have 
some therapeutic effect, as the physical nature of rubbing the eyelids nightly, even if just 
using water, could help clean and remove some of the bacterial load at the eyelid margin.262 
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This therapeutic rubbing of the eyelids could also account for the subjective improvement 
detected across all four groups. Although subjective symptoms improved across all four 
groups, the only significant reduction in symptoms was with the baby shampoo treatment. 
The authors were surprised, as baby shampoo is a detergent and has previously been 
reported to have a stinging and uncomfortable sensation when used.186,263 The authors 
postulate that although no significant difference in symptoms was found at baseline 
between the four groups, the baby shampoo group did have the highest symptoms of the 
four groups (OSDI = 15.00 IQR: 3.33 – 31.67). High baseline scores have been associated 
with high placebo responses,262 believed to be due to a ‘regression to the mean’.264  
 Tear osmolarity has been found to be one of the most effective methods for detecting 
ocular surface inflammation and DED.176,206,251 The biological range of tear osmolarity 
values in the lower tear meniscus varies from 275 mOsm/L to 400 mOsm/L; with higher 
numbers indicating greater surface inflammation.206 Tear osmolarity values between 308 
mOsm/L - 316 mOsm/L have been recommended in the literature as cut-off referent values 
for dry eye diagnosis.176,177,251 A cut-off of 308 mOsm/L is considered most sensitive to 
distinguishing normal participants from participants with mild DED.176,177 Whereas, a cut-
off of 316mOsm/L is considered to better discriminate between mild and moderate – severe 
dry eye, and has an overall predictive accuracy of 89%.251  In the current study, at baseline, 
the mean osmolarity values for the control, shampoo and face wash treatment groups were 
< 308 mOsm/L, and can therefore be considered within that normal range value. The 
OCuSOFT treatment group had a slightly higher mean osmolarity value at baseline (315.8 
mOsm/L), however it was still within the cut-off referent recommended by many previous 
studies.177,251 Although the mean osmolarity in the OCuSOFT group was slightly higher at 
baseline, KW comparison of means found no statistical significant difference between the 
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four groups. Furthermore, the aim of the study was to assess if each of the treatments used 
had a negative impact on tear film osmolarity. As can be seen from the current study, mean 
tear osmolarity dropped in all four groups: although, not significantly.  A study published 
in 2014, comparing the efficacy of thermal massagers and artificial eye drops for the 
treatment of DED, also found that osmolarity values improved post treatment in both 
groups.265 The authors concluded that the improvement in lipids to the ocular surface helped 
to improve tear film stability. The use of lid hygiene could be beneficial for reducing tear 
osmolarity by reducing the overall bacterial load at the eyelid margin, and the pressure 
applied to the eyelids during scrubbing effect may also provide an element of massage to 
the eyelids.  
A reduction in tear osmolarity suggests a reduction in ocular surface inflammation and 
improvement in tear film stability. Inter-eye variability of > 8mOsm/L is considered an 
indicator of tear film stability.176 Lemp et al176 found that the variability between two eyes 
in normal, mild to moderate dry eye and severe dry eye patients was 6.9 ± 5.9 mOsm/L, 
11.7 ±10.9 mOsm/L, and 26.5 ± 22.7 mOsm/L, respectively. In the current study, variability 
values at baseline were in good agreement with those found by Lemp et al176: 4.50 (1.00 – 
10.00) mOsm/L CoV 0.89% (control), 6.00 (4.50 – 8.00) mOsm/L CoV 0.45% 
(OCuSOFT), 3.00 (2.00 – 8.00) mOsm/L CoV 0.99% (shampoo), and 4.00 (3.00 – 11.00) 
mOsm/L CoV 1.36% (face wash). However, post treatment inter-eye variability was found 
to increase slightly in all groups, and significantly with the shampoo group: 6.00 (3.00 – 
15.00) mOsm/L CoV 1.30% (control), 4.50 (2.00 – 10.50) mOsm/L CoV 1.05% 
(OCuSOFT), 15.00 (8.00 – 21.00) mOsm/L CoV 0.63% (shampoo), and 11.00 (4.00 – 
18.00) mOsm/L CoV 1.02% (face wash). Variation in measurements detected in the current 
study have been found to be less than that previously reported. TearLabTM has previously 
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been shown to provide repeatable tear osmolarity measurements with CoV between 1.6% - 
1.9%.178 The increase in inter-eye variability detected in the shampoo group can be 
considered clinically significant, as the increase in median is >8mOsm/L.  
With the exception of OCuSOFT, post-treatment inter-eye variability values found in 
the current study suggest mild-moderate dry eye according to Lemp et al176 standards. 
Therefore, as symptoms and mean osmolarity reduced in the current study suggesting no 
adverse effects of the treatments used, the inter-eye variability in osmolarity values suggests 
the contrary. Although slight increases in inter-eye variability were detected in all groups, 
only the increase with shampoo was found to be significant. This significant instability in 
tear osmolarity with shampoo occurred even in the presence of relatively low participant 
compliance within that group (< 70% over the eight weeks). A recent study by Sung et al186 
discovered that the use of diluted baby shampoo appeared to negatively impact the tear film 
by causing a reduction in levels of MUC5AC, a goblet cell-specific mucin; suggesting that 
the use of baby shampoo caused a reduction in goblet cell density.266,267 Hyperosmolarity 
acts as a stressor to the ocular surface, causing morphological and inflammatory changes 
including a reduction in mucin producing goblet cells.268 In DED, the same is true in 
reverse: a reduction in mucin producing goblet cells can cause tear film instability and 
hyperosmolarity.269 Findings from the current study correlate well with Sung et al186: The 
increase in tear film instability and inter-eye variability found post-treatment in the 
shampoo group could be as a result of adverse changes to goblet cell density caused by the 
baby shampoo.   
 Non-invasive tear break-up time and ocular surface staining can also be indicators of 
tear film instability and ocular surface inflammation. However, in the current study none of 
the eyelid hygiene products used caused negative effects on NITBUT or ocular surface 
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staining. This was in keeping with Sung et al186 who found no significant change in 
NITBUT or ocular surface staining after four weeks of treatment with baby shampoo or 
TheraTears® SteriLid® cleanser. Similarly, in a recent study by Ngo et al241 investigating 
the short-term responses associated with eyelid hygiene products available for the treatment 
of DF; the authors found a significant decrease in NITBUT using a 50% tea tree based 
formula, but no significant change in NITBUT using any of the other eyelid cleansers, 
including OCuSOFT and two other TTO based products (TheraLid® and Cliradex ®). 
Although the timings of repeat measurements were different, and the eyelid hygiene 
products investigated were different, the outcome is similar. It appears that regardless of 
whether NITBUT was measured after 10 minutes,241 four weeks,186 or eight weeks of 
treatment; common eyelid hygiene products do not appear to have a negative effect on 
NITBUT.  
 The current study provides practitioners with a good insight into realistic compliance 
from patients. It is possible that due to reduced compliance over the course of the study, 
potential significant adverse events have not been elucidated in the current study. However, 
as the current study may be more indicative of a ‘real-world’ blepharitis treatment scenario, 
the authors believe that the study provides a good representation of the safety of the 
blepharitis eyelid hygiene products used over the course of eight weeks. Longer studies 
would be required to confirm absolute safety in the long-term. The lowest reported 
compliance in the current study was within the shampoo group at 64.77%, and the control 
group at 66.07%. However, these were still greater than that reported in a recent study 
investigating patient compliance with eyelid hygiene over six weeks, in which self-reported 
compliance was only 55%.270 In that compliance study, participants were also asked to 
clean their eyelids using a diluted solution of baby shampoo or warm water. Reasons given 
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for non-compliance included inconvenience, forgetfulness, and a belief that therapy was 
not required.270 The authors believe that these underlying reasons are likely to also exist for 
the control group in the current study. The OCuSOFT group had the highest overall 
compliance throughout the study and remained at > 70% over the eight weeks. The authors 
believe that this may be due to the convenient nature of using this type of treatment. 
However, it is also possible that as the participants in this study were optometry students, 
they may have had a better understanding of the potential benefits of eyelid hygiene and 
subsequently overall compliance may have been greater as a result. 
Participants were also asked if they would recommend the product to future blepharitis 
patients. OCuSOFT received the highest recommendation (83.33%), followed by shampoo 
(72.72%), face wash (69.23%) and control (66.67%). The control group received the lowest 
recommendation due to its presumed lack of therapeutic ability. Although the face wash 
was TTO based, and thus has anti-bacterial, anti-microbial and anti-inflammatory potential, 
it received a lower recommendation due to the discomfort associated with the product. This 
is in agreement with the study by Ngo et al241 that found that tea tree based eyelid cleansers 
marketed to treat Demodex blepharitis caused varying degrees of ocular irritation. Ngo et 
al241 also found that OCuSOFT caused minimal irritation which corresponded well with the 
higher recommendation for its use from participants in the current study.  
As participants were required to make their own 10% baby shampoo solution at home, 
this could have caused differences in the % solution being used by the participants. It is 
possible that this may have impacted the results, and future studies should have a more 
standardised % solution to avoid this. 
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6.6 Conclusion 
A low prevalence of DF was found amongst young, healthy individuals. Overall, the 
three eyelid hygiene products investigated were well tolerated. Symptoms improved for all 
groups, and there were no negative effects on NITBUT or ocular surface staining. There 
was a mild increase in tear film instability and inter-eye variability with both OCuSOFT 
and TTFW. However, this also occurred with control lid hygiene scrubs with water, and 
these changes were not found to be significant. In contrast, 10% baby shampoo caused a 
significant increase in inter-eye osmolarity variability and tear film instability, suggesting 
a possible increase in ocular surface inflammation. This study was conducted on healthy 
participants with healthy tear films and ocular surface. Future studies should consider 
inclusion of participants with compromised tear film and ocular surface to elicit a more 
magnified response to treatment. 
The results of the study indicate that Demodex blepharitis related eyelid hygiene 
products OCuSOFT and TTFW, used in the pilot and extended treatment study, 
demonstrated no significant adverse ocular reactions. A paper on the results of this study 
has been recently accepted for publication in Contact Lens & Anterior Eye. 
Thus far in this thesis, treatments for Demodex blepharitis have concentrated on the 
traditional lid hygiene method, and the safety and efficacy of the different products tested. 
As mentioned previously in Section 3.2, DF is susceptible to damage from heat. In the 
treatment of MGD, heat is often applied to the eyelids, to help soften and improve the flow 
of meibum to the tear film and ocular surface. Heat applied to the eyelids, must pass through 
the eyelash follicles to reach the meibomian glands underneath. Therefore, in theory, heat 
applied to the eyelids in the treatment of MGD, may have a dual therapeutic effect by also 
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killing DF present within the eyelash follicles. The following chapter, Chapter 7, will 
discuss the relationship between DF and MGD in more detail, and will examine the effect 
that heat therapy can have on treating Demodex blepharitis. The results of this study have 
been recently accepted for publication in Current Eye Research and has been adapted 
accordingly for Chapter 7.     
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CHAPTER SEVEN: THE EFFICACY OF WARM COMPRESSES IN THE 
TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION AND DEMODEX 
FOLLICULORUM BLEPHARITIS  
7.1 Abstract 
Purpose: To examine and evaluate the effect of warm compresses on MGD and DF 
blepharitis.   
Methods: Forty-two participants (13 males, 29 females; median age of 59.00 years) 
enrolled and completed the two-month warm compress treatment study. Three warm 
compress treatments were compared: Warm face cloth, MGDRx EyeBag® (Eyebag) and 
OPTASETM Moist Heat Mask (Optase). Participants attended for four visits: baseline, two 
weeks, four weeks, and eight weeks. Similar to previous studies, examinations at each visit 
included: subjective symptoms, osmolarity, NITBUT, ocular surface staining, Schirmer I, 
number of expressible glands and quality of expressed meibum. Eyelash manipulation and 
epilation were conducted to assess for the presence of DF.  
Results: Utilising a composite score of meibum quality and expressibility, MGD grade 
reduced significantly with the Eyebag and the Optase (p < 0.05). No significant difference 
in efficacy for treating MGD was observed between the two devices (p > 0.05). The Optase 
was the only compress that significantly reduced the quantity of DF after eight weeks of 
treatment. Symptoms and ocular surface staining also improved significantly with the 
Eyebag and the Optase (p < 0.05), but not the warm face cloth (p > 0.05). There was no 
significant change detected in osmolarity, NITBUT or Schirmer I with any treatment (p > 
0.05). 
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Conclusion: Both the Eyebag and Optase exhibited superior efficacy in treating signs 
and symptoms of MGD, compared to the use of a warm face cloth, over the eight-week 
period. The Optase demonstrated dual therapeutic abilities, treating both MGD and DF 
blepharitis. Repeated application of warm compresses remains an effective home-remedy 
for the treatment of MGD. 
7.2 Introduction 
The meibomian glands are a group of holocrine glands found in the upper and lower 
eyelids. Structurally, they consist of parallel rows of secretory acini organised around a 
central duct, which opens onto the eyelid margin.271,272 As mentioned in Section 1.7.3, the 
function of the meibomian glands is to supply meibum to the ocular surface: preventing 
tear film evaporation, improving vision, and protecting against microbial agents and 
organic matter such as dust.133–136 Disruption to this supply, often through terminal duct 
obstruction or changes in glandular secretion, can interfere with the homeostasis of the tear 
film and ocular surface: leading to inflammation and subsequent symptoms of 
discomfort.135,273  
The eyelash follicles are situated within the eyelids, anterior to the meibomian glands. 
Due to their close proximity with one-another, anomalies of the eyelash follicles and the 
meibomian glands are frequently seen in combination.4–7 For example, inhabitation of the 
eyelash follicles and meibomian glands with Demodex.  
The association between DB infestation and severe MGD and keratitis has been 
described in the literature.6,274 Although DF are generally associated with anterior 
blepharitis, the prevalence of DF in the eyelash follicles of MGD patients has been reported 
to vary between 46.5% to 85%.7,30,48   
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The mainstay treatment recommended for Demodex blepharitis is lid scrubs with 
diluted quantities of TTO.15,35,52 Although lid scrubs have been indicated as an early 
treatment option for patients with mild MGD, warm compress therapy remains the leading 
treatment for MGD.138 For warm compresses to be effective, heat must pass through the 
anterior eyelid structures, including the eyelashes, to warm and liquify thickened meibum 
within the meibomian glands. The melting temperature of normal meibum is circa 32 °C, 
and is higher at approximately 35 °C in obstructed glands with thickened secretions.138,275 
Hence, it is suggested that warm compresses need to heat the inner eyelid to a temperature 
of ≥ 40 °C, to be effective at treating MGD.192 However, both DB and DF prefer lower 
temperatures, and Zhao et al197 have shown that temperatures above 37 °C are damaging to 
DF. Higher temperatures cause death by protein coagulation and denaturation, and eventual 
paralysis of the DF nervous system.197 Murakami et al276 have demonstrated that although 
there are differences in the innermost eyelid temperatures achieved by various warm 
compresses, most methods do manage to reach outer eyelid temperatures of ≥ 40 °C. 
Therefore, as heat from the warm compress spreads through the eyelash follicles to heat the 
inner eyelid, it could conceivably have a killing effect on DF within the eyelash follicle.  
Traditionally, home based warm compresses were carried out using a warm face 
cloth.138,277 However, this method has its limitations, including poor heat retention,278 and 
inconvenience leading to reduced compliance.138 Over the years, more patient-friendly 
warm compresses have become available, such as the Eyebag and the Optase. Although 
both warm compresses are similar; they are heated in a microwave, and one heating is 
required to provide 10 minutes of therapy; there are fundamental differences between them. 
The Optase contains HydroBeadTM Technology, which absorbs moisture from the air, and 
when heated, releases it to provide a moist heat. Optase manufacturers report temperatures 
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from 50 °C to 41 °C over the 10-minute duration of therapy.279 The moist heat softens 
eyelash debris in patients with anterior blepharitis, and restores moisture to the eye and 
surrounding area, in conjunction with improving meibum flow, tear film quality and 
reduced tear film evaporation.279 In contrast, the Eyebag contains flax seed and provides a 
dry heat when applied to the eyelids. Manufacturers recommend it for relief of, including 
but not limited to: MGD, blepharitis, dry eye syndrome, and rosacea. Previous research has 
shown that the Eyebag achieves temperatures of 46 °C dropping to 39 °C after 5 minutes.280 
However, their efficacy in the treatment of Demodex blepharitis had not previously been 
investigated. As such, the aim of the current study was to assess the therapeutic effect of 
these common home-based warm compresses on DF infestation in MGD patients. 
7.3 Methods 
  This was a single-centre, interventional, randomised, controlled, examiner masked 
clinical trial. All participants were recruited through the National Optometry Centre’s 
private and student optometry clinics. Written informed consent was obtained from all 
participants prior to enrolment. 
Minimum sample size required for statistical significance was calculated using 
G*Power analysis. Effect size was calculated from the mean and SD of the difference of 
DF presentation on lash manipulation and microscopic examination from previous data 
collected: 0.84/1.59 = 0.52.  A priori analysis for repeated measures ANOVA between 
factors was conducted (α = 0.05, 1-β = 0.80, effect size = 0.5: 3 groups, 2 measurements). 
The minimum total sample size required was 33 participants; 11 participants per group. 
Fifty participants in total enrolled between April 2017 and May 2018. Participants had to 
be ≥ 18 years of age and have ≥ G1 MGD based on meibomian gland expression according 
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to the diagnostic subcommittee of the International Workshop on Meibomian Gland 
Dysfunction,185 to be eligible to participate. Participants were excluded if they: wore contact 
lenses, were pregnant, had a systemic disease or were using topical/systemic medication 
known to affect the eyes, presented with ocular disease (with the exception of MGD and 
blepharitis), were currently using MGD/blepharitis treatment or had used such treatment 
within the last six months, or had ocular surgery in the last six months. 
Participants attended the National Optometry Centre for four visits in total: baseline, 
week two, week four, and week eight. All examinations were conducted in the same room, 
at the same time of day (+/- 30 minutes), by the same examiner (author OM). All 
examinations were conducted in the same order at each visit, from least invasive to most 
invasive170,171: modified OSDI questionnaire refer (Chapter 4), NITBUT (Section 2.3.3), 
osmolarity (Section 2.3.4), ocular surface staining (Section 2.3.5), Schirmer I (Section 
2.3.6), MGD evaluation (Section 2.3.8) and Demodex investigation (Section 2.3.9). Each 
of these examination techniques has been described in detail previously. Participants were 
considered to have ‘dry eye’ if found to have three or more of the following parameters; 
modified OSDI ≥ 13, osmolarity ≥ 308 mOsm/L, inter-eye variability ≥ 8mOsm/L, 
NITBUT < 10 secs, ocular surface staining ≥ 3 Oxford score or Schirmer I score ≤ 
5mm/5min. Cut-off values employed are in keeping with those recommended by DEWS 
II.171 To grade MGD, composite scores were derived from the expressibility and quality of 
meibum from both upper and lower eyelids and used for statistical analysis.185 Similarly, a 
composite score was derived for quantities of DF found on upper and lower eyelids and 
used for statistical analysis. The percentage of participants with DF in each group was also 
determined. Positive DF infestation was defined as the presence of ≥ 1 DF detected on 
either eyelash manipulation or microscopic examination. Based on work by Randon et al65 
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the prevalence of DF was further classified into non-pathogenic (≤ 3 mites) and pathogenic 
infestation (≥ 4 mites) per eye. 
The ICC was determined to examine the agreement in pre-treatment results between 
the right and left eyes for each participant. A two-way mixed analysis with absolute 
agreement and 95% confidence intervals was conducted.281 Results are shown in Table 40. 
As recommended, data analysis was conducted on one eye only for each participant.282 As 
all correlations were between moderate to excellent, either eye was considered eligible for 
selection. Therefore, in keeping with previous studies and osmolarity measurement 
guidelines, the eye selected for data analysis was chosen based on the higher tear osmolarity 
value at baseline.174,176,177 
Table 40. Intraclass correlation co-efficient, two-way mixed effects, absolute 
agreement, average of multiple measurements, 95% confidence interval. Values of less 
than 0.5 indicate ‘poor’ agreement, between 0.5 and 0.75 ‘moderate’ agreement, between 
0.75 and 0.9 ‘good’ agreement, and greater than 0.90 ‘excellent’ agreement.281 
Outcome Measure ICC Reliability 
Quantity Demodex 
folliculorum 
0.71 Moderate 
MGD Grade 0.93 Excellent 
Osmolarity 0.68 Moderate 
Non-invasive Tear 
Brake-Up Time 
0.82 Good 
Ocular Surface Staining 0.77 Good 
Schirmer 0.91 Excellent 
Dry Eye Prevalence 0.67 Moderate 
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Participants were randomly assigned one of three treatments to use at home: Warm 
face cloth (Group 1, conventional treatment: n = 12), Eyebag (Group 2, dry heat: n = 16), 
Optase (Group 3, moist heat: n = 14). Randomisation was achieved using the random 
number generator function on Excel. Each treatment was randomly assigned a number from 
1 to 60. Each participant chose a number and was subsequently given the treatment assigned 
to that number.  
In accordance with manufacturers’ guidelines, each participant was provided with an 
instruction leaflet (refer Appendix 6 (a – c)) and was directed to use the treatment for 10 
minutes twice a day for the first two weeks. Frequency of treatment was reduced to 10 
minutes once a day from weeks three to eight.  
Participants in Group 1 were instructed to pour 200ml of boiled water into a bowl and 
allow it to cool for 10 minutes before commencing treatment. This created a water 
temperature ranging from 50 °C to 39 °C, over the 10-minute treatment time (tested using 
an Easytemp thermometer (HYGIPLAS, Wellingborough, UK) and porcelain bowl). 
Participants’ were advised to re-heat the face cloth every two minutes, by immersing it in 
the same bowl of cooled, boiled water: to maintain temperature at therapeutic levels.191,192   
Group 2 and Group 3 were instructed to heat their compress in the microwave for 15 – 30 
seconds, depending on the power of their microwave, as per manufacturers’ guidelines. 
7.3.1  Statistical Analysis 
Statistical analysis was performed using SPSS (version 25.0). Normality was measured 
using Shapiro-Wilk statistical test. Repeated measures ANOVA with Bonferroni post-hoc 
analysis was used to analyse repeated measures within each group over time for parametric 
data. Friedman’s test was used to analyse repeated measures, within each group, across 
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different visits for non-parametric data. With Friedman’s test, post-hoc analysis was 
conducted, where appropriate, using WSR test for pairwise comparisons, adjusted using 
Bonferroni correction (α = 0.05/number of comparisons: α = 0.05/6 = 0.0083).252 One way 
ANOVA with Bonferroni post-hoc analysis was used to analyse data between continuous 
variables at baseline and at different visits for parametric data. Kruskal Wallis H was used 
for non-parametric data. With KW, post-hoc analysis was conducted, where appropriate, 
using MWU test for pairwise comparison, adjusted using Bonferroni correction (α = 
0.05/number of comparisons: α = 0.05/3 = 0.0167).252  Parametric data was expressed as 
mean ± SD, non-parametric data was expressed as median and IQR. A p-value ≤ 0.05 was 
considered statistically significant, apart from Bonferroni adjusted post-hoc analysis as 
described above.   
7.4 Results 
Fifty participants were enrolled between April 2017 and May 2018. The attrition rate 
was 16%. Four participants withdrew from the study, without any known adverse reactions, 
and were lost to follow-up. Two participants stopped as they felt their symptoms were 
worsening. A further two were removed from data analysis as their records were 
incomplete. Following attrition, 42 participants (13 males and 29 females) with a median 
age of 59.00 (IQR: 50.00 – 69.00) years completed the two-month warm compress 
treatment study. At baseline, the prevalence of DF detected within the entire study cohort 
was 57.11%, with a median quantity of 0.5 (IQR 0.00 – 3.25) and 0.00 (IQR 0.00 – 2.00) 
mites on lash rotation and microscopic examination respectively (WSR: p = 0.008). There 
was no significant difference in age (Group 1: 60.00 (IQR 52.00 – 69.00), Group 2: 59.00 
(IQR 52.00 – 72.50 , Group 3: 59.50 (IQR 32.00 – 68.00), KW: p = 0.75) or quantity of DF 
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on either lash rotation or microscopic examination (KW: p = 0.78 and p = 0.85) between 
the three groups before treatment.  
Table 41 shows median and IQR for quantity of DF at each visit for each treatment 
group. Figure 30 displays the change in quantity of DF detected on eyelash rotation within 
each group over the eight weeks. Within treatment analysis showed that the quantity of DF 
dropped significantly over the duration of the study in Group 3 (Optase) (Friedman’s p = 
0.04). Post-hoc pairwise comparisons using WSR test (alpha adjusted for Bonferroni 
correction) revealed only the change from baseline to week eight to be significant (mean: 
2.64, Range: 0 – 11 versus mean: 1.42, Range: 0 – 8; WSR p = 0.008). There was no 
significant change in DF quantity in Group 1 (Warm Face Cloth) or Group 2 (Eyebag) over 
the eight weeks (Friedman’s p = 0.88 and p = 0.66, respectively). Between treatments 
analysis did not show any significant difference between the treatments over the eight 
weeks (KW p > 0.05, refer Table 39).  
The mean and range for quantity of DF detected on microscopic examination at each 
visit, for each group, are also shown in Table 41. In contrast to results detected on eyelash 
rotation, there was no significant change in DF quantity detected on microscopic 
examination over time in each group (Friedman’s p > 0.05) or between treatments (KW p 
> 0.05).  
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Table 41. Demodex folliculorum quantity (median, IQR), and MGD grade (median, IQR) 
before and after treatment. B: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. 
Statistical Tests Applied: α ≤ 0.05 significant. *Significant results highlighted in bold. 
Variable Time 
Group 1 
(Warm Face 
Cloth) 
N = 12 
Group 2 
(MGDRx Eye 
Bag®) 
N = 16 
Group 3 
(Optase Moist 
Heat MaskTM) 
N = 14 
Kruskal 
Wallis 
Quantity 
Demodex 
folliculorum 
(n) 
Lash 
Rotation 
 
BL 0.00 (0.00 – 5.25) 0.50 (0.00 – 2.00) 1.50 (0.00 – 4.25) p = 0.78 
W2 0.50 (0.00 – 1.75) 0.00 (0.00 – 2.00) 0.00 (0.00 – 1.00) p = 0.69 
W4 0.50 (0.00 – 3.50) 0.00 (0.00 – 3.00) 0.00 (0.00 – 4.00) p = 0.91 
W8 0.50 (0.00 – 8.50) 0.00 (0.00 – 0.00) 0.00 (0.00 – 1.50) p = 0.28 
Friedman’s  p = 0.87 p = 0.64 p = 0.04* 
Kruskal 
Wallis 
Quantity 
Demodex 
folliculorum 
(n) 
Microscope 
 
BL 0.00 (0.00 – 1.75) 0.00 (0.00 – 1.00) 0.00 (0.00 – 2.75) p = 0.84 
W2 1.00 (0.00 – 2.75) 0.00 (0.00 – 0.00) 0.00 (0.00 – 0.00) p = 0.02 
W4 0.50 (0.00 – 1.00) 0.00 (0.00 – 0.00) 0.50 (0.00 – 1.75) p = 0.32 
W8 0.00 (0.00 – 1.75) 0.00 (0.00 – 0.00) 0.00 (0.00 – 1.00) p = 0.49 
Friedman’s  F p = 0.72 F p = 0.67 F p = 0.18 
Chi-
square 
MGD 
Grade (0-3) 
BL 2.00 (1.00 – 2.00) 2.00 (1.00 – 2.00) 1.00 (1.00 – 2.00) p = 0.16 
W2 2.00 (1.00 – 2.00) 2.00 (1.00 – 2.00) 1.00 (1.00 – 2.00) p = 0.22 
W4 1.00 (1.00 – 1.50) 1.00 (1.00 – 2.00) 1.00 (1.00 – 1.00) p = 0.92 
W8 1.00 (0.00 – 1.50) 1.00 (0.00 – 1.00) 1.00 (0.00 – 1.00) p = 0.33 
Friedman’s  p = 0.008* p = 0.002* p = 0.002*  
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Figure 30. Box plot illustrating the change in quantity of Demodex folliculorum at 
two, four, and eight weeks, with each treatment. Post – hoc analysis: Wilcoxon signed 
ranks test pairwise comparison with Bonferroni adjusted correction applied (α ≤ 0.0083 
significant). X represents the mean change in quantity of Demodex folliculorum. B: 
Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant results highlighted 
in bold. 
 
Post - hoc Face Cloth MGDRx 
EyeBag® 
OPTASETM Moist 
Heat Mask 
B – W2 0.271 0.730 0.023 
B – W4 0.677 0.523 0.313 
B – W8 0.527 0.344 0.008* 
W2 – W4 0.496 0.713 0.500 
W2 – W8 0.173 0.713 1.000 
W4 – W8 0.831 1.000 0.125 
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Table 41 also displays MGD grade mean and SD at each visit, for each group. A 
significant improvement in MGD grade with time for each treatment was detected 
(Friedman’s p < 0.05, Table 39). The box plot in Figure 31 shows MGD grade at each visit, 
for each group. However, post-hoc analysis using alpha adjusted WSR test pairwise 
comparisons revealed; only improvements from baseline to week eight in Group 2 (Eyebag)   
(WSR p = 0.008); and improvements from baseline to week eight (WSR p = 0.002) and 
week two to week eight (WSR p = 0.003) in Group 3 (Optase); were found to be significant. 
There was no significant difference found between the treatments at any time point over 
the eight weeks (KW p > 0.05, Table 41). 
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Face Cloth MGDRx EyeBag® 
OPTASETM Moist 
Heat Mask 
Median 
(IQR) 
W2 0 (0 – 0.75) 0 (-1 – 0) 0 (0 – 0) 
W4 -1 (-1 – 0) -0.5 (-1 – 0) 0 (-1 – 0) 
W8 -1 (-1.75 - 0) -1 (-1 – 0) -1 (-1 – 0) 
p value  F p = 0.008* F p = 0.002* F p = 0.002* 
 
 
 
 
 
X represents the mean change in MGD Grade. Post – hoc analysis: Wilcoxon signed 
ranks test pairwise comparison with Bonferroni adjusted correction applied (α ≤ 0.008 
significant). BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant 
results highlighted in bold. 
Figure 31. Box plot illustrating MGD Grade, derived from composite quality and 
expressibility scores of both upper and lower eyelids, at baseline, and two, four, and eight 
weeks, with each treatment.  
  
Post - hoc Face Cloth MGDRx 
EyeBag® 
OPTASETM Moist 
Heat Mask 
BL – W2 0.414 0.527 1.000 
BL – W4 0.035 0.035 0.180 
BL – W8 0.030 0.008* 0.002* 
W2 – W4 0.021 0.025 0.414 
W2 – W8 0.018 0.024 0.003* 
W4 – W8 0.414 0.157 0.058 
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Table 42 demonstrates the prevalence of pathogenic and non-pathogenic infestation 
for each treatment group, at each point in time.  The overall prevalence of DF in each group 
at baseline was: Group 1 (Warm Face Cloth) - 66.67%, Group 2 (Eyebag) – 50.00%, and 
Group 3 (Optase) – 57.14%. No significant difference was detected between the groups 
(KW p = 0.61). This reduced to an overall prevalence of: Group 1 – 58.33%, Group 2 – 
25.00% and Group 3 – 50.00% after eight weeks. As can be seen from Table 42, Group 3 
showed the greatest change in pathogenic infestation. This likely accounted for the reason 
Group 3 appeared to have the greatest overall effect on DF quantity. Group 2 appeared to 
have the greatest overall effect on DF prevalence. Nonetheless, no significant difference in 
prevalence was established between the groups at week eight (KW p = 0.19). Furthermore, 
no significant difference in prevalence of DF infestation was established within the groups 
over the eight weeks: Group 1 (Friedman’s p = 0.99), Group 2 (Friedman’s p = 0.18) and 
Group 3 (Friedman’s p = 0.49). 
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Table 42. Prevalence of pathogenic and non-pathogenic Demodex folliculorum infestation in 
each treatment group, at each time point. B: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight.  
 
 
Time 
No Demodex % 
(n) 
Non-Pathogenic 
Infestation % (n) 
Pathogenic 
Infestation % (n) 
Overall 
Prevalence 
Group 1: 
Face Cloth 
(n = 12) 
BL 33.33 (n = 4) 33.33 (n = 4) 33.33 (n = 4) 66.67% (n = 8) 
W2 33.33 (n = 4) 41.67 (n = 5) 25.00 (n = 3) 66.67% (n = 8) 
W4 33.33 (n = 4) 41.67 (n = 5) 25.00 (n = 3) 66.67% (n = 8) 
W8 41.67 (n = 5) 25.00 (n = 3) 33.33 (n = 4) 58.33% (n = 7) 
 Difference +8.34% (n = 1) -8.34% (n = -1) 0.00% (n = 0) -8.14% (n = -1) 
Group 2: 
MGDRx 
EyeBag® 
(n = 16) 
BL 50.00 (n = 8) 31.25 (n = 5) 18.75 (n = 3) 50.00% (n = 8) 
W2 62.50 (n = 10) 12.50 (n = 2) 25.00 (n = 4) 37.50% (n = 6) 
W4 62.50 (n = 10) 25.00 (n = 4) 12.50 (n = 2) 37.50% (n = 6) 
W8 75.00 (n = 12) 12.50 (n = 2) 12.50 (n = 2) 25.00% (n = 4) 
 Difference +25.00% (n = 4) -18.75% (n = -3) -6.25% (n = -1) -25.00% (n = -4) 
Group 3: 
OPTASETM 
Moist Heat 
Mask  
(n = 14) 
BL 42.86 (n = 6) 28.57 (n = 4) 28.57 (n = 4) 57.14% (n = 8) 
W2 50.00 (n = 7) 35.71 (n = 5) 14.29 (n = 2) 50.00% (n = 7) 
W4 50.00 (n = 7) 28.57 (n = 4) 21.43 (n = 3) 50.00% (n = 7) 
W8 50.00 (n = 7) 35.71 (n = 5) 14.29 (n = 2) 50.00% (n = 1) 
 Difference +7.14% (n = 1) +7.14% (n = 1) -14.29% (n = -2) -7.14% (n = -1) 
 
Figure 32 illustrates a box plot of the modified OSDI score for each group at each 
visit. Table 43 displays the mean and SD of the modified OSDI symptoms score for each 
group, at each visit. There was a significant improvement in symptom score with time for 
each treatment (repeated ANOVA p = 0.04, p = 0.02 and p = 0.02 for Groups 1 – 3, 
respectively). As can be seen from Figure 36, the greatest reduction in symptoms appears 
to be in Group 2 and Group 3. Post-hoc analysis with Bonferroni pair-wise comparison 
revealed; only the reduction in symptoms from baseline to week two and baseline to week 
eight (p = 0.03 and p = 0.008, respectively) in Group 2, and reduction in symptoms from 
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baseline to week two and baseline to week eight (p =0.01 and p = 0.05, respectively) in 
Group 3, were found to be significant. There was no significant difference in modified 
OSDI symptom score between the treatments at any time point over the eight weeks 
(ANOVA p > 0.05, Table 43). 
 
Post - hoc Face Cloth MGDRx EyeBag® OPTASETM Moist 
Heat Mask 
BL – W2 1.000 0.033* 0.013* 
BL – W4 0.266 0.078 0.064 
BL – W8 0.054 0.008* 0.047* 
W2 – W4 0.673 1.000 1.000 
W2 – W8 0.687 0.100 1.000 
W4 – W8 1.000 0.464 1.000 
X illustrates mean change in modified OSDI score. Post – hoc analysis: Bonferroni 
(α ≤ 0.05 significant). BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. 
*Significant results highlighted in bold. 
Figure 32. Box plot illustrating modified OSDI symptom score for each treatment 
groups, at each visit. 
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Table 43. Dry eye parameters; Modified OSDI symptom score (mean ± SD), Osmolarity 
(mean ± SD), tear film instability (%), NITBUT (median, IQR), ocular surface staining 
(median, IQR), Schirmer I (median, IQR), before and after treatment. BL: Baseline, W2: 
Week Two, W4: Week Four, W8: Week Eight. α ≤ 0.05 significant. *Significant results highlighted 
in bold. 
Variable Time Group 1 Group 2 Group 3 ANOVA 
Modified 
OSDI 
Score 
(0-100) 
BL 24.21 ± 15.27 39.81 ± 23.21 39.01 ± 20.34 p = 0.12 
W2 22.05 ± 15.29 27.40 ± 19.29 24.70 ± 18.87 p = 0.69 
W4 15.71 ± 7.86 23.03 ± 19.55 23.65 ± 19.89 p = 0.41 
W8 15.14 ± 12.75 16.67 ± 13.07 26.52 ± 17.15 p = 0.10 
Repeated 
ANOVA 
 p = 0.04* p = 0.02* p = 0.02* ANOVA 
Osmolarity 
(mOsm/L) 
BL 304.17 ± 18.10 303.53 ± 9.55 318.86 ± 13.44 p = 0.008* 
W2 301.27 ± 17.47 304.71 ± 12.98 310.27 ± 16.46 p = 0.41 
W4 303.92 ± 18.88 299.93 ± 13.68 305.92 ± 14.69 p = 0.69 
W8 305.50 ± 18.82 303.07 ± 11.91 312.86 ± 13.37 p = 0.19 
Repeated 
ANOVA 
 p = 0.60 p = 0.86 p = 0.01* Chi-square 
Instability 
(%) 
BL 83.33% 40.00% 71.44% p = 0.06 
W2 54.55% 50.00% 63.67% p = 0.91 
W4 50.00% 53.33% 66.67% p = 0.78 
W8 41.67% 60.00% 64.22% p = 0.53 
Cochran’s Q  p = 0.22 p = 0.87 p = 0.79 
Kruskal 
Wallis 
NITBUT 
(secs) 
BL 4.19 (2.81 – 13.46) 5.15 (2.98 – 11.44) 4.13 (2.60 – 5.60) p = 0.16 
W2 7.63 (2.60 – 13.64) 4.90 (2.83 – 11.32) 3.97 (2.60 – 8.20) p = 0.69 
W4 6.44 (2.83 – 11.10) 6.37 (2.64 – 8.21) 4.17 (.60 – 6.90) p = 0.70 
W8 4.14 (3.14 – 9.46) 6.78 (3.56 – 14.87) 5.13 (2.97 – 5.13) p = 0.34 
Friedman’s  p = 0.95 p = 0.87 p = 0.60 
Kruskal 
Wallis 
Staining  
(0-15) 
BL 1.00 (0.00 – 2.00) 1.00 (0.00 – 1.75) 0.00 (0.00 – 2.00) p = 0.98 
W2 0.00 (0.00 – 2.00) 1.00 (0.00 – 2.00) 1.00 (0.00 – 3.25) p = 0.03* 
W4 0.00 (0.00 – 0.75) 0.00 (0.00 – 1.00) 0.00 (0.00 – 1.00) p = 0.72 
W8 0.00 (0.00 – 0.75) 0.00 (0.00 – 0.75) 0.00 (0.00 – 0.75) p = 0.95 
Friedman’s  p = 0.04* p = 0.007* p = 0.04* 
Kruskal 
Wallis 
Schirmer 
(mm/5min) 
BL 10.50 (8.25 - 19.00) 32.00 (11.00 – 35.00) 21.50 (5.25 – 28.75) p = 0.25 
W2 8.00 (5.25 – 15.25) 18.00 (11.00 – 35.00) 13.50 (6.25 – 25.25) p = 0.06 
W4 13.50 (5.75 – 17.75) 28.00 (7.00 – 35.00) 13.00 (7.00 – 27.75) p = 0.67 
W8 8.00 (8 – 13.75) 20.00 (15 – 32.00) 17.00 (6.00 – 17.00) p = 0.07 
Friedman’s  p = 0.21 p = 0.93 p = 0.57  
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Figure 33 displays a box plot of osmolarity values for each group at each visit. There 
was a significant reduction in osmolarity for participants in Group 3 over the eight weeks 
(repeated ANOVA p = 0.014, refer Table 43). Bonferroni post-hoc analysis showed that 
this was significant from baseline to week four only (p = 0.017, Figure 33). There was no 
significant change in osmolarity detected for participants in Groups 1 and 2 at any stage 
over the eight weeks (repeated ANOVA p > 0.05, Table 43). Overall, repeated measures of 
ANOVA taking treatment into consideration as a between participants’ factor, showed no 
significant change in osmolarity overtime (p = 0.107). 
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X denotes mean change in osmolarity. Post – hoc analysis: Bonferroni (α ≤ 0.05 
significant). BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant 
results highlighted in bold. 
Figure 33. Box plot illustrating osmolarity values for each treatment groups at each 
visit.  
 
Tear film instability, an inter-eye difference of ≥ 8mOsm/L, was also measured for 
each participant. Table 43 displays the prevalence of tear film instability in each group, at 
each visit.  As shown in Table 43, after eight weeks tear film instability had reduced in 
Group 1 (41.67%) and Group 3 (64.22%) but had increased slightly in Group 2 (60.00%). 
Post - hoc Face Cloth MGDRx EyeBag® OPTASETM Moist 
Heat Mask 
BL – W2 1.000 1.000 0.220 
BL – W4 1.000 1.000 0.017* 
BL – W8 1.000 1.000 0.980 
W2 – W4 1.000 1.000 1.000 
W2 – W8 1.000 1.000 1.000 
W4 – W8 1.000 1.000 0.699 
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However, none of these changes were found to be significant within each group over time 
(Friedmans p > 0.05) or between each group at any point in time (KW p > 0.05).   
Table 43 also demonstrates ocular surface staining mean and range for each group at 
each visit. As can be seen from Table 43, there was a significant reduction in ocular surface 
staining over time for each treatment (Friedman’s p = 0.04, p = 0.007 and p = 0.04 for 
Groups 1 – 3, respectively). Post-hoc analysis, with Bonferroni corrected alpha, using WSR 
test pairwise comparisons revealed; only a reduction in staining from week two to week 
eight in Group 2 (1.71, range 0 – 8 versus 0.33, range 0 – 2; WSR p = 0.006), and week 
two to week eight in Group 3 (mean: 1.77, range 0 – 9 versus mean: 0.50, range 0 – 4; WSR 
p = 0.008), were found to be significant. There was no significant difference in ocular 
surface staining detected between the treatments at any time over the eight weeks (KW p > 
0.05).  
Mean NITBUT and Schirmer I scores for each treatment group, at each time point, are 
also shown in Table 43 above. No significant change in NITBUT, or Schirmer I score, was 
detected over time in each group (Friedman’s p > 0.05), or between treatments (KW p > 
0.05). 
Employing the dry eye classification (if found to have three or more of the following 
parameters; modified OSDI ≥ 13, osmolarity ≥ 308 mOsm/L, inter-eye variability ≥ 
8mOsm/L, NITBUT < 10 secs, ocular surface staining ≥ 3 Oxford score or Schirmer I score 
≤ 5mm/5min), the prevalence of dry eye for each group, at each visit, is shown in Figure 
34. No significant change in proportion of subjects with dry eye was detected in any of the 
three treatment groups post-treatment (Group 1 – 3: Friedman’s p = 0.36, p = 0.77 and p = 
0.28, respectively). 
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Figure 34. Prevalence of dry eye disease in each warm compress treatment group at 
each time point. 
7.5 Discussion 
As mentioned previously in Section 1.4.2, DB is most commonly associated with 
MGD; however, an association between DF and MGD has also been established in the 
literature.7,30,48 Currently, lid scrubs remain the principal treatment recommended for 
Demodex blepharitis,3 and warm compress therapy for MGD.138 Intense pulsed light 
therapy has been previously used, successfully, to treat DF infestation.283 However, to the 
best of the authors’ knowledge, this is the first study to investigate the effect of heat therapy 
using warm compresses on DF infestation. This study has shown that Optase may have a 
double therapeutic effect, treating MGD and reducing DF in combination. Over the eight 
weeks, moist heat therapy from Optase significantly reduced the quantity of DF detected 
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using the eyelash rotation technique. No significant change was noted with the moist heat 
from the warm face cloth, or the dry heat from the Eyebag. The reason for this is unknown 
at present. It could be associated with the compresses ability to achieve a higher treatment 
temperature. As mentioned previously, manufacturers of Optase report temperatures 
ranging from 50 °C to 41 °C, over the 10-minute duration of therapy.279 However, the 
Eyebag achieves temperatures from 46 °C dropping to 39 °C, which is less than the 
recommended  40 °C,192 after 5 minutes.280 Similarly, the warm face cloth does not maintain 
its heat for longer than two minutes, without needing to be re-heated.191,192 This could affect 
the therapeutic temperature achieved by the face cloth with respect to treating DF 
infestation.  Furthermore, greater quantities of DF have been found in dryer skin.284,285 As 
Optase is a moist heat device and Eyebag is a dry heat device, it is possible that moisture 
may have played a role in the therapeutic efficacy demonstrated by Optase. However, 
further investigation is warranted for verification.  
There was a considerable improvement in prevalence of DF infestation in Group 2 
(Eyebag) from 50.00% at baseline to 25.00% at week eight (Table 42); yet there was no 
significant reduction in the quantity of DF detected on participants with DF in the same 
group. Although there was no significant difference in mean quantity of DF between the 
three treatment groups at baseline; Group 2 had the lowest quantity and lowest percentage 
prevalence of participants with pathogenic infestation of the three groups at baseline. 
Therefore, it is possible that these lower numbers of DF within Group 2 affected the 
compresses ability to exhibit significant changes over time. As such, a post-hoc power 
calculation was conducted on the data, and a low power (1 – β = 0.26) was detected; which 
would have affected the power and significance of the results. Future research that focusses 
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on pathogenic infestation (to ensure higher quantities of DF per participant), would help 
reduce any limitations caused by lower numbers of DF.  
Similarly, no significant change was detected in quantity of DF using the traditional 
modified Coston method,25 for any of the warm compresses studied. Limitations of this 
technique regarding under-counting of DF have been discussed previously in the 
literature,25,29,50 and in Section 7.5. Similar to results from Chapter 7, the quantity of DF 
detected whilst rotating the eyelash in-situ was significantly greater than that observed on 
microscopic examination in the current study also (paired t-test p = 0.01, p = 0.01 and p = 
0.007 for baseline, week four and week eight, respectively). No significant difference was 
observed between both techniques in week two, where overall a low quantity of DF was 
detected. The authors infer that the low quantity of DF detected in week two may be as a 
result of participants using the warm compresses for 10 minutes twice a day; thus, 
increasing the length of time DF were subjected to heat therapy. After week two, 
participants reduced treatment time to 10 minutes once a day, and the quantities of DF 
appeared to increase again slightly. The authors postulate that the reason for a lack of 
significance found using the modified Coston method was due to the limitations of the 
method, previously described (Section 7.5): resulting in under-counting and mis-
representation of the degree of DF infestation present. 
As mentioned previously in Section 2.3.4, hyperosmolarity is accepted as one of the 
characteristic signs of DED and ocular surface inflammation.117 In MGD, availability of 
meibum to the ocular surface is decreased, either through reduced secretion (possibly due 
to poor expressibility, or severe meibomian gland dropout), or a poor quality secretion; thus 
causing quicker tear evaporation and, as one would expect, hyperosmolarity.286 Although, 
reports in the literature differ with regards to this.286–289 In the current study, participants in 
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Group 3 (Optase) demonstrated a significant improvement in osmolarity overtime. 
However, participants in Group 3 had a greater osmolarity at baseline in comparison to 
participants in the other two groups, which is likely to have influenced the overall reduction 
in osmolarity values detected in Group 3. Comparable to the current study, Kim et al290 
found a significant improvement in osmolarity post-treatment in participants with a baseline 
osmolarity of > 307mOsm/L, but no significant improvement in osmolarity post-treatment 
in participants with an osmolarity of < 307mOsm/L at baseline. The authors deduced that 
heat treatment with a thermal pulsation device was effective at improving osmolarity in 
participants with abnormal tear osmolarity, but did not have an effect on those with normal 
osmolarity.290 In contrast, Godin et al287 discovered that treatment of MGD using thermal 
pulsation on a cohort of participants with Sjogrens syndrome initially caused an increase in 
osmolarity two months after treatment (305.2 vs. 315.6, p = 0.026), but no significant 
increase one year after treatment (305.2 vs 311.0, p = 0.86). Baseline osmolarity values in 
Group 1 (Warm Face Cloth) and Group 2 (Eyebag), in the current study, were similar to 
those found by Godin et al.287 However, neither the heat therapy from the warm face cloth 
or the Eyebag caused an increase in osmolarity values after two months of treatment. 
Giannaccare et al288 investigated the performance of an ocular surface work-up, using 
modern automated non-invasive techniques for diagnosing MGD: such as NITBUT, 
osmolarity, lipid layer thickness and non-contact meibography. The authors discovered 
significant differences between MGD participants and controls for NITBUT, OSDI 
symptom score and meibomian gland loss. However, they found no significant difference 
in osmolarity values between the two groups. Similar to the current study, and the study by 
Godin et al287, Giannaccare et al288 found a low mean osmolarity value within their MGD 
participants using the TearLabTM (303.5 ± 9.8 mOsm/L). The lack of significance 
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discovered in the present study may be related to the low osmolarity found amongst MGD 
patients.287,288 It has been proposed that MGD disease may not cause hyperosmolarity, as 
the disease alone may not be enough to alter the homeostatic control in many 
participants.288,289 In the present study, the authors have been unable to find an explanation 
for the higher osmolarity values observed in Group 3 (Optase). TearLabTM has been shown 
to provide repeatable and reproducible tear osmolarity measurements on a healthy ocular 
surface,178 but becomes less repeatable and shows increased variability with increasing 
disease severity.171,291 Participants in Group 3 were not significantly older, or more 
symptomatic, and did not have a significantly greater quantity of DF, MGD, ocular surface 
staining, reduced TBUT or tear secretion at baseline. Furthermore, repeated measures of 
ANOVA, with treatment as a between participants’ factor, showed no significant change in 
osmolarity overtime. Therefore, the authors infer that the hyperosmolarity observed at 
baseline in Group 3 may be coincidence, or may be due to measurement errors that can 
occur with TearLabTM.  
Heat therapy increases the availability of meibum to the tear film and ocular surface, 
helping to improve the stability of the tears, and thus, increase TBUT.191,280,292–294 In the 
current study, the greatest improvement in NITBUT was with the Eyebag, a dry warming 
device. These results are in keeping with Arita et al292 who found that only dry warming 
devices were able to significantly improve the oily tear film layer, and reduce evaporation. 
In the same study, no improvement was observed after the repeated use of a hot towel 
compress, and the authors’ concluded that moisture on the surface of the eyelid skin could 
give rise to evaporative cooling; thus limiting the beneficial effects of warming.292 There 
was no significant increase in NITBUT demonstrated in the current study. This may be 
accredited to the differences in measurement techniques and timings of measurements post-
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treatment. In previous studies, TBUT has been evaluated invasively using fluorescein,294,295 
or non-invasively using a TearScope Plus.280,293 Fluorescein dye is invasive and has been 
shown to alter the tear film and affect the natural TBUT.296,297 TearScope Plus is a non-
invasive method; however, it is a subjective measurement, and depends on the examiner 
detecting the first perceptible break in the fine line pattern. In the current study, NITBUT 
was measured using the automated Medmont E300 Corneal Topographer; which has 
demonstrated good repeatability with a high sensitivity and specificity for diagnosing 
moderate to severe DED.174 Therefore, all measurements were objectively taken by the 
topographer, which is more sensitive to small tear film instabilities. Furthermore, in 
previous studies, many TBUT measurements have been taken immediately after, 5-10 
minutes after, or up to 1 hour after heat therapy has been applied.280,292,293 However, in the 
current study, participants applied the warm compresses at home in the evenings. Therefore, 
there was a longer time period between last warm compress and time of measurement.  
While immediate effect of treatment has not been shown in the current study, the results do 
demonstrate the ‘realistic effect’ of each treatment on participants’ tear film and ocular 
surface. 
Another shortcoming of the current study is that participants were applying the heat 
therapy at home. As such, it was not possible to measure the temperature of the compress 
each time it was used. Inadequate lid warming of warm compresses have been noted 
previously.298,299 Although all participants were given written instructions, it is possible that 
participants may not have heated the compress sufficiently, or did not complete the full 10-
minute therapy requested of them. To monitor compliance, at each aftercare, participants 
were asked to report on how many evenings and for how long they used the warm compress 
as instructed. At baseline overall reported compliance was 83.61%: 81.14% warm face 
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cloth, 84.02% Eyebag, and 85.16% Optase. This remained relatively stable over the 
duration of the study. The overall reported compliance at the end of the study was 83.74%: 
77.92% warm face cloth, 86.81% Eyebag, and 85.45% Optase. Poor compliance is a 
problem with examining efficacy of treatments; thus, it would be preferable to have 100% 
compliance and treatment delivered in-house by the examiner. However, the use of warm 
compresses in the current study is likely a better indicator of warm compress use in ‘real 
world’ environments.  Nonetheless, the warm face cloth group had the lowest overall 
compliance, and the potential impact that this may have had on the compresses ability to 
demonstrate significant results for treating MGD of DF blepharitis cannot be excluded. It 
is difficult to monitor compliance for use of warm compresses in the home. However, 
following-up with participants at return visits, requesting they demonstrate how they use 
the compresses, may be a good way to remind participants of the protocol, correct any 
mistakes and overall help improve compliance. 
The Eyebag and Optase significantly reduced the presence of MGD over the duration 
of the study. Although some improvement in MGD was seen with the warm face cloth, 
these changes were not found to be significant. Furthermore, the warm face cloth compress 
had to be re-dipped every two minutes, as it lost its heat quickly. Therefore, compresses 
that can be heated once and used for 10 minutes at a time are more efficient and convenient 
for patients. A higher rate of attrition was also found in the warm face cloth group compared 
to either of the other two groups, and overall compliance was lowest in this group. The 
authors feel that this was due to the inconvenient nature of the treatment. As the study was 
conducted on participants with a relatively low grade of MGD and DF infestation, this may 
have impacted on the ability of the compresses to elicit change. Future studies should 
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examine participants with a greater severity of MGD and DF infestation to demonstrate a 
more magnified response to treatment. 
7.6 Conclusion 
The microwaveable compresses, Eyebag and Optase, exhibited a greater ability to treat 
MGD, reduce symptoms and reduce ocular surface staining, compared to the more 
‘traditional’ warm face cloth compress. Optase demonstrated the ability to provide dual 
treatment to patients with MGD and Demodex blepharitis. Further research is required to 
investigate whether moisture, heat, or a combination of both are the underlying therapeutic 
forces at play. 
It has previously been reported that DF tails are visible within the eyelash follicle while 
manipulating the eyelash in situ during a slit-lamp biomicroscope examination.50 In the 
early stages of this research project it became evident that counting DF mites on 
microscopic examination of the epilated eyelash alone was resulting in under counting and 
mis-representing the degree of infestation present. In an effort to counter-act this, from 
recruitment phase two onwards DF quantity on lash manipulation and lash epilation were 
counted. Chapter 8 discusses the comparison of the two investigative methods used 
throughout this research project. The results of this observational study have been accepted 
for publication in Eye and Contact Lens and has been adapted accordingly for Chapter 8.   
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CHAPTER EIGHT: THE CLINICAL USE OF EYELASH MANIPULATION IN 
THE EXAMINATION OF DEMODEX FOLLICULORUM BLEPHARITIS 
8.1 Abstract 
Purpose: To compare the efficacy of using an eyelash manipulation technique to the 
traditional eyelash epilation and subsequent microscopic examination technique, when 
investigating for the presence of DF in a clinical setting. 
Methods: Four hundred and twenty-eight eyelashes of 107 participants were selected 
to evaluate the association between the quantity of DF visible on eyelash manipulation to 
that counted on microscopic examination of the same epilated eyelash. Eyelash 
manipulation was conducted as described in Section 2.2.9. As the eyelash was manipulated, 
the number of DF seen emerging from the follicle was counted. The same eyelash was then 
epilated and the number of DF on the epilated eyelash was counted using the modified 
Coston method (Section 1.7.2). Data was analysed to check for agreement between the two 
techniques. 
Results: Intra-class correlation co-efficient showed moderately good agreement for 
assessing the quantity of DF (0.78) between both techniques. However, the Bland-Altman 
plot suggested consistently higher quantities were discovered on eyelash manipulation. The 
overall median quantity of DF was also greater on eyelash manipulation than on 
microscopic examination of the epilated eyelash (0.00 mites, IQR: 0.00 – 2.00 and 0.00 
mites, IQR 0.00 – 1.00, respectively) (p = < 0.001). Weighted kappa (κw = 0.56) indicated 
weak levels of agreement between the two methods for addressing severity of infestation. 
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Conclusion: Eyelash manipulation exhibited larger quantities of DF than complete 
epilation of the eyelash with microscopic examination. In a clinical setting, complete 
eyelash epilation is not necessary to accurately detect Demodex blepharitis requiring 
treatment. 
8.2 Introduction 
As mentioned in Section 1.4, DF typically reside in clusters within the eyelash 
follicles41,43,62 (Figure 35 (a)) and DB typically reside in solitude, deeper in the sebaceous 
and meibomian glands (Figure 35 (b)).41,61,62,65 The scraping movement of the mites within 
the eyelash follicles damages the follicles,43,62 causing hyperplasia and hyperkeratinisation 
of the epithelial cells, which becomes visible as CD at the base of the eyelashes (Figure 
35(c)). Chronic Demodex infestation also causes the eyelash follicles to widen and the 
eyelashes within to become looser, which can lead to trichiasis, madarosis, and eyelash 
misdirection.49,62  
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(a)     (b)  
(c)   
Figure 35. (a) Demodex folliculorum cluster on an epilated eyelash; (b) Single 
Demodex brevis; (c) Cylindrical dandruff visible as a translucent cuff along the base of 
the eyelash, black arrows. 
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Confirming the presence of DF and thus diagnosis of Demodex blepharitis can be 
achieved by eyelash epilation,25 and inspecting the eyelash under a light microscope, or 
smartphone145; or  laser confocal microscopy, to view DF in-vivo.16,65,146 Previous 
investigators have described the use of eyelash manipulation as an adjunct procedure prior 
to eyelash epilation in an attempt to stimulate DF to move towards the opening of the 
eyelash follicle.12,61 In 2013, Mastrota indicated that it was possible to view, on the slit-
lamp biomicroscope, DF tails emerging from the eyelash follicles as the eyelash was rotated 
in-situ (as can be seen in Figure 36(a)).50  
Eyelash epilation alone often results in miscounting, as many DF remain within the 
follicle after the eyelash has been removed (Figure 36(b)).25,29,50 This became particularly 
apparent during data collection for the pilot study. Clearly infested eyelash follicles were 
being given a recorded count of zero DF on microscopic examination: as the eyelash would 
fall out leaving all the DF behind within the eyelash follicle. This recurrent outcome 
prompted this investigation into evaluating the benefit of incorporating eyelash 
manipulation into the Demodex investigation routine. Furthermore, eyelash manipulation 
removes the stress and discomfort for patients that can be associated with having the eyelash 
epilated. 
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(a)  
(b)  
Figure 36. Illustrates manipulation of the eyelash within the follicle to observe 
Demodex folliculorum infestation in-situ (a) Demodex folliculorum visible emerging 
from the follicle during eyelash manipulation, black arrow. (b) Demodex folliculorum 
remaining within the follicle after the eyelash has been epilated, black arrow. 
The current study aimed to show that complete epilation of the eyelash is not always 
necessary in a clinical setting, and eyelash manipulation may be a better indicator for 
severity of infestation than eyelash epilation. 
8.3 Methods 
Four hundred and twenty-eight eyelashes of 107 participants, one from each eyelid, 
were chosen to compare the quantity of DF detected using the two techniques previously 
described: eyelash manipulation (Section 1.8.4) and microscopic examination (Section 
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1.8.2) of the same epilated eyelash. Participants were recruited through the National 
Optometry Centre, TU Dublin.  
Each participant was examined for the presence of DF on the slit-lamp biomicroscope 
as previously described (Section 2.3.9). In keeping with the modified Coston method, lashes 
with CD, if present, were selectively chosen to maximize the chance of finding DF.25 In the 
absence of CD, eyelashes were chosen at random. As described previously, eyelash 
manipulation stimulates DF within the follicle, to emerge from the follicle opening (arrow 
Figure 36 (a)). However, often in severely infested follicles, after the eyelash was epilated, 
all or most of the DF remained within the follicle (Figure 36 (b)). This resulted in an 
inaccurately low count on microscopic examination of the eyelashes. 
The quantity of DF visible on eyelash manipulation was compared to the quantity of 
DF visible on the microscope. It was difficult to count precise numbers in highly infested 
follicles, due to the greater quantities of DF present. Therefore, a ‘severity of infestation’ 
was categorised based on the quantity of DF counted on eyelash manipulation, as can be 
seen in Table 44. This system was based on work by Randon et al65 using in-vivo confocal 
microscopy, who distinguished ≤ 3 mites per follicle as a low rate of infestation, and 
deemed non-pathogenic; and ≥ 4 mites per follicle as a high rate of infestation, and 
considered pathogenic. In the current study, it was discovered that several follicles were 
extremely infested (~ 10 mites visible in the follicle). As such, a second pathogenic group 
was included for analysis: severely infested (≥ 7 mites). 
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Table 44. Severity of Demodex folliculorum infestation of the eyelash follicle. 
Grade Description 
0 No mites present 
1 
Mild: Non-Pathogenic 
(1 – 3 mites present) 
2 
Moderate: Pathogenic 
(4 – 6 mites present) 
3 
Severe: Pathogenic 
(≥ 7 mites present) 
 
8.3.1  Statistical Analysis 
There are no previous studies that have directly compared the quantity of DF mites 
visible on eyelash manipulation and microscopic examination. As a result, expected mean 
and SD were not known. Data from the first 100 eyelashes were used to calculate the 
minimum number of pairs required. This was calculated using MedCalc® (ver.18.9.1), 
alpha 0.05, beta 0.8. From this, a minimum number of 255 pairs was required for a method 
comparison study using the Bland-Altman plot. 
Statistical analysis was performed using SPSS version 25.0. Wilcoxon signed-rank test 
was used to compare the means of the two groups. Agreement between the two techniques 
was measured using ICC and Bland Altman’s limits of agreement method300 for continuous 
variables (quantity of DF) and κw for ordinal variables (severity of infestation). 
8.4 Results 
Four hundred and twenty-eight eyelashes of 107 participants (39 males: 68 females, 
median age 54.00 years, IQR 33.00 – 65.00 years) were assessed for the presence of DF by 
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means of eyelash manipulation in-situ and subsequent epilation of the same eyelash for 
microscopic examination, by the modified Coston method.25 Demodex folliculorum was 
detected on 44.16% of the eyelashes tested.  
Quantity of Demodex folliculorum 
Intra-class correlation co-efficient analysis was used to establish the level of agreement 
between both investigation techniques. With regards to examining quantity of DF detected 
using both techniques, the ICC was in moderately good agreement (ICC = 0.78: 95% 
Confidence Intervals 0.69 – 0.84). A cross-tabulation of the quantities of DF found using 
both techniques is shown in Table 45. Both techniques found no Demodex folliculorum on 
239 eyelashes, non-pathogenic infestation (≤ 3 Demodex folliculorum) on 111 eyelashes 
and pathogenic infestation on 29 eyelashes. However, pathogenic infestation was missed 
on six eyelashes using eyelash manipulation in comparison to 43 eyelashes using 
microscopic examination (WSR p < 0.001). 
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Table 45. Cross tabulation of the quantity of Demodex folliculorum detected on 
eyelash manipulation versus microscopic examination. Green numbers indicate the 
quantity of eyelashes on manipulation that failed to detect pathogenic infestation (≥ 4 
Demodex folliculorum). Purple numbers indicate the quantity of eyelashes on microscopic 
examination that failed to detect pathogenic infestation. 
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Microscope Quantity Total 
 0 1 2 3 4 5 6 7 9 16  
0 239 10 3 0 1 0 0 0 0 0 253 
1 21 22 3 1 0 0 0 0 0 0 47 
2 13 10 8 2 0 1 0 0 0 0 34 
3 8 4 3 3 3 0 1 0 0 0 22 
4 3 3 5 5 5 1 0 0 0 0 22 
5 1 0 2 3 1 2 1 0 0 0 10 
6 4 4 3 2 4 0 2 1 0 0 20 
7 2 1 0 0 0 1 0 0 0 0 4 
8 0 2 0 0 3 2 1 0 0 0 8 
9 0 0 0 1 0 0 0 0 0 0 1 
10 0 0 0 0 1 0 1 0 0 0 2 
11 0 0 0 1 0 0 0 0 1 0 2 
12 1 0 0 0 0 0 1 0 0 0 2 
13 0 0 0 0 0 0 0 0 0 1 1 
Total  292 56 27 18 18 7 7 1 1 1 428 
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The level of agreement between both techniques was assessed using the Bland-Altman 
method by examining the mean difference and constructing limits of agreement.300 As data 
was not normally distributed (Shapiro-Wilk p < 0.001), a non-parametric form of limits of 
agreement method was incorporated. This was achieved by ordering the data, and placing 
the upper and lower limits of agreement at the top and bottom 5% of the ordered data 
respectively.301 The difference between both techniques, eyelash manipulation (A) and 
microscopic examination (B) (A - B), was plotted on the y-axis against the average of both 
techniques (A + B)/2 on the x-axis (refer Figure 37). The mean difference value was 0.64 
mites, with a 95% confidence interval of 0.45 and 0.83 mites. A clear positive trend can be 
seen in Figure 37: as the average quantity of DF increases, the greater the difference 
between the two methods. This implies that eyelash manipulation (method A)  presents 
higher quantities of DF than microscopic examination (method B), especially in severe 
infestations. In agreement with this interpretation, the overall median quantity of DF 
detected was significantly greater using eyelash manipulation (0.00 mites, IQR: 0.00 – 2.00) 
compared to microscopic examination (0.00 mites, IQR: 0.00 – 1.00) (p = < 0.001). 
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Figure 37. Bland Altman plot illustrating the 95% limits of agreement between the 
quantity of Demodex folliculorum on eyelash manipulation (A) and microscopic 
examination (B). Purple lines show limits of agreement (Upper 4.0, Lower -1.00), and the 
red line shows the mean value (0.64) of the differences. 
To examine the repeatability of the eyelash manipulation versus microscopic 
examination techniques, participants were asked to return for a subsequent check two weeks 
later. Data from 280 eyelashes was analysed (70 participants, four eyelashes from each). 
The results of the second analysis were in good agreement with the original examination. 
A mean difference of 0.5 mites (95% confidence interval of 0.32 to 0.68 mites) with upper 
and lower limits of agreement at 4.0 and -1.0 as previously were found. Figure 38 illustrates 
the Bland-Altman plot constructed, which is very similar to that displayed above in Figure 
37. 
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Figure 38. Bland Altman repeatability plot illustrating the 95% limits of agreement 
between the quantity of Demodex folliculorum on eyelash manipulation (A) and 
microscopic examination (B). Purple lines show limits of agreement (Upper 4.0, Lower -
1.0), and the red line shows the mean value (0.5) of the differences. 
 
Severity of Infestation 
In an attempt to counteract estimating DF quantity during eyelash manipulation, each 
eyelash was graded from 0 – 3 according to severity of infestation. The frequency 
distribution of severity of infestation detected using both techniques are presented in Table 
46. For eyelash manipulation and microscopic examination respectively, the majority of 
eyelashes were classified as Grade 0 (59.11% and 68.22%) or Grade 1 (24.06% and 
23.69%). However, the percentage of eyelashes demonstrating pathogenic infestation, 
either Grade 2 (12.15% and 7.47%) or Grade 3 (4.67% and 0.77%) was greater using 
eyelash manipulation compared to microscopic examination.  Additionally, eyelash 
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manipulation identified a greater severity of infestation on 95 eyelashes, in comparison to 
only 20 eyelashes for microscopic examination (WSR p < 0.001). 
Table 46. Severity of infestation frequency distribution. 
 
Severity of Infestation 
Eyelash Manipulation Microscopic Examination 
Grade Description 
Frequency 
(n) 
Percent 
(%) 
Frequency 
(n) 
Percent 
(%) 
0 No D. folliculorum 253 59.11 292 68.22 
1 
Mild, non-pathogenic 
infestation 
103 24.06 101 23.59 
2 
Moderate, pathogenic 
Infestation 
52 12.15 32 7.47 
3 
Severe, pathogenic 
Infestation 
20 4.67 3 0.77 
 
Table 47 illustrates a cross-tabulation of the ‘severity of infestation’ groups. Using the 
accepted technique of examining DF on microscopic examination, 292 eyelashes were 
classified as having no DF on microscopic examination. However, of those 292 eyelashes; 
42 (14.33%) were classified as mildly infested, eight (2.77%) moderately infested, and three 
(1%) severely infested, when examined using eyelash manipulation. By comparison, 253 
eyelashes were classified as having no DF on eyelash manipulation. Of those 253 eyelashes; 
only 13 (5%) were classified as mildly infested, one (0.33%) moderately infested (grade 2), 
and none were severely infested (grade 3) on microscopic examination. 
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Table 47. Cross tabulation of the severity of infestation detected on eyelash 
manipulation versus microscopic examination. Green numbers indicate the quantity of 
eyelashes on manipulation that failed to detect pathogenic infestation (≥ 4 Demodex 
folliculorum). Purple numbers indicate the quantity of eyelashes on microscopic 
examination that failed to detect pathogenic infestation. 
Eyelash 
Manipulation 
Microscope 
Total 
 
No D. 
folliculorum 
Mild, Non-
Pathogenic 
Moderate, 
Pathogenic 
Severe, 
Pathogenic 
No Demodex 
folliculorum 
239 13 1 0 253 
Mild, Non-
Pathogenic 
42 56 5 0 103 
Moderate, 
Pathogenic 
8 27 16 1 52 
Severe, 
Pathogenic 
3 5 10 2 20 
Total 292 101 32 3 428 
 
 To examine the level of agreement between both methods on an ordinal scale,302 κw 
statistics were used. There were 313 (73.13%) observed agreements and 201 (46.96%) 
agreements expected by chance. Weighted kappa (κw = 0.56) was slightly greater than 
unweighted kappa (κ = 0.49). Nonetheless, the level of agreement between both techniques 
for measuring severity of infestation appears to be relatively weak.200 
8.5 Discussion 
Infestation of the eyelash follicle with large quantities of Demodex has become a well-
known underlying cause of recalcitrant blepharitis.7,43,46,49,63,64 Clinically in practice, the 
importance of ascertaining the quantity of DF is to establish if there is pathogenic 
infestation (≥ 4 mites per follicle) or non-pathogenic infestation present. This will help a 
practitioner in deciding whether to treat or monitor a patient. Currently, the most common 
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method of investigation for infestation has required epilating the eyelash in order to count 
any DF present. This technique, the Coston method,43 has been previously described in 
detail in Section 1.8.1. However, there were several limitations to this method. The 
modified Coston method (described in Section 1.8.2) was developed to account for these 
limitations, which is the technique predominantly used by investigators today.25,30,32,45,52,303 
However, even after modifications have been made to these epilation methods, as has been 
noted previously25,29,50 and in the current study, often DF remain within the follicle after 
the eyelash has been removed; resulting in under-counting on microscopic examination.  
The present study has shown that  eyelash manipulation without epilation is better at 
detecting pathogenic levels of infestation than the modified Coston method.25 This 
manipulation technique would work well in a clinical setting, and may help improve 
practitioners’ confidence and ability to detect pathogenic DF infestation requiring 
treatment. Although ICC revealed a moderately good level of agreement (0.78) between 
both methods, the Bland-Altman method suggested consistently greater quantities of DF 
visible on eyelash manipulation than on microscopic examination. This analysis was further 
strengthened, as the overall median quantity of DF detected was greater on eyelash 
manipulation and repeated examination on a second visit showed similar results. The 
authors believe that the strong agreement between both methods with respect to no DF 
present and low non-pathogenic levels of infestation was responsible for the higher level of 
agreement detected with ICC. However, the eyelash manipulation method appeared to be 
more effective with greater severity of infestation. 
An overall greater range of DF was detected on microscopic examination (range 0 – 
16) compared to eyelash manipulation (range 0 – 13). This was on account of the subjective 
nature of observing the number of DF tails discernable on eyelash manipulation. By 
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comparison, it is possible to precisely count the number of DF visible on a microscope slide. 
However, as mentioned above, the recognised method of eyelash epilation and counting of 
DF on the microscope can be imprecise and often leads to miscounting.25,50 Moreover, using 
the eyelash manipulation technique, the differentiation between detecting the presence of 
no DF or one to three tails compared with four to six tails, or greater than seven tails, is 
quite unmistakeable; as can be seen from the strong agreement between both techniques in 
non-pathogenic infestation (refer Table 40). Therefore, in a clinical setting where 
pathogenic infestation can be considered ≥ 4 mites per follicle, exact numbers for large 
quantities are not necessary: as it is evident that the follicle is severely infested.65  
Furthermore, as can be seen from Table 39and Table 41, only six eyelashes (1.44% of 
the eyelashes included in the study) detected pathogenic DF on the microscope and not on 
eyelash manipulation. By comparison, 43 eyelashes (10.01%) detected pathogenic DF 
infestation on eyelash manipulation but not on the microscope. Hence, there appears to be 
almost a 10-fold greater likelihood of identifying pathogenic DF infestation on eyelash 
manipulation than on microscopic examination of the epilated eyelash. This clearly 
illustrates the limitation of using eyelash epilation and microscopic examination in isolation 
when examining for DF infestation. These damaged eyelash follicles were visibly infested. 
However, as the eyelashes were removed without removing all the DF within the damaged 
follicle, the severity of infestation present was erroneous. There was an increased 
discrepancy between both methods for detecting severity of infestation as the severity of 
infestation increased, confirmed by the weak level of agreement detected with weighted 
kappa (κw = 0.56). In clinical studies, agreement analysis between two methods is 
conducted to assess if a new method is good enough to replace an old one; with a 
recommendation of 80% as the minimum acceptable agreement value.200 This high level of 
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agreement was not achieved in the current study. However, it is believed that the eyelash 
manipulation technique outperformed the accepted eyelash epilation technique: thus, 
causing the observed disagreement between the two techniques. As eyelash manipulation 
appears a better indicator of pathogenic infestation, it should be considered more often in 
clinical and research settings.   
Apart from under-counting, a second disadvantage of eyelash epilation is the 
discomfort and anxiety associated with epilating several eyelashes at each examination. 
Manipulating the eyelash without epilation is less stressful and more comfortable for the 
patient. Furthermore, in the current study, this technique was found to be more accurate for 
determining quantity and assessing severity of infestation. Additionally, madarosis as a 
result of chronic blepharitis has been previously reported in the literature.25,304 It was noted 
that several patients declined to part-take in the study; they were apprehensive about having 
their eyelashes removed when they felt they had so few eyelashes remaining. As such, from 
a cosmetic viewpoint, eyelash manipulation is a preferred technique.  
As mentioned in Section 1.8.3, confocal laser scanning microscopy is a relatively new, 
non-invasive technique that has been used to detect DF in-vivo.16,65,146 Studies have 
compared laser confocal microscopy to the modified Coston method, but found no 
significant difference in prevalence or quantity of DF detected between either method.16,65 
However, these studies had much smaller patient cohorts than the current study (n = 2565 
and n = 1516), which may account for the lack of significance found. Additionally, confocal 
laser scanning microscopes are expensive, specialised pieces of equipment, mainly utilised 
in specialised clinics and research laboratories. General optical practices are not likely to 
invest in such technology. On the other hand, all optical practices have access to a slit-lamp 
biomicroscope, and the likelihood is that all optometrists will encounter patients attending 
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with blepharitis and CD. As such, eyelash manipulation as part of a slit-lamp biomicroscope 
routine to examine for presence of DF and assess severity of infestation may be more clinic 
and practitioner friendly than a confocal laser microscope. 
8.6 Conclusion 
The results of this study confirm the early observations in the pilot and extended 
studies (Chapter 5), that counting DF visible on microscopic examination alone was often 
mis-representing the degree of infestation present. Eyelash manipulation demonstrated 
greater quantities of DF than complete epilation of the eyelash and was superior for 
identifying moderate to severe pathogenic levels of infestation. However, eyelash epilation 
and microscopic examination will still be required in certain investigative settings. 
Epilation is still required to distinguish between DF and DB, or in certain specialised 
clinics/laboratories where isolation of bacteria from Demodex may be required. However, 
in clinical practice, eyelash epilation is not essential to accurately identify pathogenic DF 
infestation and Demodex blepharitis necessitating treatment. Hence, going forward, 
practitioners should feel confident in being able to detect Demodex blepharitis in practice 
without the need to epilate patients eyelashes. 
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CHAPTER NINE: SUMMARY, CONCLUSIONS AND FUTURE RESEARCH 
9.1 Summary and Conclusions 
The research presented in this thesis provides optometrists and ophthalmologists with 
evidence-based results into the safety and efficacy of over-the-counter products available 
for the treatment of Demodex blepharitis. This provides practitioners effective alternatives 
to TTO and ivermectin, which can be managed in-house without the need for further 
referral. Furthermore, the current study highlights the ability to detect pathogenic 
infestation requiring treatment without the need for eyelash epilation and microscopic 
counting of Demodex mites on slides. In clinic, eyelash manipulation at the slit-lamp is a 
more patient- and practitioner- friendly technique that is more effective at demonstrating 
pathogenic DF infestation requiring treatment. 
9.1.1 Development and validation of a General Health and Lifestyle questionnaire 
Chapter 3 discussed the development and validation of the GHL questionnaire. Results 
found that age remains the most significant risk factor for Demodex blepharitis, which was 
in good agreement with previous research.13,28,77 An interesting potential association 
between DF and makeup was detected. It appears that makeup may have a protective 
mechanism against DF infestation. The questionnaire demonstrated moderate to good 
repeatability. However, there were several limitations, especially with the variety in number 
of response items to each question. As such, the questionnaire was not utilised after the 
second recruitment phase. Instead, the research concentrated on the efficacy of treatment 
products going forward.  
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9.1.2 Development and validation of a modified Ocular Surface Disease Index 
questionnaire 
Chapter 4 discussed the development and validation of the modified OSDI symptom 
questionnaire. The questionnaire was modified to include questions such as itch and debris 
at the base of the eyelashes, which are commonly associated with blepharitis.16,28,46,47 The 
modified OSDI questionnaire demonstrated good internal consistency and repeatability. 
Good repeatability validated the use of the questionnaire to observe subjective symptoms 
over time in a clinical setting. The questionnaire exhibited a sensitivity value of 70.75%. 
This means that there is a 70.75% chance that a positive result using the questionnaire alone 
would correctly identify the presence of DF.  However, with regards to confirming the 
presence of DF infestation and establishing which participants require further intervention, 
this would not be sufficient. To the best of the author’s knowledge, this was the first study 
to examine the prevalence of ocular DF infestation and its associated symptoms in an Irish 
population. Furthermore, it was the first study to show an association between increasing 
quantity of DF and increasing severity of the symptom ‘itchy eyes’. Results of the study 
discussed in Chapter 4 have been published in International Ophthalmology.45 
9.1.3 The efficacy of baby shampoo, OCuSOFT, TTFW and 
microblepharoexfoliation in the treatment of Demodex folliculorum blepharitis 
Chapter 5 discussed the results of the pilot study and the extended treatment study. The 
pilot study compared the efficacy of OCuSOFT to 10% baby shampoo in a two-week 
treatment study. Results showed that OCuSOFT significantly reduced the quantity of DF, 
but not presence; and baby shampoo had no effect on DF quantity or presence. The extended 
treatment study was conducted to improve on limitations of the pilot study following peer-
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review. Firstly, the study was extended to four weeks, to ensure sufficient time was given 
to treat DF infestation, given their lifespan is 14–18 days.40,42,43,61 Secondly, both eyes were 
treated with the same treatment, to prevent cross-contamination through migration of DF 
from the control eye to the treated eye. Thirdly, reviewers suggested comparing OCuSOFT 
to a tea tree-based product (TTFW) as opposed to baby shampoo. The BlephExTM device 
was also used on one group of participants to evaluate if any additional benefit was attained 
from microblepharoexfoliation of the eyelids prior to home lid scrubs. Results of the 
extended study demonstrated that both OCuSOFT and TTFW were effective at reducing 
the quantity of DF. Tea tree-based face wash also has the added benefit of being used as a 
face wash and treating DF in hair follicles all over the face and not just the eyelashes. The 
use of BlephExTM demonstrated a greater reduction in symptoms although it was not 
significantly better. Results of the extended study discussed in Chapter 5 have been 
published in Contact Lens Anterior Eye.52 
9.1.4 Effect of lid hygiene on the tear film and ocular surface 
Chapter 6 evaluated the effect blepharitis lid cleansers have on the tear film and ocular 
surface and examined the prevalence of DF in a young population. No adverse ocular events 
were detected following the use of OCuSOFT or TTFW for up to eight weeks. However, a 
significant increase in tear film instability was detected after eight weeks of lid scrubs with 
10% baby shampoo. The findings from this study are in keeping with recent studies that 
have found that baby shampoo could have a damaging effect on goblet cell density,186 and 
provides further evidence to practitioners to move away from recommending lid scrubs 
with baby shampoo when treating blepharitis.  In agreement with previous research,23 a low 
prevalence of DF was observed amongst the young study population. A paper on the results 
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of the study discussed in Chapter 6 has been accepted for publication in Contact Lens & 
Anterior Eye. 
9.1.5 Effect of warm compress therapy on Demodex folliculorum infestation 
Finally, Chapter 7 examined the efficacy of using heat from warm compresses to treat 
DF blepharitis. Three warm compress treatments were compared: Warm face cloth, 
MGDRx EyeBag® and OPTASETM Moist Heat Mask. Warm compress therapy was 
conducted for eight weeks. Both the MGDRx EyeBag® and OPTASETM Moist Heat Mask 
exhibited superior efficacy in treating signs and symptoms of MGD, compared to the use 
of a warm face cloth, over the eight-week period. The OPTASETM Moist Heat Mask 
demonstrated dual therapeutic abilities, treating both MGD and DF blepharitis. A paper on 
the results of the study discussed in Chapter 7 has been recently accepted for publication in 
Current Eye Research. 
9.1.6 Clinical use of eyelash manipulation versus microscopic examination 
Chapter 8 compared the efficacy of using an eyelash manipulation technique to the 
traditional eyelash epilation and subsequent microscopic examination technique, when 
investigating for the presence of DF in a clinical setting. A moderately good agreement for 
assessing quantity of DF was detected between both techniques. However, the Bland-
Altman plot suggested consistently higher quantities were discovered on eyelash 
manipulation. The overall mean quantity of DF was also greater on eyelash manipulation 
than on microscopic examination of the epilated eyelash. A weak level of agreement was 
detected between the two methods for addressing severity of infestation. This was caused 
by the superior ability of eyelash manipulation to detect pathogenic infestation in 
comparison to microscopic examination of the epilated eyelash. As such, complete eyelash 
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epilation is not necessary to accurately detect Demodex blepharitis requiring treatment, in 
a clinical setting. Results of the extended study discussed in Chapter 8 have been accepted 
for publication in Eye & Contact Lens.305 
9.1.7 Conclusions 
Based on the results of the research conducted throughout this research project, DF 
blepharitis can be effectively diagnosed and treated by practitioners in-house, without the 
need for further referral in many cases. Investigation to assess presence and severity of 
infestation should be performed using eyelash manipulation. The results from Chapter 7 
have proven that there is no clinical requirement to epilate an eyelash when examining for 
the severity of DF infestation. Practitioners can feel confident that recommending nightly 
lid scrubs with OCuSOFT® Lid Scrub® Plus or a tea tree-based product will reduce 
quantities of DF and improve patients’ symptoms. The use of BlephExTM is advised to help 
start the lid scrubbing regime by reducing the extent of CD and bacterial load at the eyelid 
margin. The benefit of using a tea tree-based face wash, is that it can be used to clean the 
entire face, not just the eyelids and eyelashes. Hence, treating DF infestation in other 
locations on the face. Practitioners should refrain from recommending baby shampoo for 
lid scrubs going forward, as it has no impact on Demodex blepharitis, but also may be 
harmful to the ocular surface in the long run. 
9.2 Future research  
Demodex remains a relatively novel research area within ophthalmology. Future 
research regarding treatment such as: effect of BlephExTM on lid hygiene; effect of 
OCuSOFT applied overnight versus washed off; effect of face cleansers compared to 
TTFW; comparison between in-house lid scrubs scrubs with TTO versus TTFW at home; 
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and the effect of lid scrubs used twice a day versus once a day; are all areas that require 
further investigation. However, any future treatment-based investigation should make a 
considerable effort to quantify participant compliance. Methods to improve participant 
compliance in all treatment-based studies is a field that also requires further research and 
investigation. 
Over the course of this research project, it has become clear that there are several topics 
that require further clarification with regards to Demodex, helping to improve practitioner’s 
knowledge of underlying risk factors and associations.  
There has been limited research conducted on the relationship between Demodex and 
contact lenses. The majority of references to contact lens wear and Demodex is anecdotal, 
and based around the work of Jalbert and Rejab114 and Tarkowski et al115. Both hard and 
soft contact lens wearers were included in the study conducted by Jalbert and Rejab114, and 
although this included a mix of daily, fortnightly and monthly soft contact lenses, and rigid 
gas permeable lenses; no inter-lens modality analysis was conducted: just contact lens wear 
and non-contact lens wear groups. Similarly, Tarkowski et al115 focussed on DF as a cause 
of drop-out in previously successful contact lens wearers, but did not discriminate between 
contact lens modality. Jalbert and Rejab114 found a 90%  prevalence of DF within contact 
lens wearers in their study. The authors’ suggested the higher prevalence may be due to 
increased handling of and presence of bacteria, such as Staphylococcus epidermis and 
Corynebacteria, on the eyelids of contact lens wearers,306 concluding that contact lenses 
may provide a route for micro-organisms to grow and create an environment that favours 
Demodex proliferation. However, it would be interesting to examine the relationship 
between DF and contact lens modality, as re-usable contact lenses, such as fortnightly or 
monthly lenses, are cleaned and stored in solutions that contain anti-microbial agents to 
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help prevent infection. Hence, in theory, the use of re-usable contact lenses may reduce the 
risk of DF infestation. Furthermore, if the quantity of DF is increased, handling of the 
eyelids may make contact lens wearers more susceptible to DF infestation. A comparison 
of participants who wear their contact lenses on a full-time basis compared to participants 
who wear contact lenses occasionally could be carried out to investigate which cohort has 
a higher risk of DF infestation. Contact lens modality was evaluated during the pilot study. 
In contrast to Jalbert and Rejab114, non-contact lens wearers, and daily disposable soft lens 
wearers, had higher quantities of DF than re-usable contact lens wearers. However, the 
results were significantly impacted by age. As such, no reliable results could be ascertained 
from the data. Future studies should have equal groups of contact lens wearers in the 
different modalities, with age matched control non-contact lens wearers.  
The use of makeup appeared to have a protective effect against DF infestation in the 
pilot study. Similar to contact lenses, there has been very little research conducted on the 
relationship between DF and makeup. Although several hypotheses exist, nothing 
confirmatory has been established. As mentioned in Section 1.6.5, Horváth et al116 and 
Elston and Elston79 suggested that makeup may reduce colonisation of DF in the hair 
follicles of the skin and eyelashes.  Elston and Elston79 suggested that it may be the presence 
of exogenous lipids in cosmetics that could impact the proliferation of Demodex. Horváth 
et al116 found a lower prevalence of DF among makeup wearers compared to non-makeup 
wearers and provided three theories for their results. Firstly, the authors suggested that 
makeup may obstruct follicles, inhibiting migration and proliferation of Demodex.116 
Secondly, the authors suggested that makeup may contain chemicals that are toxic to 
Demodex, thus preventing them from inhabiting skin covered with makeup.116 Thirdly, the 
authors suggested that patients who wear makeup regularly are more inclined to remove 
 239 
 
makeup and clean their faces. Thus, the increased hygiene could help prevent Demodex 
proliferation, or chemicals in the products used to clean the face may be toxic to Demodex: 
preventing proliferation.116 Providing some consensus with regards to improved hygiene, 
Koo et al13 did find that older participants with good eyelid hygiene had lower prevalence 
of DF compared to younger participants with poor eyelid hygiene. However, further studies 
are required to confirm any relationship between makeup and Demodex infestation and 
establish the underlying mechanisms if such a relationship exists. 
In Chapter 8, a low overall quantity of DF detected over the duration of the study 
affected the power of some of the study results, namely the quantity of DF on microscopic 
examination and MGDRx EyeBag®. Further investigation that concentrates on pathogenic 
infestation, to ensure larger quantities of DF when testing, is required. Similarly, with 
regards to the MGDRx EyeBag® and OPTASETM Moist Heat Mask, further research is 
required to examine the therapeutic temperature achieved, and duration of such, at the inner 
eyelid by each compress. Further investigation is required to evaluate any potential role that 
moisture may have played in the therapeutic abilities demonstrated by the OPTASETM 
Moist Heat Mask. 
9.3 Dissemination to date 
Dissemination of research findings is recognised as an integral aspect of the research 
process. Within public health, dissemination of research findings provides evidence-based 
results to practitioners, which can improve and develop their clinical management skills: 
thus, providing best-practice care to their patients.307,308 Research results can be 
disseminated in several different ways: peer-reviewed publications, research reports, 
professional magazine articles, workshops, conference proceedings and social media 
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platforms, to name a few.309 The research findings outlined in the above thesis have been 
disseminated in peer-reviewed journals, optometry magazine articles, conference posters, 
conference workshops at home and abroad, and in online lecture material. 
9.3.1 Peer-reviewed publications 
Results of the development and validation of the modified OSDI questionnaire 
discussed in Chapter 4 have been published in International Ophthalmology (refer List of 
Publications 1). 
Results of the efficacy of OCuSOFT® Lid Scrub® Plus and dr.organic® tea tree face 
wash for treating DF infestation discussed in Chapter 5 have been published in Contact 
Lens Anterior Eye (refer List of Publications 2).  
Results of the effect of OCuSOFT® Lid Scrub® Plus, dr.organic tea tree face wash 
and Johnson’s® No More Tears® baby shampoo on the tear film and ocular surface, 
discussed in Chapter 6, have been recently accepted for publication in Contact Lens & 
Anterior Eye (refer List of Publications 3). 
Results of the study examining the efficacy of warm compresses for treating DF 
infestation, discussed in Chapter 7, have been recently accepted for publication in Current 
Eye Research (refer List of Publications 4). 
Finally, results of the observational finding that eyelash manipulation is better than 
microscopic examination for detecting severity of DF infestation and is suffice in a clinical 
setting, discussed in Chapter 8, have been published in Eye and Contact Lens (refer List of 
Publications 5). 
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9.3.2 Conferences and workshops 
Murphy O. Demodex Blepharitis, Workshop, DIT, Dec 2014. 
Murphy O, et al., Prevalence of Demodex folliculorum in symptomatic and 
asymptomatic individuals and the efficacy of 1,2-Octanediol at treating Demodex 
infestation, Poster Presentation, British Contact Lens Association, May 2015. 
Murphy O, et al. The effectiveness of topical treatment with OCuSOFT Plus on ocular 
Demodex folliculorum, Poster Presentation, European Academy of Optometry and Optics, 
May 2015. 
Murphy O. Dry Eye: Blepharitis – Meibomian gland dysfunction – Demodex, Lecture 
Presentation, Association of Optometrists Ireland AGM, November 2015. 
Murphy O. Dry Eye: Blepharitis – Meibomian gland dysfunction – Demodex, Lecture 
Presentation, Irish Association of Dispensing Optometrists AGM, April 2016. 
Murphy O. Demodex blepharitis: Diagnosis and Treatment, Workshop, Optometry and 
Eye Health Conference, Sofia, Bulgaria, Oct 2018. 
9.3.3 Other publications 
Murphy O. Demodex blepharitis. Online Lecture. Wales Optometry Postgraduate 
Education Centre. April 2018 
Murphy O. Demodex blepharitis in practice. Optometry Today. May 2018, p.77-80. 
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APPENDICES 
Appendix 1: Informed Consent Letter 
Patient Information Sheet 
Project title: Comparison of traditional treatment methods and new techniques 
including OCuSOFT® Lid Scrub® PLUS, BlephExTM and warm compress treatment 
on Demodex folliculorum blepharitis and meibomian gland dysfunction. 
 
You are being asked to consent to taking part in a post-graduate student clinical trial, 
comparing traditional treatment methods for blepharitis with newer techniques.  
Each participant will be asked complete a dry eye symptom questionnaire and will 
undergo a series of dry eye tests and thorough examination of the front surface of the eye. 
Each visit should take approximately 30 minutes. 
One eyelash from each eyelid will be epilated using sterile forceps to confirm presence 
or absence of Demodex. This procedure will be done using sterile forceps and is generally 
painless. It is common for eye lashes to fall out and re-grow.  
You may be allocated any treatment. Treatment will be administered for home use for 
up to 8 weeks. You will be asked to return to the clinic for mid-treatment and post-treatment 
check-ups. 
1. Dry Eye: Blepharitis and Demodex 
Blepharitis is a common condition of the eyelids where debris (crusts/scales similar to 
dandruff) can build up around the base of the eyelash. It may be present with a common 
mite which is found in skin and hair follicles called Demodex. This may result in symptoms 
of itching and irritation around the eyelid margins.  
Traditional treatment includes cleaning the eyelids with a diluted shampoo. New 
treatment includes OCuSOFT® Lid Scrub® PLUS and tea tree face wash, both of which 
containing antibacterial ingredients that has been shown to be effective against bacteria 
commonly found on the eyelid. 
BlephExTM is a handheld device with a spinning micro-sponge that is used to remove 
scruff and debris by exfoliating along the base of the lashes. (BlephExTM will only be 
administered in the clinic). 
2. Dry Eye: Meibomian Gland Dysfunction (MGD) 
MGD is a common condition which affects the glands around the eyelid margins. 
These glands become blocked and cannot release oily secretions into the tears sufficiently. 
This results in a reduced quality tear film which can result in gritty/dry eyes and blurred 
vision. Traditional treatment includes applying heat compresses with a warm face cloth and 
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massage to try to unblock the glands. Newer treatment includes wearing microwaveable 
heat masks, MGDRx EyeBag® and OPTASETM Moist Heat Mask, which apply dry and 
moist heat respectively to the glands over a longer time period. 
A patch test will be carried out before proceeding with lid scrubs to ensure you have 
no adverse reactions to the treatment. This will involve applying treatment to a small area 
near the eyebrow with samples of each treatment. After 24hours if you have had no reaction 
you may proceed with the treatment as instructed.  In the rare event that you may experience 
an adverse reaction; e.g. redness, itching, irritation, rash etc… - use cool compresses to 
help soothe and do not proceed with treatment. We ask that you contact us to inform us if 
this occurs. 
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CONSENT FORM 
 
Researcher’s Name:   ORLA MURPHY Title:  MS 
Faculty/School/Department:   
SCIENCE/PHYSICS/OPTOMETRY 
Title of Study:  COMPARISON OF TRADITIONAL TREATMENT METHODS AND NEW 
TECHNIQUES OCuSOFT® PLUS, BlephExTM AND WARM COMPRESS THERAPY ON DEMODEX 
FOLLICULORUM BLEPHARITS AND MEIBOMIAN GLAND DYSFUNCTION. 
 
 
To be completed by the: PATIENT 
 
 
3.1 Have you been fully informed/read the information sheet about this study?                YES/NO 
 
3.2   Have you had an opportunity to ask questions and discuss this study?                        YES/NO 
 
3.3.  Have you received satisfactory answers to all your questions?                                    YES/NO 
 
3.4 Have you received enough information about this study and any associated health and 
        safety implications if applicable?                                                                                   YES/NO 
 
3.5 Do you understand that you are free to withdraw from this study? 
 
• at any time 
• without giving a reason for withdrawing 
• without affecting your future relationship with the Institute                                         YES/NO 
 
3.6 Do you agree to take part in this study the results of which are likely to be published? 
                                                                                                                                                YES/NO 
 
3.7 Have you been informed that this consent form shall be kept in the confidence  
        of the researcher?                                                                                                            YES/NO 
                                                                                              
 
Signed_____________________________________                        Date __________________ 
 
Name in Block Letters __________________________________________________________ 
 
Signature of Researcher ________________________________     Date __________________ 
 
 284 
 
Appendix 2: Ethics Approval Letter 
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Appendix 3: General Health and Lifestyle Questionnaire 
Name: ____________________________ Reference: _______________ 
DOB: ____________ Age: ________________ Sex:________________                         
The following questions relate to your general health and lifestyle. Please tick the 
appropriate box: 
1. Do you wear contact lenses?  
Dailies [] Two weekly []  Monthly [] Extended wear []  
I don’t wear contact lenses [] 
2. Do you wear make – up? Yes []   No [] 
a. What type of mascara do you use?  Regular []  Waterproof []  None [] 
b. What type of eyeliner do you use?  Liquid [] Pencil [] None [] 
3. How often do you clean your eyelids/lashes?   
Every night []   3-4 times/week [] 1-2times/week []  <once a week [] 
Never [] 
4. What type of lid hygiene regime do you mainly use?   
Cleanser/Toner []  Eye makeup remover []  Face wipes [] 
J+J Lid scrubs [] Other lid scrubs [] Other [] None []            
If other, please specify: __________________ 
5. How often do you currently wash your pillowcase/bed linen?   
> Once a week [] Once a week []  Once a fortnight []   
Once a month []  < Once a month [] 
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6. At what temperature do you currently wash your pillowcase/bed linen?   
≤30°C []      40oC []     ≥55 oC [] 
7. How do you currently dry your bed linen?   
Air dry []       Tumble dry []      Launderette []          Dry Cleaner [] 
8. Do you suffer with any underlying medical conditions?    
Diabetes [] High Blood Pressure []  Thyroid []  Arthritis []  Other [] 
None []      
If other, please specify: ______________________________ 
9. Are you taking any systemic medications?  Yes []   No [] 
If Yes, please specify: ____________________________________________ 
10. Do you suffer with any allergies? 
Seasonal (e.g. hay fever) [] Asthma [] Dust []      Skin sensitivities []    None [] 
11. Do you currently suffer with any of the following skin conditions? 
Rosacea [] Dermatitis [] Eczema [] Acne [] Sensitivity skin [] 
Psoriasis []   None []  
If you do not understand any of the above questions, please ask the Optometrist to help 
clarify. 
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Appendix 4: Modified OSDI symptom questionnaire 
Answer the questions below in relation to dry eye symptoms. Please circle/tick 
appropriately.  
Please use this frequency list as a reference guide. 
4: All of the time: All day, every day. 
3: Most of the time: At least once a day, every day. 
2: Half the time: e.g. At least once every second day 
1: Some of the time: e.g. at least once every 2-3days 
0: Rare/Not at all: Very rarely affected, practically not at all, never. 
 
1. In the past fortnight have you experienced any of the following? Please circle the 
most appropriate: 
 All of the 
time 
Most of the 
time 
Half of the 
time 
Some of 
the time 
Rare/Not at 
all 
Dry eyes? 4 3 2 1 0 
Gritty/Irritated eyes? 4 3 2 1 0 
Itchy eyes? 4 3 2 1 0 
Red eyes? 4 3 2 1 0 
Burning sensation? 4 3 2 1 0 
Sensitivity to light? 4 3 2 1 0 
Watery eyes? 4 3 2 1 0 
Eyelids stuck together 
in the mornings? 
4 3 2 1 0 
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2. With regards to the symptoms above, what time of the day are your symptoms worst?  
Tick all that apply. 
I don’t have any symptoms []  In morning on waking []  In the afternoon [] 
At night []                 All day long []   
3.  In the past fortnight, have problems with your eyes limited your ability in 
performing any of the following? Please circle the most appropriate: 
 
All of the 
time 
Most of 
the time 
Half of 
the time 
Some of 
the time 
None of 
the time 
Reading? 4 3 2 1 0 
Driving at night? 4 3 2 1 0 
Using a computer? 4 3 2 1 0 
Watching television? 4 3 2 1 0 
 
4. In the past fortnight, have your eyes felt uncomfortable in any of the following 
situations? Please circle the most appropriate: 
 
All of the 
time 
Most of the 
time 
Half of 
the time 
Some of 
the time 
None of 
the time 
Windy Conditions 4 3 2 1 0 
Cold Conditions 4 3 2 1 0 
Air-conditioned environments 4 3 2 1 0 
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Appendix 5: Instruction Leaflet for 10% solution of baby shampoo 
(a) Pilot Study 
Blepharitis is a common condition of the eyelids which can result in symptoms of eye 
irritation (itchy, gritty, stinging eyes), intermittent blurred vision or you may have no 
symptoms in the early stages. Demodex is a mite which commonly lives in the base of the 
eyelashes and skin follicles, it becomes increasingly prevalent as we get older and can 
sometimes cause irritation around the eyes.  
You have been recommended the following treatment by your optometrist in order to 
alleviate any symptoms or signs of this condition. Your progress will be monitored at a 
check-up in two weeks’ time.  
 
Ensure you wash and dry your hands thoroughly before beginning. 
 
Right / Left Eye: 
 
A. Traditional method: Diluted solution of Johnson’s and Johnson’s Baby Shampoo  
1. Fill the vial to the point shown (see arrow) 
with boiled water that has cooled.  
2. Shake well to thoroughly mix the solution. 
3. Pour the solution onto one of the cotton 
pads provided. 
4. Squeeze out excess liquid from the cotton 
bud to prevent drips getting into your eyes, 
which may irritate.  
5. Gently clean down across the eye in 
circular movements. Try to ensure you rub 
along the base of the lashes. 
6. With eyes still closed use side – to – side strokes to gently scrub the eyelid. 
Again, paying particular attention, try to clean off any crusts at the base of the 
eyelids.  
7. Open the eyes, wrap the cotton pad around your index finger, as instructed, 
look up and still using side to side strokes at the base of the bottom eyelashes 
make sure all crusts have been removed and the lid is fully clean.  
8. For the top lashes use side to side strokes in an upward movement as 
instructed to ensure lashes are completely clean. Be careful not to scratch the 
ocular surface. 
9. After cleaning the eyelids, rinse off the shampoo from the eyelids, using a new 
clean cotton wool pad.  
10. Please do not dispose of vials. Keep and return them to the National 
Optometry Centre on your aftercare visit. 
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(b) Phase Four 
Blepharitis is a common condition of the eyelids which can result in symptoms of eye 
irritation (itchy, gritty, stinging eyes), intermittent blurred vision or you may have no 
symptoms in the early stages. Demodex is a mite which commonly lives in the base of the 
eyelashes and skin follicles, it becomes increasingly prevalent as we get older and can 
sometimes cause irritation around the eyes.  
 
Ensure you wash and dry your hands thoroughly before beginning. 
 
Johnson’s and Johnson’s Baby Shampoo: 
  
1. Using the syringe provided, insert 2ml of baby shampoo into the test vial 
provided.  
2. Fill the vial with boiled water that has cooled.  
3. Shake well to thoroughly mix the solution. 
4. Pour half the solution onto one of the cotton pads provided. 
5. Squeeze out excess liquid from the cotton bud to prevent drips getting into 
your eyes, which may irritate.  
6. Gently clean down across the eye in circular movements. Try to ensure you 
rub along the base of the lashes. 
7. With eyes still closed use side – to – side strokes to gently scrub the eyelid. 
Again, paying particular attention, try to clean off any crusts at the base of the 
eyelids.  
8. Open the eyes, wrap the cotton pad around your index finger, as instructed, 
look up and still using side to side strokes at the base of the bottom eyelashes 
make sure all crusts have been removed and the lid is fully clean.  
9. For the top lashes, look down, and gently pull up on the upper lid. Using side 
to side strokes in an upward movement as instructed to ensure lashes are 
completely clean. Be careful not to scratch the ocular surface. 
10. For the lower lid, look up, and still using side to side strokes at the base of the 
bottom eyelashes make sure all crusts have been removed and the lid is fully 
clean. 
11. After cleaning the eyelids, rinse off the shampoo from the eyelids, using a new 
clean cotton wool pad.  
12. Repeat from 4-11 for the other eye. 
 
Repeat this routine at night for two weeks and then return to the National Optometry Centre 
for a follow-up appointment. 
 
If you have any questions or need to re-arrange please contact: 
Orla Murphy 
E-mail: orla.murphy@dit.ie 
Please note:  Should you notice any discomfort or irritation of the eyes or skin around the 
eyes please cease treatment and contact your Orla in the National Optometry Centre. 
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Appendix 6: Warm Compress Instructions 
(a) Warm Face Cloth 
Warm Face Cloth Compress 
Read the instructions carefully before using the Warm Face Cloth Compress and keep 
them for reference. Always follow these instructions 
1. Bring the kettle to the boil. 
2. Pour boiling water into a bowl. Allow to cool for approximately 10 mins. 
3. Place flannel in the water. 
4. Remove flannel and squeeze excess water out. Ensure it is not too hot. 
5. Laying in a comfortable position place the warm flannel over the eyes. 
6. Keep in place for 10 minutes. Re-dip every two mins to keep flannel as hot as 
possible (re-dip at 2 min, 4 min, 6 min, and 8 min).  
7. Immediately after warming, massage the closed eyelids – upper and lower, to express 
oil from the Meibomian glands. Gently but firmly sweep your clean finger, in circular 
movements, over the skin at the edge of the closed eyelid from the nose outwards. 
Repeat this several times for about 30 seconds.  
8. Clean eyes of any loose debris from the eyelids. 
Weeks 1+2: Twice a day 
Weeks 3-8: Once a day 
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(c) MGDRx EyeBag® 
Read instructions carefully before use and keep them for reference 
1. Remove the EyeBag® from packaging and place on a clean, microwaveable 
plate. Do not use the metal griddle supplied with some microwaves as this may burn 
your EyeBag® 
2. Place in microwave and heat on full power according to the table below 
Caution: If your microwave is greater than 1000w, you may need to reduce the time. 
Power Heating Duration 
Above 750W 30 seconds 
750W and below 40 seconds 
3. Check the EyeBag® is comfortably warm but not too hot before placing it over the 
closed eyelids and relaxing with the EyeBag® in place for 10 minutes. 
4. Use the silk side as this is warmer and will stay warmer for the duration of the 
therapy. 
5. Immediately after warming, massage the closed eyelids – upper and lower, to express 
oil from the Meibomian glands. Gently but firmly sweep your clean finger over the 
skin at the edge of the closed eyelid from the nose outwards. Repeat this several times 
for about 30 seconds. 
6. Clean the eyelids of any loose debris. 
Weeks 1+2: Twice a day 
Weeks 3-8: Once a day 
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(c) OPTASETM Moist Heat Mask 
Read the instructions carefully before using the OPTASETM Moist Heat Mask 
and keep them for reference. Always follow these instructions 
1. Remove OPTASETM Moist Heat Mask from all packaging and place on a clean, 
microwaveable plate. Do not use the metal griddle supplied with some microwaves as 
this may burn and damage the heat mask. 
2. Place in microwave and heat on full power according the table below. 
Power Heating Duration 
900W and above 15 seconds 
800W 25 seconds 
Do not exceed a maximum of 30 seconds of heating 
3. Check the heat mask is comfortably warm but not too hot before placing it over 
closed eyelids.  
4. Relax and keep the heat mask in place for 10 minutes. 
5. Immediately after warming, massage the closed eyelids – upper and lower, to express 
oil from the Meibomian glands. Gently but firmly sweep your clean finger in circular 
movements, over the skin at the edge of the closed eyelid from the nose outwards. 
Repeat this several times for about 30 seconds. 
6. Clean the eyelids of any loose debris.  
Weeks 1+2: Twice a day 
Weeks 3-8: Once a day 
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